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Cardiovascular diseases (CVD) are the leading cause of death in the Westernized world. 
In the Netherlands, 30% of the reported deaths were a result of CVD.1 Similar percentages 
are listed globally, according to the World Health Organization.2 Despite substantially 
improved treatment options during the last decades, the number of patients suffering 
from CVD is still increasing.2 
Risk factors for CVD can be subdivided into non-modifiable and modifiable risk factors. 
Non-modifiable factors include genetic variation, gender and age, whereas modifiable 
factors include lifestyle (smoking, physical inactivity, diet, overweight), hypertension, 
hyperlipidemia and hyperglycemia.3 Adequate changes in lifestyle such as a more healthy 
diet, smoking prevention, increased physical activity and weight control can avoid over 
75% of deaths attributed to CVD.4 However, harsh reality shows that this is rarely feasible 
for individuals. As a result, in the last decade research on the treatment options for 
CVD is increasingly focused on the role of non-modifiable factors. Primary prevention 
strategies focus on the identified risk factors, such as lowering of plasma lipid levels 
using statins. Despite all efforts CVD are projected to remain the leading cause of death 
in the future.2 Therefore it is urgent to expand the knowledge of underlying mechanisms 
in order to develop new therapies based on targeting different pathways.
The main CVD events are myocardial infarction (MI) and stroke, both caused by 
atherosclerosis. An MI occurs when, due to a vicious cycle of lipid accumulation and 
inflammation, the assembled atherosclerotic lesion in the coronary artery ruptures 
thereby releasing thrombotic factors, causing formation of a thrombus that can occlude 
the blood flow. This results in ischemia in distal areas, which can cause damage and 
death of the myocardial cells, eventually leading to cardiac remodeling and dysfunction. 
Figure 1  Schematic representation of the role of inflammation and lipids on cardiac 
pathophysiology.  In a healthy heart with a normal functioning left ventricle a disturbed lipid 
metabolism as well as inflammation can contribute to cardiac dysfunction and atherosclerosis. The 
latter may lead to coronary occlusion and subsequent ischemia or even infarction, finally resulting 
in a dilated and less functional left ventricle.
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The research reported in this thesis investigates the role of inflammation and lipid 
metabolism in the development of CVD (see figure 1). These two components are of 
particular interest as each, both individually and collectively, can lead to the onset or 
maintenance of pathological cardiac conditions. To study the influence of lipids and 
inflammation on cardiac function, specialized hemodynamic measurements were 
performed in mice. This chapter offers a general introduction to heart physiology and 
pathophysiology as well as to lipids and inflammation, two effectors of CVD that are 





A well-functioning heart is essential for life as it pumps oxygen-rich blood with life-
maintaining nutrients via the circulation to every part of the body. The blood flow 
originates by the coordinated contraction of the four chambers of the heart; two superior 
atria and two inferior ventricles. Via the right-sided cardiac chambers deoxygenated 
blood is pumped into the pulmonary circulation where it is enriched with oxygen. The 
left chambers of the heart pump blood into the systemic circuit. When left ventricular 
pressure is plotted as a function of its instantaneous volume, a pressure-volume loop (PV-
loop) is generated, describing the function of the left ventricle (LV) during the different 
phases of one contractile cycle. These include a: filling phase, isovolumic contraction, 
ejection phase and isovolumic relaxation (see figure 2; upper panel). 
The first phase in the cardiac cycle is passive filling of the LV (A), when blood flows 
from the atrium to the ventricle as a result of the atrial-ventricular pressure gradient. A 
second active ventricular filling is established by atrial contraction thereby increasing 
the atrial pressure and thus re-establishing a pressure gradient between the atrium and 
ventricle. The end-diastole (B), is the point where the ventricular volume is maximal, 
just prior to activation of the myocardium. Then isovolumic contraction takes place (C). 
After mitral valve closing, the ventricular chamber gradually develops sufficient pressure 
that exceeds the pressure in the aorta, thereby opening the aortic valve (D), followed 
by active ejection of the blood from the ventricular chamber into the aorta (E). Once 
the LV pressure drops below the aortic pressure the aortic valve closes as a result (F). 
This is described as the end-systolic point, with the lowest ventricular volume and a 
high ventricular pressure. During the subsequent isovolumic relaxation period (G) the 
ventricle muscle relaxes. When the LV pressure falls below atrial pressure the mitral 
valve opens (H), thereby starting the filling phase of the LV. From this loop a range 
of indices can be derived characterizing systolic and diastolic function of the LV and 
general hemodynamic indices (figure 2; middle and lower panel). 
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1The following parameters can be obtained from PV-loops (figure 2):
Systolic function: 
  end-systolic pressure (ESP): pressure in the ventricle at the end of systole, approximates 
mean arterial blood pressure
  end-systolic volume (ESV): blood volume remaining in the ventricle at end of systole 
(normally approximately the end of ejection)
  ejection fraction (EF; calculated as [EDV-ESV]/EDV): fraction of blood ejected from 
a ventricle per heartbeat, under normal circumstances ejection fraction is >60%
  dP/dtMAX: maximum rate of pressure change in the LV, characterizing cardiac 
contractility 
  end-systolic elastance (EES): the slope of the end-systolic pressure-volume relation 
(ESPVR). An increased slope as well as a leftward shift of the ESPVR indicates an 
increase in contractility 
Figure 2 Illustrations of left ventricular PV-loops. 
 
Upper panel: PV-loop of a regular cardiac 
cycle; see text for comprehensive explanation. 
 
Middle panel: Calculations of end-systolic pressure–
volume relation (ESPVR) and end-diastolic 
pressure–volume relation (EDPVR). A cluster 
of PV-loops under different loading conditions 
reveals the ESPVR and the EDPVR. The slope of the 
ESPVR indicates the end-systolic elastance (EES). 
 
Lower panel: Illustration of a PV-loop from a dilated 
and failing left ventricle. A decrease in contractility is 
indicated by a decreased slope and a rightward shift of 
the ESPVR. The end-diastolic stiffness has increased 
indicated by the slope of the EDPVR. The left ventricular 
distensibility has decreased indicated by the upward 
shift of the EDPVR. Furthermore, LV performance 
has decreased indicated by decrease in the ventricular-
arterial coupling ratio (EES/EA). ESPVR, end-systolic 
pressure-volume relation; EDPVR, end-diastolic 





  end-diastolic pressure (EDP): pressure in a ventricle at the end of diastole, a measure 
of cardiac preload
  end-diastolic volume (EDV): blood volume at end of diastole at maximal stretch of 
cardiomyocytes prior to contraction (measure of preload)
  Tau: time constant of isovolumic exponential pressure decay during relaxation, 
measurement of LV relaxation
  -dP/dtMIN: minimal rate of pressure change in the LV 
  end-diastolic elastance (EED): the slope of the end-diastolic pressure-volume relation 
(EDPVR), representing the diastolic stiffness of the ventricle
General function: 
  heart rate (HR): number of heart beats per minute
  stroke volume (SV; calculated as EDV-ESV): volume of blood ejected from a ventricle 
at each heartbeat, during heart failure stroke volume usually decreased or maintained 
only at the expenses of substantially increased filling pressure
  cardiac output (CO; calculated as HRxSV): total blood volume expelled by a ventricle 
per minute
  stroke work (SW): external work performed by the ventricle by ejecting stroke volume, 
represented by the area within the PV-loop
  effective arterial elastance (EA; calculated as ESP/SV): index for afterload, load that the 
heart must eject blood against 
  EES/EA: ventricular-arterial coupling ratio, describes the coupling 
between LV performance and the systemic arterial system. Normal 
coupling ratio is approximately 1, the values decreases with heart failure 
Assessment of left ventricular function in mice
Humans and mice display a 99% gene similarity5, making mice suitable models for 
studying the function of human genes in health and disease. In addition, mice and rats 
are the most commonly used species for basic animal studies, as the understanding 
of their biology and genetics is well developed, breeding and housing are relatively 
inexpensive and a large number of specifically designed tools and techniques exist for 
this very purpose. 
To reach the objectives of the current research program, functional assessment of the 
heart is essential. Considering the small size of the mouse heart and the high heart rate 
(approximately 500 beats per minute), highly specialized techniques are required to 
assess hemodynamic and ventricular function in the intact mouse. Magnetic resonance 
imaging (MRI), echocardiography and invasive PV-loop measurements have become 
available for cardiac phenotyping of small animals. 
GEnERAl InTRoduCTIon
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1In this thesis, PV-loops by conductance catheter and transthoracic echocardiography were used to acquire cardiac function data. PV-loops are considered the gold standard in 
hemodynamic measurement, as they provide a direct volume signal and by combining 
these with LV pressure, pressure volume-relations can be obtained.6 In addition, 
the pressure volume-relations yield very sensitive and load-independent indices. A 
disadvantage is that PV-loop measurements are highly invasive as the catheter is inserted 
in the right carotid artery and positioned into the LV. As a result, these measurements 
are routinely performed in mice as study ending. In contrast, echocardiography is a 
safe and non-invasive measurement and is one of the most widely used imaging tools 
in cardiology.7, 8 It can be used relatively easy to obtain two dimensional movies and 
provides valuable information about cardiac chamber shape and size and allows tissue 
damage visualization. 
Metabolism of the heart 
Energy supply to the heart
Continuous contraction and relaxation of the heart results in a high energy demand 
by this organ. However, the heart has almost no internal energy reserves and thus 
has to produce energy (as adenosine triphosphate (ATP)) to maintain contractile 
function. Under normal conditions the heart preferably oxidizes fatty acids (FA), 
generating 70% of the cardiac energy demand. The remainder is covered by utilization 
of glucose (20-30%), lactate and ketones.9 If necessary, the heart can shift its substrate 
utilization preferences during changed substrate availability and certain pathological 
conditions.10 As de novo synthesis of FAs is low in heart tissue, the majority of FAs 
is derived from the circulation. FA uptake occurs via passive diffusion or via FA 
transporters (CD36/FATP)11 by the cardiomyocytes which represent 75% of the 
cardiac cells and are the main site for fat oxidation.12 After several modification 
steps FAs undergo β-oxidation yielding acetyl CoA, which subsequently enters the 
Krebs cycle and result in nicotinamide adenine dinucleotide hydrogen (NADH) 
and flavin adenine dinucleotide hydrogen (FADH2) production, which are both used 
by the electron transport chain to generate ATP. Glucose is taken up via the glucose 
transporter (GLUT) and converted via the glycolysis pathway to acetyl CoA. Similar to 
FA derived Acetyl CoA, glucose derived Acetyl CoA is further processed in the Krebs 
cycle and electron transport chain. Since glucose utilization results in less production 
of ATP per carbon molecule, FAs are the preferred substrate in the aerobic heart. 
Oxygen supply to the heart
To maintain adequate ATP concentrations in the heart, aerobic production of ATP is 
necessary since insufficient energy is produced in anaerobic conditions. Consequently, a 
constant supply of oxygen is essential to sustain cardiac function and viability.13 The heart 
consumes large amounts of oxygen, especially compared to other organs. Under basal 
conditions the heart uses ~5–10 mL O2/min/100g tissue, which can increase to more 
than ~70 mL O2/min/100g myocardial tissue during heavy exercise. This is significantly 
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more than that consumed by the brain (~4 mL O2/min/100g tissue) or skeletal muscle 
(~0.2 mL O2/min/100 g) tissue under basal conditions.
14
Adequate cardiac oxygen supply is achieved via the coronary circulation, as the 
myocardium itself is too thick to allow direct oxygen delivery from the chambers. 
Blockage of a coronary artery, for example by thrombus formation, therefore has major 
implications for the oxygen supply to the surrounding myocardium. 
Pathophysiology
Atherosclerosis
Atherosclerosis is a complex, chronic and progressive inflammatory disorder which is 
characterized by thickening and hardening of medium-sized and larger arteries. Lipids, 
smooth muscle cells (SMC) and immune cells inside the vessel wall accumulate, resulting 
in narrowing of the blood vessel. Rupture of an advanced atherosclerotic lesion can lead 
to an MI, one of the most common causes of death in the Western world.15
The first step in the development of atherosclerosis is endothelial dysfunction, which 
has an impact on the cellular structure and function of the endothelium. Dysfunction 
can, among others, be caused by hypercholesterolemia, cigarette smoking, hypertension, 
diabetes mellitus or infections.15, 16  As a consequence of the endothelial dysfunction, 
the vessel wall expresses adhesion molecules, such as vascular cell adhesion molecule 
(VCAM)-1, intercellular adhesion molecule (ICAM)-1 and E-selectin. Leukocytes, like 
monocytes and T-cells are attracted from the circulation by adhesion molecules and 
migrate through the endothelial layer into the intima via monocyte chemoattractant 
protein-1 (MCP-1).17, 18 Monocytes differentiate into macrophages upon migration 
into the sub-endothelial space, where the macrophages start to ingest modified lipids, 
resulting in lipid-rich macrophages or foam cells. The foam cells excrete cytokines and 
chemokines that attract and activate additional immune cells, thereby amplifying the 
intralesional inflammatory response.19 Lesions consisting of macrophage foam cells and 
T-cells are the earliest type of lesions, the so-called fatty streak. However, these lesions 
do not result in clinical symptoms.20 At this stage the development of the lesion is still 
reversible, since cholesterol can be exported to cholesterol acceptors as high density 
lipoprotein (HDL) and lipid-poor apoA1 via cholesterol transporters like ATP-binding 
cassette transporter A1 (ABCA1).15 Inflammatory stimuli activate SMC to migrate into 
the intima leading to the formation of an advanced lesion.16, 20 In the lesion SMC are able 
to take up cholesterol and thereby contributing to the foam cell formation. Furthermore, 
they secrete extracellular matrix components like elastin and collagen which form an 
elastic fibrous cap covering the lesion. This cap forms a barrier between the circulating 
blood on one side and the content of the lesion on the other side, consisting of a core of 
extracellular lipid, necrotic material derived from death foam cells, macrophages, SMC, 
T-cells and other inflammatory cells.16 
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1The lesion stability depends on the thickness of the fibrous cap and on the lesion composition. Matrix metalloproteinases, produced by foam cells, degrade the 
extracellular matrix, thereby reducing the stability of the atherosclerotic lesion.20 In 
addition, a large number of macrophages and a relative high lipid content of the lesion 
also diminish the stability. Lesion instability can lead to rupture, thereby releasing pro-
thrombotic material into the bloodstream which triggers thrombus formation. This can 
result in an occlusion of a blood vessel which may lead to an MI or stroke.
It is important to emphasize that atherosclerotic lesions in mice are not prone to rupture, 
although mouse lesions resemble human lesions in several aspects. As a consequence, 
atherosclerotic mouse models do not develop MIs and in order to study the effects of 
an MI an alternative intervention is required. The model of permanent ligation of the 
left anterior descending (LAD) artery is often used to induce MI in mice as well as the 
ischemia/reperfusion model.21 
Myocardial infarctions
Occlusion of a coronary artery interrupts the blood flow towards the downstream 
myocardial tissue, causing ischemia and initiating tissue damage and starvation. Damage 
can be reduced by timely reperfusion of the tissue, which is the preferred clinical therapy 
after an MI. Prolonged occlusion of the coronary arteries initiates a slow cascade of 
events which transforms the endangered zone in order to maintain cardiac output.22 
This process is usually completed in 6 to 8 weeks in humans and is referred to as infarct 
healing or LV remodeling. 
Infarct healing can be divided into three, somewhat overlapping, stages: inflammation, 
proliferation and maturation.23 In the first stage apoptosis occurs, which is a major 
contributor to cardiomyocyte loss.24 Subsequently, danger signals are released by 
the necrotic cardiomyocyte, thereby activating the innate immune mechanism, e.g. 
complement system and Toll-like receptors (TLR), causing an intense inflammatory 
response.25, 26 Chemokines and cytokines are released, resulting in leukocyte infiltration 
and clearance of necrotic cells and debris in the infarcted zone. After approximately 3 
days the acute inflammatory response diminishes, marking the onset of the next stage. 
Concomitantly, activated macrophages produce growth factors and cytokines leading 
to the formation of granulation tissue which replaces the dead cardiomyocytes.25 
Proliferation of fibroblasts deposits a network of extracellular matrix and collagen, 
thereby strengthening the wound.27 Furthermore, neovascularization realizes renewed 
blood supply to the infarcted area, via new vessels derived from pre-existing blood 
vessels or from migrating endothelial cells.28 As repair proceeds, in the maturation stage, 
fibroblasts undergo apoptosis and a collagen-rich scar is formed. 
The ischemic inflammatory response is a critical factor in the balance between cardiac 
repair and adverse LV remodeling. Experimental models suggest that prolonged or 
expanded inflammation or a non-controlled infarct healing result in adverse remodeling 
of the infarcted heart.29, 30 For instance, both TLR2 and TLR4 have shown to play an 
unfavorable role in LV remodeling, since disrupted TLR4 signaling prevents adverse 
remodeling and TLR2 inhibition reduces ischemia/reperfusion injury and improves 
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cardiac function.31-33 Although morbidity after an MI is decreasing due to improved 
reperfusion strategies and medical therapy, 5-year morbidity remains high. Therefore, 
strategies to interfere with inflammatory pathways after MI are intensively studied. 
Metabolic dysfunction
Lipid metabolism 
FAs are preferentially used as energy source by the heart and derive from our diet or are 
produced de novo in the liver. Since FAs themselves are cytotoxic, they are transported 
through the circulation either bound to serum albumin or incorporated as triglycerides 
(TG) in lipoproteins. TG-derived FAs are also a main source of energy for activity of 
skeletal muscle, for heat production by brown adipose tissue or for storage in white 
adipose tissue (WAT) for usage at a later point in time. In addition to TGs, cholesterol 
is also an essential lipid for many of our body’s functions. Cholesterol is of critical 
importance for maintenance of cellular membranes and serves as a precursor for steroid 
hormone and bile acid synthesis.34, 35 
Lipids are insoluble in an aqueous environment like blood, therefore they are transported 
in the circulation in water-soluble spherical particles called lipoproteins. Lipoproteins 
consist of a lipid-rich core of neutral lipids containing TGs and cholesteryl esters (CE), 
surrounded by a single layer of phospholipids (PL), free cholesterol and proteins called 
apolipoproteins. The latter are necessary for lipoprotein formation, modulation of 
enzymes and proteins, and act as ligands for receptor-mediated binding.
Based on their composition and size, lipoproteins can be divided in several subclasses: 
chylomicrons, very low-density lipoproteins (VLDL), intermediate-density lipoproteins 
(IDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL).36 The two 
particles with the lowest density, chylomicrons and VLDL, contain mainly TGs, whereas 
LDL and HDL particles mainly transport cholesterol in the form of CE. The metabolism 
of these lipoproteins and the subsequent distribution and cellular processing of TG-
derived FA is described in the following sections and a schematic overview is depicted 
in figure 3.
After a meal, in the postprandial state, dietary TGs are lipolyzed by pancreatic lipases 
into 2-monoacylglycerol and FA. Together with dietary cholesterol these components 
are taken up by the intestinal cells and assembled into chylomicrons. These particles are 
transported from the lymph to the blood circulation, where TG in the core of the particle 
is hydrolyzed into glycerol and FA by endothelium-bound lipoprotein lipase (LPL).37 
FAs are taken up by the underlying peripheral tissue as an energy source for activity, 
thermogenesis or for storage.38 The chylomicron-remnant particles, which are relatively 
enriched in CE and apolipoprotein E (apoE), are removed from the circulation by the 
liver e.g. via recognition of apoE by the LDL receptor (LDLr) and the LDLr-related 
(LRP).39 Since remnant clearance results in the uptake of dietary cholesterol by the liver, 




In the fasted state no food is taken up in the intestines and the body’s energy supply 
rely on the production of TG-rich VLDL particles by the liver. These TG-rich VLDL 
particles serve as main donor of TG-derived FA for extrahepatic tissues. Cholesterol 
and FA, derived from WAT or de novo synthesis, are packed as TG into VLDL particles 
in the hepatocytes of the liver.40 They are secreted into the circulation and, similarly to 
chylomicrons, the core TGs are hydrolyzed by LPL. The depletion of TG from the VLDL 
particle results in the formation of VLDL remnants. These remnant particles are partly 
cleared by the liver, while the remaining particles undergo further lipolysis that results in 
the formation of LDL particles. LDL particles are relatively enriched in CE as compared 
to TG and apolipoprotein B (apoB) is its  primary apolipoprotein. The majority of LDL 
particles are taken up from the plasma by the LDLr, while the remainder is taken up by 
extrahepatic tissues where the CE are used for e.g. maintenance of cellular membranes. 
High levels of apoB-containing lipoproteins (VLDL, VLDL remnants and LDL) can lead 
to deposition of these lipoproteins in the vessel wall, where they are modified and taken 
up by macrophages. This is the initial step of atherosclerosis development. 
In contrast to apoB-containing lipoproteins, HDL is generally believed to have anti-
atherogenic properties. This is attributed to its involvement in reverse cholesterol 
transport (RCT). In RCT, excessive cholesterol from the periphery is transported 
via the plasma to the liver. In the liver, HDL-derived cholesterol can be recycled or 
converted to degradation products like bile acids which are excreted via the bile into 
the intestine and feces. ApoA1, the major HDL apolipoprotein, is synthesized in the 
Figure 3  Schematic representation of lipoprotein metabolism. See text for explanation. 
ABCA1, ATP-binding casette transporter A1; ABCG1, ATP-binding casette transporter G1; 
CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FFA, free fatty acids; HDL, high 
density lipoprotein; HL, hepatic lipase; LCAT, lechitin-cholesterol acyltransferase; LDL, low 
density lipoprotein; LDLr, LDL receptor; LPL, lipoprotein lipase; LRP, LDLr related protein; PL, 
phospholipid; PLTP, phospholipid transfer protein; SR-B1, scavenger receptor B1; TG, triglycerides; 
VLDL, very low density lipoprotein
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liver and the intestine and is secreted into the plasma in complex with PL.41 The apoA1-
rich nascent HDL particle is subsequently further lipidated with PL and cholesterol 
from peripheral cells, through the involvement of the cholesterol transporter protein 
ABCA1. The initial lipidation of HDL via ABCA1 is a crucial step in HDL formation 
since patients with ABCA1 gene mutations as well as mice lacking ABCA1 have very 
low HDL levels.42,43 The acquired cholesterol is esterified by lecithin-cholesterol acyl 
transferase (LCAT) generating spherical mature HDL. This mature particle can take 
up PL from chylomicrons and VLDL particles, via interaction with the phospholipid 
transfer protein (PLTP). In addition, loading with cholesterol from the periphery 
can occur via Scavenger Receptor B1 (SR-B1) and/or another ABC-transporter, 
ABCG1. The accumulated CE are stored in the core of the HDL particle and these 
CE can be taken up directly by the liver via SR-B1.41 Indirect uptake of CE can take 
place after exchange of CE from HDL with TGs from apoB-containing lipoproteins 
and this transport is facilitated by the cholesteryl ester transfer protein (CETP).44 
Importantly, CETP is not expressed in rodents, except for hamsters, and therefore in 
mice there is no bidirectional exchange of CE and TG between HDL and (V)LDL. 
Cholesterol and triglycerides as risk factors for CVD
Numerous clinical studies have shown that both elevated LDL-cholesterol levels and 
low HDL-cholesterol levels correlate with an increased CVD risk.45-48 Several anti-
atherogenic drugs have been developed aimed at reduction of LDL-cholesterol levels in 
plasma. Statins (or HMG-CoA reductase inhibitors) are the most widely used drugs that 
efficiently lower plasma (V)LDL-cholesterol levels, leading to a decreased cardiovascular 
morbidity and mortality.49 However, a substantial residual cardiovascular risk remains, 
thereby indicating that additional treatment is required.47, 50 One of the experimental 
strategies aims at increasing the anti-atherogenic HDL-cholesterol concentration. It is 
thought that the removal of excess cholesterol from macrophages and foam cells by HDL 
is one of the important mechanisms underlying the atheroprotective property of HDL. 
Increase in HDL levels can be achieved through inhibition of CETP. As described above, 
CETP facilitates the transfer of CE from HDL to (V)LDL in exchange for TGs. Via this 
mechanism, cholesterol in the anti-atherogenic HDL particles is lowered whereas it is 
increased in the atherogenic (V)LDL particles. Lowering CETP activity can be achieved 
by using drugs such as anacetrapip and niacin.51, 52
In addition to cholesterol, elevated levels of plasma TGs, known as hypertriglyceridemia, 
are also associated with an increased risk for CVD. It has been debated to which extent 
TG independently promote CVD risk53. Previous population studies showed that high 
TG levels are inversely related with HDL-cholesterol levels. Thus, an adjustment of HDL-
cholesterol attenuates the relationship between TG and CVD. Nevertheless many clinical 
studies provided evidence that increased TG levels act as an independent risk factor.54-57 
 
Ectopic fat deposition
In a healthy person, FA that are not directly used as energy source, are stored in WAT for 
usage at a later point in time. Through a tightly regulated process only a small portion 
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1of FAs are directed for storage to non-adipose tissue such as liver, pancreas, skeletal muscle, kidney and heart.58 Despite the ability of WAT to increase adipocyte cell size 
(hypertrophy) as well as cellular number (hyperplasia), the expandability of WAT is 
limited, particularly when the FA flux is increased over a long period of time.59 As a 
result, transportation of FAs towards the non-adipose tissue will be increased, leading to 
ectopic fat accumulation. While limited ectopic FA accumulation may be physiological, 
in pathological conditions, excess ectopic fat may disrupt cellular function probably 
via toxic intermediary metabolites like ceramides and diacylglycerol. This is believed 
to contribute to insulin resistance, non-alcoholic hepatosteatitis (NASH) or heart 
dysfunction.60, 61 
Metabolic inflammation and the innate immune system
Although the exact molecular mechanisms responsible for the activation of inflammatory 
pathways in obesity are still poorly understood, both adipose tissue and the liver are 
thought to be involved in the onset and development of metabolic inflammation. In 
obese subjects, expanded adipocytes secrete chemokines and cytokines, including 
tumor necrosis factor alpha (TNFα) and monocyte chemotactic protein-1 (MCP-1), 
resulting in the recruitment and activation of macrophages.62 These pro-inflammatory 
macrophages in turn produce large amounts of TNFα and interleukine-1ß thereby 
providing a negative feedback loop and further amplification of the inflammation.63 
Similar to adipose tissue, the liver also becomes inflamed during obesity, which is 
reflected by an increase in hepatic inflammation markers such as serum amyloid A and 
C-reactive protein and nuclear factor ĸB (NF-ĸB) activation in high-fat diet fed mice.64, 
65 In general, the consequent chronic low-grade systemic inflammation increases the risk 
for associated inflammatory diseases like atherosclerosis and type 2 diabetes mellitus.
TLRs, which are part of the innate immune system, are suggested to play an important 
role in the development of obesity, insulin resistance and atherosclerosis.66-68 Several 
studies demonstrated that saturated FAs exert pro-inflammatory effects through these 
receptors, particularly via the subtypes TLR2 and TLR4. TLRs are pattern-recognition 
receptors (PRRs) and are predominantly expressed on immune cells, like macrophages 
and dendritic cells, but have also been identified on non-immune cells such as adipocytes 
and cardiomyocytes. TLRs, of which 12 different types have been identified thus far, 
are expressed on the cell surface or in intracellular compartments.69 These PRRs detect 
microbial components and ‘danger’ signals released by injured host cells, thereby 
activating the immune system as a first line of defense.70 In mammals, ligand recognition 
by TLRs leads to recruitment of cytoplasmic myeloid differentiation factor (MyD)88, a 
universal TLR adaptor protein. MyD88 recruits proteins of the IRAK family and TRAF6, 
resulting in the phosphorylation and activation of the IKK complex. Finally, this process 
causes translocation of NFĸB to the nucleus and the transcription of pro-inflammatory 
cytokines (figure 4).71 
It is interesting to note that medium-chain FAs might serve as exogenous ligands for TLR2 
and TLR4, provoking a nutritionally or metabolically induced inflammatory response.72, 
73 The lipoid structures in bacterial membranes recognized by TLR2 (lipoteichoic acid, 
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(LTA)) and TLR4 (lipopolysacharide, (LPS)) share homology with endogenous lipids. 
Consequently, those TLRs can be activated by endogenous lipids and lipoproteins74, 
including oxidized LDL75, medium-chain FA component of LPS, as well as saturated 
FA.76 In vivo animal experiments demonstrated that inhibition of TLR4 in mice resulted 
in protection from acute infused lipid induced insulin resistance73, and also protection 
against diet-induced obesity has been reported.68, 77 Similar findings, including improved 
insulin sensitivity78 protection against died-induced adiposity and hepatic steatosis79, are 
reported for TLR2 knock-out models. Furthermore, deletion of TLR2 or TLR4 reduces 
atherosclerotic lesion development in murine models.80, 81
Figure 4  TLR2 and TLR4 mediated signaling pathway. Ligand recognition by TLR2 or 
TLR4 leads to the activation of MyD88 and the IRAK family, which in turn activates TRAF6. This 
results subsequently in the phosphorylation and activation of the IKK complex allowing NFĸB to 
translocate into the nucleus. LTA, lipoteichoic acid; LPS, lipopolysaccharide,; IRAK, Interleukin-1 




The studies in this thesis are performed to provide additional and improved insight 
into the effects and interplay of dietary lipids and metabolic inflammation on cardiac 
performance in the presence or absence of atherosclerosis and myocardial infarctions. 
All studies are performed in mice and during the beginning of this PhD project little 
was known about the effect of gender on the relationship between diet-induced obesity, 
lipid metabolism and cardiac function in mice. Therefore, the effects of LV function after 
intermediate and long-term high-fat diet feeding in male and female mice are studied in 
Chapter 2. Subsequently, in Chapter 3 the question is addressed if high-fat diet feeding 
results in more severe cardiac dysfunction after an MI, due to an increased inflammatory 
response induced by the dietary lipids, as compared to low-fat diet feeding. Chapter 4 
also examines effects after an MI, as the role of ABCA1 after an infarction is studied. 
Chapter 5 focuses on the role of RP105, the physiological inhibitor of TLR4-signalling, 
in the process of LV remodeling after an MI. These effects are studied to investigate 
the role of TLR4 in cardiac function after an infarction. In addition, Chapter 6 reports 
on the direct effects of TLR2 and TLR4 deficiency on cardiac function after high-fat 
diet feeding. In Chapter 7, it is investigated whether treatment with the LDL lowering 
drug simvastatin, in combination with the HDL raising drug niacin, leads to beneficial 
effects regarding plasma lipids and atherosclerotic development. Chapter 8 provides a 
summary of the results obtained from the studies and discusses their implications.
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Gender-dependent effects of high-fat lard 
diet on cardiac function in C57Bl/6J mice
Abstract
Increased availability of fatty acids released from insulin-resistant adipose tissue may 
lead to excess fatty acid uptake in nonadipose organs, including the heart. Accumulation 
of toxic fatty acid intermediates may affect cardiac function. Our aim was to identify to 
which extent high-fat diet feeding leads to alterations in cardiac function and whether 
this depends on gender and/or duration of high-fat diet feeding. 
Male and female C57Bl/6J mice (n = 8 per group) of 12 to 16 weeks old were fed a low-fat 
(10% energy) or high-fat (45% energy) lard diet for 6 or 12 weeks. Plasma lipid levels, 
echocardiography, and left ventricular pressure–volume relationships were obtained at 
2, 1, and 0 weeks before termination, respectively. 
In both male and female mice, the high-fat diet increased body weight and plasma lipid 
content. At 10 weeks, significant increases were observed for plasma total cholesterol 
(males: +44%; females: +86%), phospholipids (+16% and +34%), and triglycerides 
(+27% and +53%) (all p< 0.001). In male mice, but not in female mice, the high-fat diet 
significantly affected cardiac function at 12 weeks with increased end-systolic volume 
(25.4 ± 6.2 vs. 17.0 ± 6.7 μL, p< 0.05), increased end-systolic pressure (72.1 ± 6.9 vs. 
63.6 ± 6.9 mm Hg, p< 0.01), and decreased ejection fraction (61.2% ± 4.5% vs. 68.1% ± 
3.7%, p< 0.01), indicating reduced systolic function. Multiple linear regression analysis 
indicated a significant diet–gender interaction for end-systolic volume and ejection 
fraction. 
In conclusion, high-fat diet feeding increased body weight and plasma lipid levels in 





A drastic increase in caloric intake combined with lifestyle changes and immobilizing 
technical innovations have caused an unprecedented epidemic of obesity in the western 
world. It is assumed that obesity-related heart disease, in combination with diabetes, 
is predominantly related to coexisting disorders such as coronary artery disease and 
hypertension.1, 2 However, studies suggest that increased myocardial lipid deposition, 
resulting from fatty acid (FA) overload of cardiac myocytes, is directly associated with 
cardiac dysfunction.3, 4 
Oxidation of long-chain FAs by mitochondrial β-oxidation supplies most of the energy 
for the heart under normal conditions.5 However, the uptake of FAs by the heart in 
relation to FA oxidation is not always tightly controlled, which may lead to excessive 
storage of FAs as triglycerides in cardiac myocytes. These myocardial triglyceride stores 
per se are probably inert, but triglycerides are involved in hydrolysis-reesterification 
cycles, yielding FAs, fatty acyl coenzyme A esters, and diacylglycerol as intermediates. 
Accumulated cardiac FAs and metabolites are described in several diseases like diabetes 
and obesity 6-9, as well as in the ischemic and hypertrophic heart 10, 11, and can result in 
cardiac dysfunction and cell damage. 
In humans, gender-dependent differences in myocardial function are reported in certain 
conditions. For instance, following ischemia, males as compared with females have 
decreased diastolic function, cardiac contractility, and an increased mortality risk.12 
Furthermore, evidence is accumulating that gender differences also influence metabolic 
changes of the heart in presence of obesity, insulin resistance, and the related lipotoxicity 
and cardiac steatosis. Likewise, in animal models of myocardial infarction and 
hypertension, males are more prone to develop heart failure 13 and detrimental effects of 
lipotoxicity were shown in rodent models14.w However, the impact of gender on the effect 
of lipotoxicity is not fully understood. Earlier, large gender differences have been observed 
in mice lacking the PPARα receptor, a nuclear receptor controlling lipid utilization. A 
combination of PPARα-deficiency and pharmacological carnitine palmitoyltransferase 
(CPT1) inhibition resulted in extreme myocardial lipid accumulation leading to death 
in 100% of the males but only in 25% of the females.15 Despite the fact that gender effects 
are relevant in studies on cardiac pathophysiology, little is known about the effect of 
gender on the relationship between diet-induced obesity, lipid metabolism, and cardiac 
function. 
Therefore, the aim of our study was to investigate to what extent high-fat diet (HFD) 
feeding as compared with low-fat diet (LFD) feeding leads to alterations in cardiac 
function in a widely used C57Bl/6J mouse model, and whether this depends on gender 
and/or duration of HFD feeding. We used pressure-volume (PV) conductance catheters 
to obtain accurate assessment of left ventricular performance. This PV-loop method is 
the gold standard for assessing intrinsic myocardial function in humans and animals.16 
Our data indicate a gender-specific effect of HFD feeding on cardiac function: in 
particular we observed a more pronounced effect on systolic function in male vs. female 
mice, despite less pronounced effects on plasma lipids.
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group gender diet echo cardiography
1 male low fat x x x x pv-loops
2 high fat x x x x
3 female low fat x x x x
4 high fat x x x x
5 male low fat x x x x x
6 high fat x x x x x
7 female low fat x x x x x
8 high fat x x x x x
week 0 1 2 3 4 5 6 7 8 9 10 11 12
Materials and methods 
Animals and study protocol
The experiments were performed in 12- to 16-week-old male and female C57Bl/6J mice (Charles 
River, Maastricht, the Netherlands). Mice were housed in a temperature and humidity-controlled 
room on a 12-h light / 12-h dark cycle with ad libitum access to water and food. In all animals, the 
specific diets were started in week 0 and continued throughout the protocol. Body weights were 
measured weekly. The experimental protocol to study the effects of gender, dietary fat content, and 
diet duration is shown schematically in figure 1. Briefly, we studied 8 groups of mice (8 animals 
each). Measurements of plasma lipids, echocardiography, and PV-loops were performed in weeks 
4, 5, and 6 (groups 1–4) and in weeks 10, 11, and 12 (groups 5–8), respectively. At the end of 
the experiments the animals were sacrificed. The protocol was approved by the Animal Ethics 
Committee from the Leiden University Medical Center and conformed to the Guide for Care and 
Use of Laboratory Animals (NIH publication no. 85–23, revised 1996). 
Diets
Starting in week 0, all animals received either a lard-based LFD or HFD for 6, 10, or 12 weeks. The 
diets were obtained from Research Diets Inc. (Wijk bij Duurstede, the Netherlands) and supplied 
ad libitum. As a percentage of the total energy, the LFD contained 10% fat (4.5% lard and 5.5% soy 
bean oil) and 70% carbohydrate (34.5% energy from sucrose, 32% from corn starch, and 3.5% from 
maltodextrin). The HFD contained 45% energy from fat (39.5% lard and 5.5% soy bean oil) and 




Blood was sampled after a 4-h fast (09.00 to 13.00 h) via tail vein bleeding and was collected 
in potassium EDTA coated plastic tubes (Starstedt, Nümbrecht, Germany). Total plasma levels 
of cholesterol, triglyceride, phospholipid, and glucose were measured by using commercially 
available kits and standards according to the instructions of the manufacturer (kit no. 1489232, 
11488872, and 101140; Roche Diagnostics, Mannheim, Germany; and 2942 Instruchemie, Delfzijl, 
the Netherlands). Plasma insulin concentrations were determined by ELISA (Crystal Chem Inc., 
Downers Grove, Ill., USA). 
Echocardiography
Transthoracic echocardiography was performed using a VisualSonics Vevo 770 with a 30 MHz 
ultrasound transducer (VisualSonics, Toronto, Ont., Canada). During examination, mice were 
anesthetized with 2% inhaled isoflurane and placed on a temperature-controlled platform. 
Electrocardiogram, heart rate (HR), and respiratory rate were monitored continuously and 
recorded during the imaging process. Parasternal long axis and short axis images were recorded 
in all animals. Analysis of the data was performed with software provided by VisualSonics. Briefly, 
left ventricle (LV) internal diameters at end-diastole and end-systole (DED, DES) were obtained 
from short-axis M-mode images as average of 3 consecutive cardiac cycles. M-mode derived end-
diastolic volume (EDV) and end-systolic volume (ESV) were estimated as 17:
EDV = ((7.0 / (2.4 + DED)) x DED
3
 ESV = ((7.0 / (2.4 + DES)) x DES
3
Ejection fraction (EF) and cardiac output (CO) were calculated as:
 EF = 100% x (EDV – ESV) / EDV
 CO = HR x (EDV – ESV)
Left ventricular PV-loops
Hemodynamics and LV function indices were assessed by invasive PV-loops. Mice were 
anesthetized with an intraperitoneally injected mix of 6.25 mg·kg–1 body weight Ventranquil 
(Ceva Sante Animale, Naaldwijk, the Netherlands), 6.25 mg·kg–1 body weight Midazolam (Actavis, 
Hafnarfjordur, Iceland), and 0.3125 mg·kg–1 body weight Fentanyl (Hameln Pharmaceuticals, 
Hameln, Germany) diluted in sterile water. Thereafter the mice were placed supine under a 
surgical microscope on a temperature-controlled warming pad to maintain a normal body 
temperature. Via the right carotid artery a 1.2F PV catheter (FTS-1212B-4518, Scisense Inc., 
London, Ont., Canada) was placed into the LV. The catheter was connected to a Scisense ADV 
signal processor (Scisense Inc.) to generate high-fidelity pressure and volume signals. Positioning 
of the catheter was guided by online pressure and volume signals. On-line display and acquisition 
of the signals (2000 samples·s–1) was performed with a PowerLab 8/30 data acquisition system and 
LabChart Pro software (AD Instruments GmbH, Spechbach, Germany). Off-line data analysis was 
performed with custom-made software (CircLab, P. Steendijk). Raw LV volume signals obtained 
by conductance were calibrated by matching EF and CO with corresponding echocardiographic 
values. PV signals were acquired in steady state to obtain general hemodynamics via HR, stroke 
volume (SV), CO, and stroke work (SW). Effective arterial elastance (EA) was calculated as the 
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ratio of end-systolic pressure (ESP) and SV.18 Systolic LV function was quantified by ESP, ESV, 
EF, and maximal rate of pressure increase (dP/dtMAX). In addition, we determined end-systolic 
elastance (EES) as a load-independent index of intrinsic LV function, using a validated single-beat 
approach.19 Ventricular-arterial coupling was quantified as EES/EA.
20 Diastolic LV function was 
assessed by end-diastolic pressure (EDP), EDV, relaxation time constant τ, and the maximal rate 
of pressure decline (–dP/dtMIN). Intrinsic LV diastolic function was quantified by end-diastolic 
stiffness (EED) (1/compliance) and the diastolic stiffness constant (KED). Thus, all presented 
hemodynamic data were obtained from invasive PV loops and echocardiographic volumes were 
used to calibrate the conductance-derived volumes. 
Statistical analyses
Results for body weight, plasma lipids, insulin and glucose levels, and cardiac function are shown 
as means ± SD and were compared using unpaired t-tests and DEXA scan data followed by a 
Tukey’s multiple comparison test (SPSS for windows 17.0, SPSS Inc., Chicago, IL, USA). 
To investigate the effects of gender, and type and duration (time) of the diet intervention, and 
in particular the interaction between these factors, the data were submitted to a multiple linear 
regression model: 
Y = AO + AG x G + AD x D + AT x T+ AGD x G x D + AGT x G x T + ATD x T x D
In this model, Y represents the independent measurement variable, G codes the gender (female: G 
= –1, male: G = 1), D the type of diet (LFD: D = –1, HFD: D = 1), and T codes the diet intervention 
duration (6 weeks: T = –1, 12 weeks: T = 1). By using effects coding, coefficient AO provides the 
overall mean value of Y; AG, AD, and AT are the magnitude of the main effects; and AGD, AGT, and ADT 
are the magnitude of the corresponding interactive effects.21 The p values of the various coefficients 
indicate whether the corresponding effects are statistically significant. Grubb’s test for detecting 
outliers was used to identify and exclude outliers. p< 0.05 was considered significant. All data are 
presented as means ± SD. 
Results
HFD feeding increases body weight in males and females 
To determine the effect of duration of HFD feeding on cardiac function, male and female 
mice underwent diet intervention for 6 or 12 weeks. All male and all female groups had 
similar body weights at the start of the study (figure 2). Weekly monitoring of body 
weight showed that HFD feeding gradually increased body weight as compared with 
LFD feeding, the difference reached statistical significance from 5 weeks onwards for 
males and from 4 weeks onwards for females (not shown) and remained significant until 
the end of the study. After 6 weeks, body weight was increased for males by 19% ± 8% 
in the HFD group vs. 5% ± 2% in the LFD group (p< 0.01), which was similar to the 
females with increases of 18% ± 12% vs. 2% ± 5%, respectively (p< 0.05). After 12 weeks 
the difference between the HFD and LFD groups was more pronounced with 32% ± 
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10% vs. 5% ± 3% for the males (p< 0.001) and 32% ± 15% vs. 7% ± 2% for the females, 
respectively (p< 0.01). HFD-induced body weight gain was not significantly different 
between males and females after 6 and 12 weeks of diet intervention.
HFD feeding increases plasma lipids in males and females
After 4 and 10 weeks, blood samples were obtained and plasma levels of total cholesterol, 
phospholipid, and triglyceride levels were determined (figure 3). After 4 weeks of HFD 
feeding, total cholesterol levels were significantly increased in males (+31%, p< 0.05) and 
females (+55%, p< 0.001) as compared with the LFD groups. Furthermore, after 4 weeks 
of HFD feeding, phospholipid levels were increased in females only (+20%, p< 0.01) as 
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Figure 2 Effect of diet intervention on body weight. Male and female C57Bl/6J mice were 
fed a low-fat diet (LFD) or high-fat diet (HFD) for 6 weeks (A) or 12 weeks (B). Body weight was 
measured at baseline and at the end of dietary intervention. Values represent means ± SD (n=8 per 
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Figure 3 Effect of diet intervention on plasma lipids. Male and female C57Bl/6J mice were fed 
a low-fat diet (LFD) or high-fat diet (HFD) for 6 weeks or 12 weeks. Plasma levels of cholesterol 
(A), phospholipids (B) and triglycerides (C) were measured at 4 and 10 weeks, respectively. 
Values represent means ± SD (n=7-8 per group). *p<0.05, **p<0.01, ***p<0.001, compared to the 
corresponding LFD group.
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both genders. After 10 weeks, all plasma lipid parameters for both males and females were 
significantly increased in the HFD group in comparison with the corresponding LFD 
group: total cholesterol (males: +44%, p< 0.001; females: +86%, p< 0.001), phospholipids 
(males: +16%, p< 0.001; females: +34%, p< 0.01) and triglycerides (males: +27%, p< 
0.001; females: +53%, p< 0.001). 
HFD feeding increases insulin and glucose levels in males
To determine the effect of HFD feeding on glucose metabolism, insulin and glucose 
levels were measured in plasma. As compared with the LFD group, 4 weeks of HFD 
feeding did not increase plasma insulin levels in males and females, whereas glucose 
levels were mildly increased in only male mice (+28%, p=0.01) (figure 4). After 10 weeks 
of HFD feeding, insulin (+186%, p< 0.05) as well as glucose levels (+22%, p< 0.05) were 
significantly increased in males, while the levels for females fed a LFD and HFD were 
not different.
HFD feeding selectively impairs cardiac function in males
Cardiac function measurements, obtained by combined echocardiography and PV-
loops, are summarized in table 1. Based on the mean values for end-diastolic and end-
systolic pressures and volumes, schematic PV-loops were created for all groups and 
corresponding end-systolic and end-diastolic PV-relations were added, based on mean 
EES and EED values (figure 5).
When compared with LFD, in male mice, but not in female mice, the HFD significantly 


































Figure 4  Effect of diet intervention on plasma insulin and glucose levels. Male and female 
C57Bl/6J mice were fed a low-fat diet (LFD) or high-fat diet (HFD) for 6 weeks or 12 weeks. 
Plasma levels of insulin (A) and glucose (B) were measured at 4 and 10 weeks, respectively. Values 
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p< 0.05) and at 12 weeks with increased ESV (at 12 weeks: 25.4 ± 6.2 vs. 17.0 ± 6.7 μL, 
p< 0.05), increased ESP (72.1 ± 6.9 vs. 63.6 ± 6.9 mm Hg, p< 0.01), and decreased EF 
(61.2 ± 4.5 vs. 68.1 ± 3.7%, p< 0.01), indicating reduced systolic function after 12 weeks 
of HFD feeding (table 1).
Subsequently, we used a multiple linear regression model to test whether the gender, 
the type of diet, or the duration of the diet interventions had significant effects on the 
various hemodynamic indices. In addition to these main effects, this approach was used 
to statistically analyze possible interactive effects, in particular to investigate if the diet 
effects were statistically different for male and female mice. The statistical analyses are 
presented in table 2.
To explain the results of the multiple linear regression model, ESV is taken as an 
example. The coefficient A0 (16.66) yields the mean value of ESV averaged over all mice. 
Since pF, reflecting the overall significance of the model, was significant (p = 0.004), the 
investigated effects (gender, diet, and/or time) apparently significantly affected ESV. A 
significant effect was observed for gender (p = 0.032): the positive value of AG (1.72) 
indicates that the average ESV in male mice (G = 1) was higher (16.66 + 1.72 mL) than 
in females (G = –1, thus 16.66 – 1.72 mL). The significant (p = 0.017) coefficient AD 
indicates that average ESV in mice subjected to HFD (D = 1) was 1.94 mL higher than 
the overall mean, and for mice with a LFD (D = –1) ESV was 1.94 mL lower. Finally, 
the coefficient AGD indicates a significant (p = 0.012) gender-diet interaction (thus, the 
diet effect is different between males and females) with an additional 2.03 mL increase 
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Figure 5  Effect of diet intervention on pressure-volume loops and pressure-volume relations. 
Male and female C57Bl/6J mice were fed a low-fat diet (LFD) or high-fat diet (HFD) for 6 weeks 
(A) or 12 weeks (B). Pressure-volume loops were recorded in each mouse, and average pressure-
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First, calculations were made for the entire model fit for each hemodynamic index. The 
p values are presented in the Intercept block in table 2, reflecting the significance of this 
F test. The model showed significant effects for general hemodynamic function (SV, CO, 
SW, and EA), for systolic function (ESP, ESV and EES), and diastolic function (EDV and 
τ). 
Then, the effects of the separate factors, gender, type of diet, and duration of diet 
intervention were calculated for the affected indices. These calculations are presented 
in the main effects block in table 2. All these indices showed a significant gender effect 
(except SV, which just fell short of statistical significance at p = 0.052), with higher CO, 
SW, ESV, and EDV (indicated by the positive AG) and lower EA, ESP, EES, and τ (negative 
AG) in males (G = 1) compared with females (G = –1). The type of diet (coefficient AD) 
had a significant main effect on SV, SW, EA, (marginal, p=0.074) ESV, EES, and EDV. HFD 
feeding (D = 1) resulted in higher values for SV, SW, ESV, and EDV, and lower values 
for EA and EES. For none of the indices, diet duration (reflected by coefficient AT) had a 
significant main effect, indicating that for the full cohort (thus males and females on 
both LFD and HFD) there was no significant difference between 6 weeks and 12 weeks 
diet intervention.
Furthermore, the interaction of the different factors on the hemodynamic indices was 
calculated (interactive effects block, table 2). For several indices there was a significant 
interaction between gender and diet duration, indicating that either the effect of diet 
duration was different between males and females or the effect of gender was significantly 
different between the 6 and 12 weeks groups. This significant interaction was found for 
SV, CO, SW, EES, EDV, and τ. Furthermore, a significant interactive diet duration–diet 
type effect was found for ESP, whereas interaction between gender and diet type was 
present for ESV, EF, ESP, and EDV, the latter being only marginally significant.
Discussion
The present study was designed to investigate to what extent high-fat feeding leads to 
alterations in cardiac function in C57Bl/6J mice and whether this depends on gender 
and/or durations of high-fat feeding. The data obtained from both echocardiography 
and conductance catheter indicates that in male mice cardiac function was significantly 
altered by prolonged HFD feeding. HFD feeding also increased the insulin and glucose 
levels in males, implying an impaired glucose tolerance. These effects were absent in 
female mice despite their more pronounced elevation of plasma lipid levels, indicating 
the relevance of gender in this mouse model of obesity-related cardiac disease. 
Previous studies have provided strong evidence that excessive accumulation of 
triglycerides in cardiac myocytes of obese animals results in impaired cardiac function, 
as characterized by an increase in LV end-diastolic diameter and a significant reduction 
in cardiac contraction.4,22 In addition, increased triglyceride stores are found in cardiac 
myocytes of streptozotocin-induced diabetic rats 23, 24 and cholesterol-fed hyperlipidemic 
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rats 25. However, in these experiments it has never been investigated whether there is a 
difference in cardiac function between male and female mice, and thus whether gender 
choice of the animal model is of importance in future research of obesity-induced 
cardiac disease. 
We have now showed that 12 weeks of intervention with HFD induced obesity and 
increased plasma lipid levels in both male and female mice. However, insulin and 
glucose levels, as well as the effects on cardiac function, were only affected in males. The 
difference in heart function was observed by comparing the HFD fed animals to the 
corresponding LFD group, revealing that only in males systolic function was attenuated 
by feeding HFD for 12 weeks. This was evidenced by increased ESP and ESV and a 
reduced EF. The most pronounced effect of the diet is seen in males after 12 weeks as 
compared with 6 weeks of HFD feeding, which explains that a longer exposure results in 
a stronger effect. In females the HFD did not affect any cardiac function parameter after 
6 or 12 weeks. 
We further quantified the contributions of the separate factors and their interactions in 
a multiple linear regression model. This analysis (table 2) showed that gender had the 
most prominent effects on cardiac function. Also, these gender effects were not confined 
to a sole parameter, but were observed in most parameters for general, systolic, and 
diastolic indices. Fully consistent with previous studies in humans 26, 27, the males showed 
higher ventricular volumes and cardiac output and lower pressures, whereas EES and EA, 
representing intrinsic systolic function and afterload, respectively, were also both lower 
in males. Thus, lower systolic function is more prominent in males and is compensated 
by lower afterload resulting in maintained, or even higher, cardiac output compared with 
females. 
The multiple linear regression model further showed significant main effects of the diet 
intervention on cardiac function as indicated by increased volumes and a decreased EES. 
This is in line with studies in humans, which show an association between obesity and 
impaired cardiac function.1, 28 However, to our knowledge no studies investigated possible 
differences between men and women on this association. In our study, the overall effects 
of diet did not reach significance in all individual groups (table 1). In particular, the 
females showed limited or no changes in volume, whereas the changes were much more 
pronounced in males. This differential effect was indeed reflected by (nearly) significant 
interactive gender–diet effects on ESV (p= 0.012) and EVD (p= 0.068). With regard to 
EES, the overall significant decrease with HFD feeding was reflected by clear trends for a 
decrease in all individual groups, except for males after 12 weeks on HFD (table 1). This 
is interesting since in this particular group ESP and ESV both increased significantly, 
but EES remained unchanged. However, given the EES of approximately 2 mm Hg·μL
–1, 
the observed increase in ESV (8.4 μL) could not be explained merely by the higher ESP 
(8.5 mm Hg). Thus, in this group the end-systolic pressure-volume relation apparently 
showed a more or less parallel rightward shift (as shown in figure 5B), which is also 
associated with a decreased contractile state.29, 30 
Furthermore, while in our study HFD feeding resulted in a reduced systolic function, it 
had only minor effects on diastolic function. This is in contrast with earlier findings in 
GEndER-dEPEndEnT EffECTs of Hfd on CARdIAC funCTIon
43
2
literature, which showed that in obese patients mainly the diastolic function seemed to 
be affected.31,32 Although this discrepancy could be due to species differences, additional 
factors are likely to play a role. In particular, we studied the effect of a single isolated 
factor, the lard diet, whereas previous studies in humans are clearly multifactorial. 
A possible explanation for the different response in cardiac function between males and 
females may be a difference in susceptibility to obesity. Unpublished data from our group 
(S.A.A. van den Berg 2008, unpublished data) showed that sex hormones are the main 
contributing factors to obesity. We observed that HFD fed males compared with HFD 
fed females have a similar lean body mass, while males have an excessive increase in fat 
mass, which is not observed in females. Furthermore, ovariectomized females fed a HFD 
showed similar weight gain as males fed a HFD, which is explained by an increase in body 
fat. Conversely, male mice treated with estrogen fed a HFD showed a largely decreased 
weight gain, similar to HFD fed females, which is explained by a largely reduced body 
fat (supplementary figure S1). Collectively, these data indicate that sex hormones greatly 
influence HFD-induced increase in fat mass. 
Besides the effect of estrogen on obesity, differences in sex hormones in males and 
females themselves can also influence heart function. Cardiac protection by estrogen is 
reported in several studies in different species. Studies with gene-targeted mouse strains 
revealed protection against hypertrophy in females.33, 34 Also in male rats an accelerated 
progression to heart failure is reported after hypertension.35 Additionally, comparable 
results are observed in humans: in postmenopausal women estrogen replacement 
reduced the risk of cardiovascular events.36 Similarly, the survival rate after ischemic 
heart failure is higher in females compared with males.37 Thus, it can be speculated that 
gender differences in sex hormones and fat content may contribute to the alterations in 
cardiac function we observed in our study. 
Several limitation of our study should be mentioned. The number of animals investigated 
was relatively small (8 mice per group). Thus, potential group differences that currently 
showed clear trends could have reached significance with larger sample sizes. Assessment 
of PV relations was based on a single-beat estimates rather than load interventions. 
This approach has been validated, but its accuracy remains debated. We quantified 
afterload by effective EA based on ventricular parameters, rather than a more detailed 
but complex aortic impedance analysis based on aortic pressure and flow data. However, 
the present study was mainly focused on ventricular function and EA has been shown 
useful parameter to study ventricular-arterial coupling.38 Calibration of the conductance 
catheter was based on echocardiographic data obtained 4 days earlier, thus using a non-
simultaneous reference method. However, the same protocol was followed in all animals 
so this approach is unlikely to have influenced the observed effects or comparisons 
between groups. 
In conclusion, the present study indicates that high-fat feeding gradually increases body 
weights and plasma lipids levels in C57Bl/6J mice independent of gender. However, 
at 12 weeks cardiac function is impaired in male mice, but not in female mice. These 
results indicate a gender-specific effect of high-fat feeding on cardiac function in mice, 
independent of increased plasma lipids. This was confirmed by additional statistical 
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analyses, calculating the impact of the separate factors and their interactions. We thus 
propose that male mice are the preferred model to investigate effects of ischemia and 
drug treatments on cardiac function in a setting of diet induced obesity.
Acknowledgements
We thank C.J.A. van der Wee-Pals for her excellent technical assistance. This research 
was performed within the framework of CTMM, the Center for Translational Molecular 
Medicine (www.ctmm.nl), project PREDICCt (grant 01C-104), and was supported by 
the Netherlands Heart Foundation, Dutch Diabetes Research Foundation and Dutch 
Kidney Foundation. PCN Rensen is an Established Investigator of the Netherlands Heart 
Foundation (grant 2009T038).
References
 1  Abbasi F, Brown BW, Jr., Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, 
insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002 September 4;40(5):937-43.
 2  Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. 
Hypertension 2002 October;40(4):441-7.
 3  McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern 
Med 2006 April 4;144(7):517-24.
 4  Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human 
obesity. Proc Natl Acad Sci U S A 2000 February 15;97(4):1784-9.
 5  Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and 
failing heart. Physiol Rev 2005 July;85(3):1093-129.
 6  Lopaschuk GD, Tsang H. Metabolism of palmitate in isolated working hearts from spontaneously 
diabetic “BB” Wistar rats. Circ Res 1987 December;61(6):853-8.
 7  Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell 
Biochem 1998 March;180(1-2):53-7.
 8  Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc 
Natl Acad Sci U S A 1999 March 2;96(5):2327-32.
 9  Unger RH, Orci L. Lipotoxic diseases of nonadipose tissues in obesity. Int J Obes Relat Metab 
Disord 2000 November;24 Suppl 4:S28-S32.
 10  Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides/low high-density lipoprotein 
cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. Am Heart J 2003 
January;145(1):103-8.
 11  Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty 
heart, the most common unrecognized disease in America. Circ Res 2007 October 12;101(8):759-67.
 12  Luczak ED, Leinwand LA. Sex-based cardiac physiology. Annu Rev Physiol 2009;71:1-18.
 13  Jain M, Liao R, Podesser BK, Ngoy S, Apstein CS, Eberli FR. Influence of gender on the 
response to hemodynamic overload after myocardial infarction. Am J Physiol Heart Circ Physiol 2002 
December;283(6):H2544-H2550.
 14  Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010 March;1801(3):311-9.
GEndER-dEPEndEnT EffECTs of Hfd on CARdIAC funCTIon
45
2
 15  Djouadi F, Weinheimer CJ, Saffitz JE et al. A gender-related defect in lipid metabolism and glucose 
homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest 1998 
September 15;102(6):1083-91.
 16  Georgakopoulos D, Mitzner WA, Chen CH et al. In vivo murine left ventricular pressure-
volume relations by miniaturized conductance micromanometry. Am J Physiol 1998 April;274(4 Pt 
2):H1416-H1422.
 17  Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume 
determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am 
J Cardiol 1976 January;37(1):7-11.
 18  Kelly RP, Ting CT, Yang TM et al. Effective arterial elastance as index of arterial vascular load in 
humans. Circulation 1992 August;86(2):513-21.
 19  Ten Brinke EA, Klautz RJ, Verwey HF, van der Wall EE, Dion RA, Steendijk P. Single-beat 
estimation of the left ventricular end-systolic pressure-volume relationship in patients with heart failure. 
Acta Physiol (Oxf) 2010 January;198(1):37-46.
 20  Chantler PD, Lakatta EG, Najjar SS. Arterial-ventricular coupling: mechanistic insights into 
cardiovascular performance at rest and during exercise. J Appl Physiol 2008 October;105(4):1342-51.
 21  Slinker BK, Glantz SA. Multiple regression for physiological data analysis: the problem of 
multicollinearity. Am J Physiol 1985 July;249(1 Pt 2):R1-12.
 22  Christoffersen C, Bollano E, Lindegaard ML et al. Cardiac lipid accumulation associated with 
diastolic dysfunction in obese mice. Endocrinology 2003 August;144(8):3483-90.
 23  Heyliger CE, Scarim AL, Eymer VP, Skau KA, Powell DM. Characteristics of the myocardial PM-
FABP: effect of diabetes mellitus. Mol Cell Biochem 1997 November;176(1-2):281-6.
 24  Myrmel T, Forsdahl K, Larsen TS. Triacylglycerol metabolism in hypoxic, glucose-deprived rat 
cardiomyocytes. J Mol Cell Cardiol 1992 August;24(8):855-68.
 25  Hexeberg S, Willumsen N, Rotevatn S, Hexeberg E, Berge RK. Cholesterol induced lipid 
accumulation in myocardial cells of rats. Cardiovasc Res 1993 March;27(3):442-6.
 26  Celentano A, Palmieri V, Arezzi E et al. Gender differences in left ventricular chamber and midwall 
systolic function in normotensive and hypertensive adults. J Hypertens 2003 July;21(7):1415-23.
 27  Hayward CS, Kalnins WV, Kelly RP. Gender-related differences in left ventricular chamber 
function. Cardiovasc Res 2001 February 1;49(2):340-50.
 28  Vasan RS. Cardiac function and obesity. Heart 2003 October;89(10):1127-9.
 29  Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via 
pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart 
Circ Physiol 2005 August;289(2):H501-H512.
 30  Steendijk P, Baan J, Jr., Van der Velde ET, Baan J. Effects of critical coronary stenosis on global 
systolic left ventricular function quantified by pressure-volume relations during dobutamine stress in the 
canine heart. J Am Coll Cardiol 1998 September;32(3):816-26.
 31  Fischer M, Baessler A, Hense HW et al. Prevalence of left ventricular diastolic dysfunction in the 
community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 
2003 February;24(4):320-8.
 32  Powell BD, Redfield MM, Bybee KA, Freeman WK, Rihal CS. Association of obesity with left 
ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J 
Cardiol 2006 July 1;98(1):116-20.
 33  van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-
estradiol attenuates the development of pressure-overload hypertrophy. Circulation 2001 September 
18;104(12):1419-23.
 34  Xin HB, Senbonmatsu T, Cheng DS et al. Oestrogen protects FKBP12.6 null mice from cardiac 
hypertrophy. Nature 2002 March 21;416(6878):334-8.
 35  Wallen WJ, Cserti C, Belanger MP, Wittnich C. Gender-differences in myocardial adaptation to 
afterload in normotensive and hypertensive rats. Hypertension 2000 November;36(5):774-9.
 36  Adams KF, Jr., Dunlap SH, Sueta CA et al. Relation between gender, etiology and survival in 
patients with symptomatic heart failure. J Am Coll Cardiol 1996 December;28(7):1781-8.
CHAPTER 2
46
 37  Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various 
cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study 
Investigators. N Engl J Med 1993 April 15;328(15):1069-75.
      38  Kass DA. Age-related changes in venticular-arterial coupling: pathophysiologic implications. Heart 
Fail Rev 2002 January;7(1):51-62.
 
GEndER-dEPEndEnT EffECTs of Hfd on CARdIAC funCTIon
47
2



















Supplemental figure S1  Effect of sex hormones on lean body mass and fat mass. Male and 
female C57Bl/6J mice were fed a high-fat diet (HFD) for 10 weeks. M= male, OVX= ovariectomy, 
F= female, M-E= male treated with estrogen. Values represent means ± SD (n=5-6 per group). 
***p<0.001, compared both with males and OVX females for fat mass; #p<0.05, compared with 
females for lean body mass.
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High-fat diet does not aggravate cardiac 
function after a myocardial infarction in 
C57Bl/6J mice
Abstract
Obesity is accompanied by a low-grade systemic inflammation and associated with 
increased risk of cardiovascular diseases (CVD) including myocardial infarction (MI). 
We studied whether high-fat diet (HFD) feeding results in aggravated cardiac dysfunction 
after an MI, due to an increased inflammatory response.
C57Bl/6J male mice were fed a low-fat diet (LFD) or HFD for 14 weeks. Lipid levels were 
measured 10 weeks after the start of diet feeding. At 12 weeks mice were subjected to 
MI induction or a sham procedure, and cardiac function was measured 2 weeks later 
(at week 14) by echocardiography and invasive pressure-volume loop measurements. 
Subsequently, mice were sacrificed for histological analyses and determination of infarct 
sizes.
Prior to MI induction, HFD fed mice had increased body weights (+31%, p<0.001) and 
increased plasma levels of total cholesterol (+51%, p<0.01) and phospholipids (+20%, 
p<0.001), whereas triglyceride levels were not different compared to LFD fed mice. Two 
weeks after MI induction, MI size was not different between LFD and HFD groups. 
Cardiac function measurements showed that HFD feeding per se induced mild cardiac 
dysfunction, although HFD did not lead to a more pronounced cardiac dysfunction 
compared to LFD after MI. Interestingly, HFD fed MI mice showed a tendency towards 
more macrophages in the infarcted area compared to LFD fed MI mice (+327%, p=0.07). 
HFD does not aggravate cardiac dysfunction after MI compared to LFD fed mice, despite 




Obesity is a rapid developing epidemic which is caused by a disturbed energy balance 
due to decreased physical activity and excess consumption of high energy foods. In 
Western countries, where obesity is most prevalent, cardiovascular diseases due to 
myocardial infarctions (MI) are a leading cause of death. The pathogenesis of obesity-
related disorders is complex and involves multiple pathways, including lipotoxicity and 
inflammation associated with disturbed lipid and adipose tissue metabolism. In humans, 
high-fat diets (HFD) rapidly increase plasma triglycerides (TG)1, increase hepatic TG 
content2 and cause insulin resistance.3 In addition, HFDs also increase intramyocellular 
TG content in skeletal muscle and the myocardium, which is associated with alterations 
in myocardial function.4, 5 
An important hallmark of obesity is systemic inflammation that contributes to obesity-
related complications, including atherosclerosis and cardiac dysfunction.6, 7 It is known 
that inflammation in the heart, for example by local macrophage accumulation, 
impairs heart function.8, 9 Interestingly, saturated fatty acids (FA) have been shown to 
cause inflammatory responses via Toll-like receptors (TLR) on macrophages.10, 11 In 
addition, excessive FA influx in macrophages, due to absence of Angptl4, causes massive 
macrophage activation.12 Altogether, these data indicate that HFDs activate macrophages 
which may lead to deleterious effects on heart function.
Therefore, this study was designed to test the hypothesis that increased FA intake 
associated with HFD feeding results in more severe cardiac dysfunction per se and after 
an MI due to an increased inflammatory response as compared to normal FA intake 
associated with low-fat diet (LFD) feeding. We fed C57Bl/6J mice a HFD for 12 weeks 
and induced MI by permanent ligation of the left anterior descending (LAD) coronary 
artery. Two weeks after MI, extensive hemodynamic measurements were performed 
and we found that HFD fed mice had no aggravated cardiac dysfunction compared to 
LFD-fed mice, despite a clear tendency towards increased macrophage infiltration in the 
infarcted area. 
Materials and methods
Animals, diets, and experimental design
Twelve week old C57Bl/6J male mice (Charles River, Maastricht, the Netherlands) received either a 
lard-based LFD or HFD for 14 weeks. These diets were obtained from Research Diets Inc. (Wijk bij 
Duurstede, the Netherlands) and supplied ad libitum. As percentage of the total energy, the LFD 
contained 10% fat (4.5% lard and 5.5% soy bean oil) and 70% carbohydrate (34.5% energy from 
sucrose, 32% from corn starch and 3.5% from maltodextrin). The HFD contained 45% energy 
from fat (39.5% lard and 5.5% soy bean oil) and 35% carbohydrate (17% energy from sucrose, 8% 
from corn starch and 10% from maltodextrin).
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Mice were housed in a temperature and humidity-controlled room on a 12:12 h light-dark cycle 
with ad libitum access to water and food. Body weights (BW) were measured weekly. After 10 
weeks blood was drawn to measure plasma lipids. At 12 weeks, mice were subjected to either 
sham surgery or MI induction by coronary ligation (see below, LFD sham (n=8), LFD MI (n=26), 
HFD sham (n=8) and HFD MI (n=27) mice. Heart function was assessed using echocardiography 
and pressure-volume loops (PV-loops), 10 days and 14 days post MI, respectively (see below). At 
the end of the experiment mice were sacrificed and hearts were isolated for further examination. 
Mice that died before the completion of the entire study protocol were excluded from analysis. 
The protocol was approved by the Animal Ethics Committee from the Leiden University Medical 
Center and was conform to the Guide for Care and Use of Laboratory Animals (NIH publication 
No.85-23, Revised 1996).
Plasma lipids
After 4 hour fasting (9.00-13.00 h), blood was collected via tail vein bleeding in potassium EDTA-
coated plastic tubes (Starstedt, Germany). Plasma total cholesterol, TGs and phospholipids were 
determined individually using commercially available kits (kit no. 1489232; 11488872 and 101140, 
Roche Diagnostics Mannheim, Germany) in 96-wells plates (Greiner Bio-One), according to the 
manufacturer’s protocols. 
Induction of myocardial infarctions
Mice were anesthetized by intraperitoneal injection of a mixture of Dormicum (0.7 mg/kg BW), 
Dexdomitor (7.2 mg/kg BW), and Fentanyl (0.07 mg/kg BW). Body temperature was maintained 
at 37°C by using a temperature controlled, automatic heating pad. Mice were artificially ventilated 
using a dedicated mouse ventilator (model 845, Harvard apparatus, Holliston, MA, USA). The 
LAD was ligated with a 7-0 Ethilon suture (Johnson and Johnson, New Brunswick, NJ, USA) just 
distal to the left atrial appendix. Ischemia was confirmed by bleaching of the left ventricle (LV). The 
thorax was closed and the mice subcutaneously received Anexate (0.5 mg/kg BW) Antisedan (2.5 
mg/kg BW) and Naloxon (1.2 mg/kg BW) and 50 µL Temgesic/MilliQ (1.5 µg/50 mL MilliQ). The 
mice were allowed to recover on a temperature-controlled heating pad. The operation procedure 
was similar in sham mice, except for the ligation of the LAD.
Hemodynamic measurements 
Ten days after induction of the MI transthoracic echocardiography was performed using a 
VisualSonics Vevo 770 with a 30 MHz ultrasound transducer (VisualSonics, Toronto, Canada) as 
described earlier.13 The following parameters were obtained: heart rate (HR), stroke volume (SV), 
cardiac output (CO), end-diastolic volume (EDV) end-systolic volume (ESV), ejection fraction 
(EF), fractional area change (FAC) and area change. Briefly, mice were anesthetized with a starting 
dose of 4% isoflurane (in 1:1 (v/v) oxygen:air) and a maintenance dose of 1.5% isoflurane (in 
1:1 (v/v) oxygen:air) and placed on a temperature controlled platform. Parasternal long axis and 
short axis images were recorded in all animals. Analysis of the data was performed with software 
provided by VisualSonics. Four days later (14 days post MI), LV function was assessed by invasive 
PV-loops as described earlier.13 Briefly, mice were anesthetized with a starting dose of 4% isoflurane 
(in 1:1 oxygen:air) and a maintenance dose of 1.5% isoflurane (in 1:1 oxygen:air). After intubation 
mice were ventilated and the jugular vein was cannulated for infusion of hypertonic saline to 
determine parallel conductance. Via the right carotid artery a 1.2F PV catheter (FTS-1212B-4518, 
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Scisense Inc., London, Ontario, Canada) was placed into the LV. The catheter was connected to 
a Scisense ADV signal processor (Scisense Inc) to generate high-fidelity pressure and volume 
signals. Positioning of the catheter was guided by online pressure and volume signals. On-line 
display and acquisition of the signals (2000 samples/s) was performed with a PowerLab 8/30 data 
acquisition system and LabChart Pro software (AD Instruments GmbH, Spechbach, Germany). 
Off-line data analysis was performed with custom-made software (CircLab, P. Steendijk). 
The following parameters were measured: HR, SV, CO, EDV, ESV, EF, end-diastolic pressure (EDP) 
and end-systolic pressure (ESP). Stroke work (SW) was determined as the area of the PV-loop 
and the maximal and minimal rate of LV pressure change, dP/dtMAX and dP/dtMIN were obtained. 
Raw LV volume signals, obtained by conductance, were calibrated by matching EF and CO with 
corresponding echocardiographic values and data from PV-loop measurements are presented.
Infarct size and (immuno)histochemistry
Hearts were fixed overnight in paraformaldehyde and cut into five 1 mm-thick slices, perpendicular 
to the long axis of the heart. These slices were flat embedded in paraffin and 5 µm-thick sections 
were prepared. To delineate LV area and MI area sections, the lower 3 sections were stained 
histochemically for collagen with Sirius Red. Total LV wall area (including septum) and infarct 
area were measured with cell^D imaging software (Olympus Soft Imaging Solutions). The infarct 
area was expressed as percentage (v/v) of the LV wall area.
Additionally, sections were immunohistochemically stained for macrophages (F4/80, 1:10; 
kindly provided by Dr. P.J. Nijweide, Dept. of Molecular Cell Biology, Leiden University Medical 
Center, the Netherlands). Three specific regions of the myocardium were distinguished based on 
the Sirius Red staining: the infarcted area, the border zone and the remote ‘undamaged/healthy’ 
myocardium. For each region, the macrophage content was quantified as percentage of the total 
cardiac tissue area using ImageJ software package (http://rsb.info.nih.gov/ij). To this end, the area 
of F4/80 staining within the cardiac tissue was measured within a representative image (200x 
magnification). The chosen threshold for quantification had a maximum staining within the 
macrophage and minimal (unspecific) staining of other cells. 
Statistical analysis
Significance of differences between groups was calculated non-parametrically using a Kruskal-
Wallis test followed by a Mann-Whitney U-test. P-values ≤0.05 were considered statistically 
significant. SPSS 20.0 for Windows (IBM SPSS, Armonk, NY, USA) was used for statistical analysis. 
Values are presented as means ± SD. 




HFD feeding increases body weight and induces dyslipidemia
At 12 weeks, the HFD fed mice had a higher body weight compared to the LFD-fed 
control mice (LFD: 29.4±1.8 g versus HFD: 38.6±2.7 g, p<0.001). Body weights between 
sham and MI groups were comparable. Immediately after MI, all groups lost weight. 
However, they recovered quickly and 1 week post-MI an increase in body weight was 
observed. At termination of the study, body weight in HFD sham and HFD MI groups 
was higher compared to both LFD fed groups (figure 1). In addition, LFD sham mice 
were slightly, but significantly, heavier compared to LFD MI mice (sham: 28.9±1.5 g 
















































































Figure 1 Effect of LFD and HFD feeding on body weight and plasma lipids. Male C57Bl/6J 
mice were fed a low-fat diet (LFD) or a high-fat diet (HFD) for 14 weeks. Body weight results at 
14 weeks of diet feeding (A). Plasma total cholesterol (B) triglycerides (C) and phospholipids (D) 
were measured after 10 weeks of diet feeding. Values are means ± SD (n≥8 per group). ** p<0.01, 
*** p<0.001 versus LFD fed group, # p<0.05 versus sham group. 
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After 10 weeks (2 weeks prior to MI induction), plasma lipid levels were determined 
after a 4 hour fast. Compared to the LFD group, total cholesterol levels were increased 
in HFD fed mice (HFD sham: +43% versus HFD MI: +52%; both p<0.01) as well as 
phospholipids levels (HFD sham +20% p=0.07, HFD MI: +19% p<0.01). TG levels were 
not affected by the HFD feeding. 
HFD feeding does not result in a higher mortality rate after a 
myocardial infarction
Sham surgeries and MI inductions were performed after 12 weeks of diet feeding. 
Surgical mortality for the sham animals was 0% (0/8 mice) in both LFD and HFD fed 
groups. HFD feeding in combination with an MI resulted in a mortality rate of 60% 
(16/27 mice). This was comparable to the mortality rate after LFD feeding and MI 54% 
(14/26 mice), indicating that HFD feeding per se did not influence the mortality after MI 
induction.
HFD feeding does not lead to aggravation of cardiac function after a 
myocardial infarction
To investigate whether HFD feeding influences cardiac function after MI, 14 days 
post MI PV-loops were recorded in each mouse and results are summarized in table 
1. We confirmed that HFD feeding per se induced mild cardiac dysfunction compared 
to LFD feeding as reflected by changes of several parameters, including increased 
end-systolic volume (+21%, p=0.05) and relaxation constant tau (+17%, p<0.05). As 
Figure 2  Effect of LFD and HFD feeding on PV-loops and PV-relations without (sham) and 
with an MI. Male C57Bl6/J mice were fed a low-fat diet (LFD) or a high-fat diet (HFD) for 14 
weeks. Two weeks after induction of a myocardial infarction (MI), pressure-volume loops (PV-
loops)were measured in each mouse and average PV-loops are shown for the sham group (A) and 
the MI group (B). Values are means ± SD for end-diastolic and end-systolic volumes and pressures 
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expected, induction of an MI also compromised cardiac dysfunction by a decreased 
ejection fraction (-32% LFD versus -43% HFD; both p<0.01) and increased end-systolic 
volume (LFD MI: +115% versus HFD MI: +192%; both p<0.05) both compared to their 
respective sham group.
Based on the mean values for end-diastolic and end-systolic volumes, average PV-loops 
for LFD and HFD MI groups were generated and corresponding end-diastolic and end-
systolic PV-relations were calculated (figure 2). Cardiac function measurements revealed 
that HFD feeding did not lead to a more pronounced LV cardiac dysfunction after an MI 
compared to LFD fed mice with an MI. 
HFD feeding does not lead to differences in infarct size 
Differences is MI size may influence cardiac function. For this reason hearts were isolated 
directly after PV-loop measurements. Infarct area of the LV was determined by staining 
for collagen using Sirius red. Figure 3 shows that infarct size did not differ between LFD 
and HFD fed mice (LFD: 20±15% versus HFD: 22±12%; p=0.50). Hearts were unaffected 
in both sham operated groups (data not shown). Furthermore, total LV wall area was 
measured, and was found to be slightly elevated in the HFD fed groups. After correction 
for increased body weights in the HFD groups, no differences were found in LV wall area 
per gram body weight between all the groups (data not shown).
Figure 3  Effect of LFD and HFD feeding on infarct size and LV wall area. Male C57Bl/6J mice 
were fed a low-fat diet (LFD) or a high-fat diet (HFD) for 14 weeks. Two weeks after induction of 
a myocardial infarction (MI), infarct size was determined (A), total left ventricular (LV) wall area 





































HFD feeding increases macrophages in the infarcted area of the 
myocardium
To study the effect of HFD feeding and MI induction on macrophage infiltration in 
the myocardial tissue, macrophage content in three specific areas of the myocardium 
was analyzed; the remote ‘undamaged/healthy’ myocardium, the zone adjacent to the 
infarcted area (border zone) and the infarcted zone. The macrophage area (as percentage 
of the total area) stained in the undamaged or healthy area of the sham as well as the 
Figure 4  Effect of LFD and HFD feeding on macrophages after an MI. Male C57Bl/6J mice 
were fed a low-fat diet (LFD) or a high-fat diet (HFD) for 14 weeks. Two weeks after induction 
of a myocardial infarction (MI) macrophages were stained in the ventricles. (A) Percentage of 
macrophage stained for F4/80 per photograph for healthy myocardium, myocardium adjacent to 
the infarcted area (border) and the infarcted area. Values are means ± SD (n≥6 per group). * 
p<0.05 versus healthy, *** p<0.001 versus healthy; # p<0.05 versus border. (B) The upper panels 
show macrophage staining in LFD fed mice with a section from the healthy myocardium remotely 
from the infarcted area (1), the border zone (2), and the infarcted area (3). The lower panels show 
macrophage staining in a HFD fed mice with a section from the healthy myocardium remotely 
from the infarcted area (4), the border zone (5), and the infarcted area (6). Magnification 200x.
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MI groups was very low and did not differ between the four groups (figure 4A). In the 
border zone a higher percentage of macrophage staining was detected compared to the 
undamaged zones (LFD MI: +346%, p<0.05 and HFD MI: +383%, p<0.05), although no 
differences were observed between the LFD and HFD MI groups. In the infarcted area of 
the LFD fed group the percentage of macrophages was comparable to the border zone. 
Interestingly, the percentage of macrophages in the infarcted area in the HFD groups 
tended to be higher than the LFD fed group (+327%, p=0.07). Furthermore, in the 
infarcted area of the HFD mice the percentage of macrophages was significantly higher 
compared to the macrophages in the border zone of HFD fed mice (+424%, p=0.05). 
Figure 4B shows representative images of macrophage infiltration in the three selected 
areas of the myocardium in both LFD and HFD fed mice after MI induction.
Discussion
We tested the hypothesis that HFD feeding, as compared to LFD feeding, aggravates 
cardiac dysfunction after MI. Although we found that HFD per se leads to small 
deleterious changes in cardiac function, no differences in MI size and cardiac function 
after MI induction were observed between LFD and HFD fed mice. However macrophage 
infiltration in infarcted areas of HFD fed mice was more prominent.
As mentioned before, we found that HFD per se leads to cardiac dysfunction prior to 
the MI as indicated by e.g. a tendency towards reduction of end-systolic pressure, a 
reduction in contractility marker dP/dtMAX and an increase in end-systolic volume. These 
results are in agreement with a previous study from our group showing that HFD feeding 
leads to cardiac dysfunction.13 However, our data are not in agreement with the study 
of Berthiaume et al. who described a cardio-protective role of high saturated fat diet 
feeding subsequent to an MI in rats.14 Although, their study was performed in another 
species and HFD feeding was initiated after MI, whereas in our study HFD was started 
12 weeks before MI. This could indicate that the timing of HFD is important for the effect 
on cardiac dysfunction after MI induction and this aspect requires further investigation.
We did not observe a difference in mortality rate between LFD fed and HFD fed mice 
after MI. This is in contrast with findings in clinical studies where an ‘obesity paradox’ 
is observed among patients hospitalized for an acute MI. It is shown that patients with 
higher body mass indices (BMI) are associated with lower long-term mortality.15, 16 
Although some investigators suggest that patient demographics like age, gender and 
smoking might be confounding factors in these studies15, others observed this effect 
to be independent of patient characteristics.16 One of the proposed mechanisms of the 
latter findings is an increased awareness of the risk of having an MI for obese people and 
due to earlier presentation these patients have less severe LV dysfunction. Furthermore, 
patients with a low BMI might have a worse prognosis after MI due to a lack of a 
metabolic reserve that may lead to unfavorable hemodynamic changes.17 Since in our 
experiment all mice were treated similarly, the first explanation is not relevant in this 
research setting. Although the LFD MI group had a lower body weight gain compared 
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to the LFD sham group we did not observe differences in cardiac function. Therefore 
we cannot rule out that severe cardiac dysfunction in lean individuals play a role in the 
higher mortality observed in the clinical situation.
Apart from the effects of HFD on cardiac function post-MI, inflammation in the 
heart by for example local macrophage accumulation can also contribute to cardiac 
malfunctioning. Macrophages are not only involved in clearance of cellular debris post-
MI, but also secrete cytokines and growth factors like TGF-β which stimulate fibroblast 
activation eventually resulting in LV remodeling.18 Although the increased presence of 
macrophages at this time point did not lead to differences in cardiac function, we cannot 
exclude that, in the long-term, secondary effects might cause such differences. 
LFD sham HFD sham LFD MI HFD MI
General
HR (beats/min) 564±31 534±86 521±56 550±49
SV (µL) 29±9 31±9 27±5 26±9
CO (mL/min) 16±5 17±7 14±4 15±5
SW (mm Hg.µL) 1958±739 1647±566 1024±349# 1186±388
EA (mm Hg/µL) 2.6±0.9 2.1±0.7 2.1±0.4 2.4±3.3
PHT (ms) 5.1±0.8 7.2±2.8 p=0.07 5.8±1.4 6.0±1.0
Systolic
ESP (mm Hg) 69±3 60±14 p=0.09 52±7### 60±10
ESV (µL) 24±4 29±6* 52±40# 85±50#
EF (%) 57±10 52±11 39±13# 29±17#
dP/dtMAX (mmHg/ms) 5907±1341 4487±1130* 3965±1132# 4519±961
SB-EES(mm Hg/µL) 1.8±0.5 1.0±0.5* 1.0±0.7# 1.1±0.4
Diastolic
EDP (mm Hg) -0.1±1.4 4.6±9.3 -1.2±4.5 0.9±3.5
EDV (µL) 53±11 61±7 79±44 112±47#
Tau (ms) 10.4±1.7 12.2±1.0 12.2±2.1 12.1±1.6
-dP/dtMIN (mm Hg/ms) -5173±1141 -3589±911** -3255±902# -3716±862
SB-EED (mm Hg/µL) 0.14±0.05 0.12±0.08 0.17±0.11 0.19±0.11
Table 1 Effect of diet intervention on cardiac function after MI.
Mice were fed a low-fat diet (LFD) or a high-fat diet (HFD) for 14 weeks, after 12 weeks the left 
anterior descending aorta was ligated to induce a myocardial infarction (MI). Two weeks post-
MI cardiac function was determined. Left ventricular volume signals obtained by conductance 
catheter were calibrated by matching EF and CO with corresponding echocardiographic values 
obtained by measurements four days earlier. Values represent means ± SD (n≥7 per group). * 
p<0.05; ** p<0.01 as compared to corresponding LFD group; # p<0.05, ### p<0.001 as compared 
to corresponding sham group. HR, heart rate; SV, stroke volume; CO, cardiac output; SW, stroke 
work; EA, arterial elastance (afterload); PHT, pressure half time; ESP, end-systolic pressure; ESV, 
end-systolic volume; EF, ejection fraction; dP/dtMAX, maximal rate of pressure increase; SB-EES, 
end-systolic elastance; EDP, end-diastolic pressure; EDV, end-diastolic volume; Tau, relaxation 
time constant; -dP/dtMIN, minimal rate of pressure decline; SB-EED, end-diastolic elastance 
(diastolic stiffness).
Hfd doEs noT AGGRAvATE CARdIAC funCTIon AfTER MI
61
3
We are confident that study design and hemodynamic measurements are appropriate 
to conclude that cardiac dysfunction after MI does not differ significantly between LFD 
and HFD fed mice. 
First, HFD feeding resulted in an anticipated increase in body weight, total cholesterol 
and phospholipids levels. In addition, ligation of the coronary arteries resulted in an 
expected dilation of the LV, contractile dysfunction and a subsequent remodeling which 
are all considered to be hallmarks of heart failure.19-21
Second, induction of MI was successful as relevant infarctions were observed at histology. 
Although literature reports about both similar infarct sizes22, 23 as well as increased 
infarct sizes21, 24 in obese rodents, we observed no differences in infarct sizes between 
LFD and HFD groups. This discrepancy might be due to the fact that in studies that 
found a different infarct size transgenic mice and rats were used, while we used C57Bl/6J 
mice on a HFD. This also suggests that HFD feeding per se could be of importance as in 
studies that did not observe infarct size differences, including our study, diets were fed 
for a minimum of 8 weeks.
Third, as cardiac remodeling is a prolonged process, one could suggest that the time 
course of our study was too short to observe significant differences in cardiac function 
between HFD and LFD. However, studies in chow fed mice with a follow-up period 
up to 6 months post-MI demonstrated that the most prominent decline in LV function 
occurs 7-14 days after MI.25, 26 Therefore if HFD leads to deteriorated cardiac function, 
this would have been observed in our study. 
In summary, we tested the hypothesis that HFD feeding affects cardiac function 14 days 
post-MI. We found that HFD feeding leads to mild cardiac dysfunction, but does not 
influence infarct size and cardiac dysfunction after MI.   
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ABCA1 deficiency protects the heart against 
injury following myocardial infarction
Abstract
ATP-binding cassette transporter A1 (ABCA1) exerts anti-atherogenic functions in 
the pathogenesis of atherosclerosis. We aimed to explore the role of ABCA1 after acute 
myocardial infarct (MI) induction. 
In ABCA1 knockout (KO) mice, wild-type (WT) controls and in WT mice transplanted 
with ABCA1 KO or WT bone marrow an MI was induced and mice were allowed to 
recover for two weeks. In addition, isolated hearts from ABCA1 KO and WT mice were 
subjected to MI induction in a Langendorff perfusion system.
MI size was reduced in both ABCA1 KO mice (-59%, p=0.03) and WT mice transplanted 
with ABCA1 KO bone marrow (-43%, p=0.12) both compared to their WT controls. 
MI induction in isolated hearts by Langendorff perfusion showed no effect of ABCA1 
deficiency on infarct size. The smaller infarct size in vivo in ABCA1 KO mice is thus 
likely not due to a direct effect of ABCA1 deficiency on myocyte function. Interestingly, 
after MI, ABCA1 KO mice compared to WT controls, showed higher levels of CD19+ 
B-lymphocytes (+300%, p=0.02) and CD3+ T-lymphocytes (+420%, p=0.002). Both CD4+ 
and CD8+ lymphocytes (+460% and +370%; both p=0.002) contributed to the observed 
increase in CD3+ T-lymphocytes. There were no differences in leukocyte numbers after 
bone marrow transplantation. However, white blood cell counts were increased 2-7 fold 
compared to the first experiment. 
Although ABCA1 has a protective role in atherosclerosis, it exerts detrimental effects on 
cardiac function after MI, possibly caused by a reduced activation status of immune cells 




Tangier Disease (TD), resulting in extreme HDL deficiency, is caused by detrimental 
mutations in the ABCA1 gene.1-3 Since HDL plays a key protective role in atherosclerosis, 
by exerting several cardioprotective functions, including anti-oxidative, anti-
inflammatory and vasomotor activities4, the mechanism of action of ABCA1 and its 
regulation have been investigated extensively.5-8 Mice deficient for ABCA1 exhibit low 
plasma HDL levels as well as cholesterol accumulation in peripheral macrophages, a 
phenotype similar to that of TD patients.9 Although atherosclerosis-prone mouse models 
deficient for ABCA1 display impaired cellular cholesterol efflux10, atherosclerotic lesion 
development does not increase in these mice11, probably due to a less atherogenic lipid 
profile despite the almost complete absence of protective HDL. Deletion of ABCA1 in 
bone marrow-derived cells, however, did increase atherosclerotic lesion development, 
coinciding with increased numbers of peritoneal foam cells and impaired cholesterol 
efflux from macrophages towards apoA-I and HDL, indicating a pronounced anti-
atherosclerotic effect of leukocyte ABCA1.12, 13 In humans, low HDL levels have been 
correlated to an increased risk of MI; an acute cardiovascular event, often resulting from 
rupture of advanced atherosclerotic lesions and superimposed thrombus formation.14 
Inflammatory responses are a critical factor in the balance between adverse ventricular 
remodeling induced by MI on the one hand15, 16, and cardiac repair on the other hand.17 
Ischemia induces the Janus kinase 2/signal transducer and activator of transcription 
3 (JAK2/STAT3) pathway, an important regulator of cytokine signaling, which plays 
a vital role in cardioprotection by inducing cytoprotective and survival signals in 
infarcted hearts.18 Interestingly, ABCA1 acts as an anti-inflammatory mediator in baby 
hamster kidney (BHK) cells by inducing signaling through the JAK2/STAT3 pathway 
in response to binding of lipid-poor apoA-I.19 Furthermore, ABCA1 exerts important 
anti-inflammatory properties, due to its key role in modulating the cholesterol content 
of the plasma membrane and within intracellular compartments.20, 21 ABCA1 is thus 
anticipated to be cardioprotective during MI, indirectly by generating HDL as well as 
directly by its anti-inflammatory effects through JAK2/STAT3 signaling. The actual role 
of ABCA1 during MI, however, is currently unknown.
In order to investigate the importance of ABCA1 with respect to MI, we performed 
permanent coronary artery ligation experiments in ABCA1 KO and WT control mice 
as well as in WT mice transplanted with ABCA1 KO or WT bone marrow. Our results 
evidently show that ABCA1 has unanticipated unfavorable cardiac effects after MI.




Animals and bone marrow transplantation
Female WT mice (C57Bl/6J background) and ABCA1 KO mice (kindly provided by Dr. G. 
Chimini, Centre d’Immunologie de Marseille-Luminy; more than 7 times backcrossed onto a 
C57Bl/6J background) were used. 
To generate mice that specifically lack ABCA1 in bone marrow-derived cells, bone marrow from 
WT mice and ABCA1 KO mice was transplanted into WT mice as previously described.22 Briefly, 
irradiated WT recipients received 5×106 bone marrow cells by intravenous injection into the 
tail vein. After 8 weeks, myocardial infarctions were induced or mice were subjected to a sham 
operation. 
All animals had ad libitum access to food and water. At the end of each experiment the mice were 
sacrificed and hearts and/or blood were isolated for further examination. Animal experiments were 
approved by the Ethics Committee for Animal Experiments of Leiden University and performed at 
the Gorlaeus Laboratories of the Leiden Academic Centre for Drug Research in accordance with 
the National Laws.
Induction of myocardial infarctions
Mice were anesthetized by intraperitoneal injection of a mixture of dormicum (0.7 mg/kg b.w.), 
dexdomitor (7.2 mg/kg b.w.), and fentanyl (0.07 mg/kg b.w.). Body temperature was maintained 
at 37°C with an automatic heating pad. Mice were artificially ventilated using a dedicated rodent 
ventilator (model 845, Harvard Apparatus, Holliston, MA). The left anterior descending (LAD) 
coronary artery was ligated with a 7-0 Ethilon suture (Johnson and Johnson, New Brunswick, NJ, 
USA), just distal to the left atrial appendix. All mice that had ischemia, confirmed by bleaching 
of the left ventricle (LV), and the emergence of arrhythmias, were included in the study. The 
thorax was closed and the mice received a subcutaneous injection of Anexate (0.5 mg/kg b.w.), 
Antisedan (2.5 mg/kg b.w.), Naloxon (1.2 mg/kg b.w.), and 50 µL Temgesic/PBS (1.5 µg/50 mL 
PBS). Thereafter, the mice were allowed to recover on a temperature-controlled heating pad. Mice 
received another 50 µL Temgesic/PBS (1.5 µg/50 mL PBS) at 24 h after surgery.
Infarct size and immunohistochemistry
Two weeks after MI induction, mice were sacrificed and the arterial tree was perfused in situ 
with PBS (100 mm Hg) for 10 min via a cannula in LV apex. Subsequently, hearts were isolated 
and cut into four equal 1-2 mm thick slices, perpendicular to the long axis of the heart. The two 
lower slices, from the middle of the heart to the apex, represent the infarcted area, and were used 
for infarct quantification. These slices were flat embedded and serial sections (10 µm) were cut 
using a Leica CM3050S cryostat. To delineate the LV area and infarct area, sections were stained 
immunohistochemically with Sirius red for collagen. Total LV wall area (including septum) and 
infarct area were measured with cell^D imaging software (Olympus Soft Imaging Solutions, 
Tokyo, Japan). Infarct areas were normalized to total LV areas and averaged for individual hearts. 
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Leukocyte content and flow cytometry
Upon sacrifice, 2 weeks after MI, blood was collected by retro-orbital venous plexus puncture. 
Leukocyte content was analyzed using an automated Sysmex XT-2000iV Veterinary Hematology 
analyzer (Sysmex Corporation, Kobe, Japan). For fluorescent activated cell sorting (FACS) analysis, 
erythrocytes were lysed using erythrocyte lysis buffer (0.15 M NH4 Cl, 10 mM NaHCO3, 0.1 mM 
EDTA, pH 7.3). Blood cells were subsequent stained (0.25 µg Ab/200,000 cells) for T-lymphocytes 
(CD3, CD4, and CD8), B-lymphocytes (CD19), monocytes/macrophages (F4/80) and dendritic 
cells (DC; CD11c). Antibodies were purchased from eBioscience (Vienna, Austria). FACS analyses 
were performed on a FACS Canto II (BD Biosciences, Mountain View, CA, USA). Data were 
analyzed using FACSDiva software (BD Biosciences).
Ex vivo Langendorff perfusion
To isolate the heart for Langendorff perfusion, the chest was opened excising the sternum and 
attached costal cartilages to give adequate access to the mediastinum. The heart was rapidly 
removed and placed in ice cold (4°C) Krebs–Henseleit buffer and the aorta cannulated. Hearts 
were then perfused with a Krebs–Henseleit buffer (118.0 mM NaCl; 24.0 mM NaHCO3; 4.0 mM 
KCl; 1.0 mM NaH2PO4; 2.5 mM CaCl2; 1.2 mM MgCl2; 0.5 mM EDTA.Na2; 10 mM glucose, pH 7.4; 
gassed with 95% O2/5% CO2 at 37°C) in a retrograde fashion with a constant pressure of 110 cm 
H2O. The coronary flow rate was measured by timed collection of the perfusate. The hearts were 
stabilized for 20 min and subsequently exposed to 35 min of no-flow global ischemia followed by 
45 min of reperfusion. At the end of the reperfusion period, the heart was immediately frozen. 
Frozen hearts were cut into 6-7 slices, perpendicular to the long axis of the heart, and incubated 
with triphenyltetrazolium chloride (TTC) to stain viable myocardium. Total myocardium and 
infarcted areas were measured from computed images using NIH Image software.
Statistical analysis
Statistically significant differences among the means of the different populations were tested using 
the unpaired Student’s t-test (GraphPad InStat and Prism 4 software). The probability level (alpha) 
for statistical significance was set at 0.05. Results are expressed as mean ± SEM.
Results
ABCA1 KO mice show decreased coronary artery ligation-induced 
myocardial infarction
To investigate the effects of ABCA1 deficiency on MI-induced damage in vivo, we subjected 
ABCA1 KO and WT mice to LAD coronary artery ligation. Two weeks after induction 
of MI, infarct size was quantified. Surprisingly, despite the anticipated cardioprotective 
functions of ABCA1, ABCA1 KO mice displayed a substantial 59% reduction in MI size 
as compared to WT mice (p=0.03; figure 1, left panel). No differences in total LV wall 
area were found (figure 1, right panel), indicating that the observed reduction in MI did 
not result from alterations in LV size.
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4ABCA1 KO mice have higher circulating white blood cell and 
lymphocyte numbers after coronary artery ligation-induced 
myocardial infarction
Before MI induction, no differences in leukocyte subsets were observed between ABCA1 
KO and WT mice (data not shown). Two weeks after MI, however, total leukocyte counts 
were 2.9-fold higher in ABCA1 KO mice (p<0.05; figure 2), which was primarily the 
result of augmented numbers of circulating lymphocytes (4.6-fold; p=0.002). To further 
investigate the increased lymphocyte population in the circulation of ABCA1 KO mice 
after MI, blood cells were subjected to FACS analysis (figure 3). Before MI, no differences 
Figure 1 Reduced myocardial infarct size in ABCA1 KO mice after coronary artery ligation. 
Two weeks after induction of myocardial infarction (MI) by ligation of the left anterior descending 
(LAD) coronary artery, infarct size was determined (left panel). Representative cross sections are 
shown, stained with Sirius red to visualize the collagen-rich infarcted area (middle panels). Total 
left ventricle (LV) wall area was determined as a general indicator of heart size (right panel). Values 
are means ± SEM (n≥4 per group). *p<0.05
Figure 2  Increased WBC and lymphocytes in ABCA1 KO mice after MI induction by 
coronary artery ligation. Two weeks after induction of a myocardial infarction (MI), total white 
blood cells (WBC) and lymphocytes in plasma were determined with a hematology analyzer. 
Values are means ± SEM (n≥4 mice per group). *p<0.05, **p<0.01
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in T-lymphocytes (CD3+, CD4+, and CD8+), B-lymphocytes (CD19+), dendritic cells 
(CD11c+) or monocytes/macrophages (F4/80+) were observed between both genotypes 
(figure 3 left panel). After MI, however, CD3+ T-lymphocytes increased a striking 4.2-fold 
(p=0.002; figure 3 right panel). CD4+ T-helper lymphocytes (4.6-fold increase; p=0.002) 
and CD8+ cytotoxic T-lymphocytes (3.7-fold increase; p=0.002) both contributed to this 
phenomenon. In addition, ABCA1 KO mice displayed a clear 3.0-fold increase (p=0.02) 
in CD19+ B-lymphocytes after MI. In contrast, monocytes/macrophages (F4/80+) 
and dendritic cells (CD11c+) did not change between both genotypes upon MI. This 
indicates that the induction of MI in ABCA1 KO mice primarily induced common 
lymphoid progenitor (CLP)-derived cells, such as T- and B-lymphocytes, rather than 
common myeloid progenitor (CMP)-derived cells including monocytes/macrophages 
and dendritic cells.
ABCA1 KO hearts show unaltered myocardial infarction in a 
Langendorff perfusion system ex vivo
ABCA1 KO mice have been shown to develop cardiomegaly.23 To determine the direct 
effects of ABCA1 deficiency on myocyte function during ischemia, MI was induced ex 
vivo in isolated hearts from ABCA1 KO mice and WT controls using the Langendorff 
perfusion method. After 35 minutes of no-flow global ischemia followed by 45 minutes 
of reperfusion, only a tendency towards a 15% decrease (p=0.47; figure 4) in infarct size 
was observed in hearts from ABCA1 KO mice. These data thus indicate that ABCA1-
deficiency in cardiomyocytes is not contributing to the smaller infarct size observed in 
ABCA1 KO mice after coronary artery ligation. 
Figure 3 Increased circulating T- and B-cells in ABCA1 KO mice after MI induction by 
coronary artery ligation in vivo. Isolated white blood cells (WBC) were stained for T-cells (CD3+, 
CD4+, and CD8+), B-cells (CD19+), monocytes/macrophages (F4/80+) and dendritic cells 
(CD11c+) and analyzed by flow cytometry before (left panel) and after myocardial infarction (MI) 
(right panel). Values are means ± SEM (n≥4 mice per group). *p<0.05, **p<0.01
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Hematopoietic deficiency for ABCA1 tends to reduce coronary artery 
ligation-induced myocardial infarction
Next, we investigated if the observed decrease in MI in ABCA1 KO mice results from 
ABCA1-deficiency in bone marrow-derived cells that may be involved in MI-induced 
cardiac remodeling. Hereto, we induced MI in WT mice, transplanted with bone 
marrow from ABCA1 KO vs WT mice. Quantification of infarct size two weeks after MI 
induction showed a strong trend towards a reduction in MI size (-43%; p=0.12) (figure 
5, left panel) without an effect on LV wall area (figure 5, right panel) in mice transplanted 
with ABCA1 KO as compared to WT bone marrow. 
Hematopoietic deficiency for ABCA1 does not affect circulating white 
blood cell numbers after coronary artery ligation-induced myocardial 
infarction
Two weeks after MI induction, blood cells were subjected to FACS analysis to investigate 
the numbers of circulating lymphocytes (figure 6). No difference in T-lymphocytes (CD3+, 
CD4+, and CD8+), B-lymphocytes (CD19+), dendritic cells (CD11c+) or monocytes/
macrophages (F4/80+) were observed between mice transplanted with ABCA1 KO 
vs WT bone marrow. Strikingly, the number of white blood cell (WBC) counts per se 
was 2-7 fold higher in mice transplanted with WT bone marrow compared to the WT 
mice in the first in vivo experiment. Since a WT control group without bone marrow 
transplantation in the second experiment also did not show an increase in WBC counts 
(data not shown) this indicates that the observed increase in WBC counts is induced by 
the transplantation procedure, combined with MI induction. 
Figure 4 Unaltered infarcted area of isolated hearts from ABCA1 KO mice subjected to 
ischemia/reperfusion ex vivo. Isolated hearts were stabilized for 20 minutes in a Langendorff 
perfusion system, followed by 35 minutes of no-flow global ischemia, and 45 minutes of reperfusion. 
Infarct size was measured with cell^D imaging software. Infarct areas were normalized to total left 
ventricular areas and averaged for individual hearts (left panel). Values are means ± SEM (n≥5 
mice per group). Representative cross sections are shown, stained with TTC to determine viable 




In the current study we show for the first time that mice lacking ABCA1, thereby having 
reduced HDL levels, are protected against cardiac damage after permanent coronary 
artery ligation. At first sight, this is remarkable as several studies have revealed protective 
effects of HDL after MI.24, 25 HDL protects against MI by inhibiting ischemia-induced 
cardiomyocyte apoptosis and by reducing the recruitment of inflammatory neutrophils 
into the infarcted area.25 In addition, intravenous injection of apoA-I before the onset 
of reperfusion after MI reduced TNF-α and IL-6 expression in the heart, as well as 
suppressed ICAM-1 expression in the heart, thereby diminishing neutrophil adherence 
and subsequent reduced myocyte injury.24 On the other hand, mice lacking the HDL 
receptor scavenger receptor BI (SR-BI), have high levels of HDL but spontaneously 
develop MI.26, 27 Deficiency of ABCA1 not only results in the lack of HDL, but also 
highly attenuates total cholesterol levels.28 Although cholesterol levels are positively 
correlated with MI risk in humans29, differential results have been obtained in murine 
MI models.30-32 
Interestingly, induction of MI in ABCA1 KO mice resulted in a substantial increase 
in circulating leukocytes due to higher numbers of circulating B- and T-lymphocytes. 
No differences in leukocyte numbers or subsets were found prior to coronary artery 
ligation. Therefore, the increased inflammatory environment, caused by the induction 
of MI, might have attributed to induce this phenotype in ABCA1 KO mice. Proliferation 
of LSK stem cells and committed CMPs is regulated by cholesterol efflux mechanisms, 
whereby HDL suppresses proliferation by facilitating cellular cholesterol efflux via the 
ABC-transporters ABCA1 and ABCG1.33 However, mice lacking ABCA1 and ABCG1 
did not show an increase in CLP cells that give rise to B-and T-lymphocytes.33 
Figure 5 MI size tends to be lower in WT mice transplanted with ABCA1 KO bone marrow. 
WT mice were transplanted with bone marrow from WT or ABCA1 KO mice. After 8 weeks, 
myocardial infarction (MI) was induced by ligation of the LAD coronary artery. Two weeks later, 
infarct size was determined (left panel). Representative cross sections are shown, stained with 
Sirius red to visualize the collagen-rich infarcted area (middle panels). Total left ventricle (LV)
wall area was determined as a general indicator of heart size (right panel). WT->WT, WT mice 
transplanted with WT bone marrow, ABCA1 KO->WT, WT mice transplanted with ABCA1 KO 
bone marrow. Values are means ± SEM (n≥4 per group).
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Importantly, we have previously shown that deficiency of leukocyte ABCA1 increases 
circulating lymphocytes upon induction of atherosclerosis12, similarly as observed in the 
current study upon coronary artery ligation. Since the infarct size in ABCA1 KO mice 
was drastically attenuated, the higher number of circulating lymphocytes might have 
been mediating tissue repair. This hypothesis is strengthened by the fact that studying 
the effect of ischemia on isolated hearts from ABCA1 KO and WT mice, thus in absence 
of blood cells, did not show differences in infarct size using the Langendorff perfusion 
system. 
T-lymphocytes rapidly accumulate in the heart after ischemia/reperfusion injury. 
Specifically, CD4+ T-lymphocytes were identified as protective mediators of myocardial 
perfusion injury after MI.33, 34 Recently, Wara et al. showed that LSK-derived CMPs, but not 
CLPs, can differentiate into proangiogenic cells, thereby promoting neovascularization.34 
Instead, CD4+ lymphocytes modulate the influx of among others monocytes, which is 
a prerequisite for proper myocardial wound healing.35, 36 Moreover, intramyocardial 
injection of B-lymphocytes into early post-ischemic myocardium has been shown to 
preserve cardiac function37, emphasizing the protective roles of B- and T-lymphocytes 
upon MI.
The most pronounced lipid phenotype of ABCA1 deficiency is the near absence of HDL 
cholesterol in the circulation.23 It is therefore plausible that the absence of HDL, at least 
in part, promoted the observed secondary effects on lymphocyte numbers upon MI. In 
agreement, Wilhelm et al. observed increased circulating lymphocytes in Western-type 
diet fed LDLr KO mice lacking apoA-I.38 ApoA-I KO mice, like ABCA1 KO mice, have 
virtually no circulating HDL. To provide definitive proof for the distinct importance of 
ABCA1 and HDL, MI should be induced in apoA-I KO mice, which express ABCA1, but 
have virtually no HDL.
Figure 6  Comparable circulating T- and B-lymphocytes in WT mice transplanted with 
ABCA1 KO and WT bone marrow after MI induction by coronary artery ligation in vivo. 
Isolated white blood cells (WBC) were stained for T-cells (CD3+, CD4+, and CD8+), B-cells 
(CD19+), monocytes/macrophages (F4/80+) and dendritic cells (CD11c+) and analyzed by flow 
cytometry after MI. Values are means ± SEM (n≥4 mice per group). 
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To elucidate the effect of ABCA1-deficiency in leukocytes on MI, bone marrow was 
transplanted from ABCA1 KO and WT mice to WT mice, after which MI was induced 
by coronary artery ligation. A strong trend was observed towards a reduction in MI size 
(-43%), which just did not reach statistical significance because of large interindividual 
variation. However, these data strongly suggest that hematopoietic ABCA1 deficiency 
underlies the difference in MI size observed in the first experiment. No differences 
were observed in CLP- nor in CMP-derived cells after bone marrow transplantation. 
However, it should be noted that WBC numbers were dramatically higher in both 
transplanted groups compared to the non-transplanted animals in the first experiment. 
Hofmann et al. previously showed that the mere presence of CD4+ T-lymphocytes was 
not sufficient for proper wound healing and that T-cell receptor activation by released 
cardiac autoantigens after MI is a prerequisite.35 Furthermore, Wilhelm et al. was the 
first to show that not only monocytes/macrophages become cholesterol enriched but 
also T- and B-lymphocytes and this cholesterol enrichment seems to be the stimulus 
that initiates T-lymphocyte activation.38, 39 One could hypothesize that the inability of 
immune cells to efflux cholesterol could enhance the activation status of these cells 
towards more efficient repair of damage induced by MI. However, it remains to be 
determined how ABCA1 expressing leukocytes exactly exert their detrimental effects 
during cardiac wound healing.
In conclusion, despite its protective effects regarding the development of atherosclerosis, 
ABCA1 has adverse effects on cardiac function after MI, which is possibly related to an 
increased activation status, rather than an increase in the absolute numbers of B- and 
T-lymphocytes. Importantly, although ABCA1 is considered a potential therapeutic 
target to treat atherosclerosis, strategies aiming at upregulation of ABCA1 function 
should be pursued with care in the light of potential adverse effects on cardiac 
remodeling following MI.
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RP105 deficiency aggravates cardiac 
dysfunction after myocardial infarction in mice
Abstract
Toll-like receptor 4 (TLR4), a receptor of the innate immune system, is suggested to have 
detrimental effects on cardiac function after myocardial infarction (MI). RP105 (CD180) 
is a TLR4 homolog lacking the intracellular signalling domain that competitively inhibits 
TLR4-signalling. Thus, we hypothesized that RP105 deficiency, by amplifying TLR4 
signalling, would lead to aggravated cardiac dysfunction after MI.
First, whole blood from RP105-/- and wild-type (WT) male C57Bl/6N mice was stimulated 
with LPS, which induced a strong inflammatory TNFα response in RP105-/- mice. Then, 
baseline heart function was assessed by left ventricular pressure-volume relationships 
which were not different between RP105-/- and WT mice. Permanent ligation of the left 
anterior descending coronary artery was performed to induce MI. Infarct sizes were 
analysed by (immuno)histology and did not differ. Fifteen days post MI heart function 
was assessed and RP105-/- mice had significantly higher heart rate (+21%, p<0.01), end-
systolic volume index (+57%, p<0.05), end-systolic pressure (+22%, p<0.05) and lower 
relaxation time constant Tau (-12%, p<0.05), and a tendency for increased end-diastolic 
volume index (+42%, p<0.06), compared to WT mice. In the area adjacent to the infarct 
zone, compared to the healthy myocardium, levels of RP105, TLR4 and the endogenous 
TLR4 ligand fibronectin-EDA were increased as well as the number of macrophages, 
however this was not different between both groups.
Deficiency of the endogenous TLR4 inhibitor RP105 leads to an enhanced inflammatory 
status and more pronounced cardiac dilatation after induction of MI, underscoring the 




Cardiovascular diseases remain the leading cause of death in the western countries, 
which is mainly accounted for by the high incidence of myocardial infarction (MI). 
Although survival after MI has improved significantly due to novel medical strategies 
and interventions, the incidence and prevalence of MI related morbidity is increasing 
which is mainly due to development of congestive heart failure (CHF).1, 2 CHF is the 
result of a remodelling response of the ventricle upon reduced contraction capacity 
after cardiac damage such as MI.2 During the last decades the immune system was 
demonstrated to a play major role in myocardial repair and remodelling. Evidence 
accumulates that prolongation of the post-infarction inflammatory response leads to 
increased remodelling and thereby CHF progression.3-5 Therefore, new strategies to 
intervene in the pathogenesis of CHF may be worthwhile, which can be achieved by 
immediate anticipation and tackling of the inflammatory- and matrix degeneration 
processes that have been initiated by the immune system.6
Toll like receptors (TLR) are part of the innate immune system and are capable of 
recognizing Pathogen Associated Molecular Patterns (PAMPs) as well as Damage 
Associated Molecular Patterns (DAMPs). PAMPs are parts of exogenous pathogens such 
as bacteria while DAMPs, like fibronectin-extra domain-A (EDA) or Heat Shock Protein, 
may become available after cell stress or tissue damage/injury without the involvement 
of exogenous pathogens.7 They have been widely associated with atherosclerotic plaque 
formation, restenosis and vein graft failure; all processes that may initiate ischemia or 
MI, resulting in cardiac remodelling.8-10 One of the most studied TLRs is TLR4, which 
is present on circulating cells and cardiomyocytes. Cardiac expression of TLR4 was 
shown to be upregulated in cardiomyopathy.11 In preclinical studies TLR4 was shown to 
Figure 1  Schematic model of the TLR4-MD2 and RP105-MD1 complex. Activation of the 
TLR4-MD2 heterodimer by ligand binding results in activation of the intracellular signaling 
domain thereby initiating a downstream signaling cascade (left panel). The formation of the 
unusual 2:2 homodimer by TLR4-MD2 and RP105-MD1 alters the TLR4 signaling cascade, 
whereas RP105 dimerization by itself has no signaling capacity at all as it lacks the intracellular 
Toll Interleukin Receptor (TIR) domain (right panel). Adapted from Otho et al.25
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play an important role in MI healing, left ventricular (LV) remodelling and functional 
impairment following MI.12 Additionally, intervention with a specific TLR4 antagonist 
Eritoran was demonstrated to be protective against remodelling.13
TLR-signalling is mainly regulated by accessory molecules14, and no role for these 
accessory molecules in cardiac remodelling has been defined yet. RP105, one of these 
molecules, resides on the cell surface and has a high extracellular structural similarity 
to TLR4 (figure 1).15 In addition, like TLR4, whose signalling depends on association 
with the extracellular accessory protein MD-2, RP105 surface expression depends on 
co-expression of the MD-2 homolog: MD-1. However, in contrast to TLR4, RP105 
lacks the intracellular Toll Interleukin Receptor (TIR) domain that is essential to initiate 
cellular activation. As such RP105 is an inhibitor of the TLR4 signaling pathway.16, 17 
Whereas no direct ligands have been found for RP105, strong indications exist that 
it can bind TLR4 ligands, thereby influencing TLR4 signalling and dampening the 
inflammatory responses induced by TLR4 activation.
As TLR4 activation has been shown to enhance cardiac remodelling after MI, we 
hypothesized that RP105 deficiency would aggravate these effects, through reduced 
inhibition (thus by stimulation) of TLR4 signalling. In this study we demonstrate that 
RP105 deficiency indeed has a functional role in cardiac remodeling, since systolic and 
diastolic cardiac function indices are affected after MI. 
Materials and methods
Animals and experimental design
Studies were performed with 10-12 week old, male RP105-deficient (RP105-/-) mice bred in our 
animal facility and wild-type (WT) mice (Charles River, Maastricht, the Netherlands), both on a 
C57Bl/6N background. Animals were housed in a temperature and humidity controlled room on a 
12:12-h light-dark cycle with ad libitum access to water and normal chow diet. Body weights were 
measured weekly. MI was induced by coronary ligation (see below) at day 0 in RP105-/- (n=12) 
and WT (n=12) mice. Subsequently, cardiac function assessments by pressure-volume loops 
(PV-loops) were performed at day 15. To obtain baseline cardiac function, additional PV-loop 
measurements were performed in a separate group of animals (RP105-/-, n=4; WT, n=4) without 
MI. After PV-loop measurements the mice were sacrificed and hearts were isolated for further 
examination. The protocol was approved by the Animal Ethics Committee from the Leiden 
University Medical Center and was conform to the Guide for Care and Use of Laboratory Animals 
(NIH publication No.85-23, Revised 1996).
Whole blood TNFα stimulation assay
In order to investigate the inflammatory response at baseline of the different groups, venous 
blood via a tail vein cut was collected and suspended 1:25 with RPMI 1640 (Gibco 52400-025, 
Paisley, UK) supplemented with non-essential amino acids (PAA M11-003, Pasching, Austria) 
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and glutamax (Gibco 35050). Blood from both WT and RP105-/- mice was incubated overnight at 
37ºC in absence and presence of LPS in the concentrations 25 ng/mL and 50 ng/mL. Subsequently, 
TNFα levels were measured by ELISA (BD Biosciences).
Induction of myocardial infarctions
Mice were anesthetized by an intraperitoneal injection of a mixture of dormicum (0.7 mg/kg BW), 
dexdomitor (7.2 mg/kg BW) and fentanyl (0.07 mg/kg BW). Body temperature was maintained at 
37°C using a temperature controlled, automatic heating pad. Mice were artificially ventilated using 
a dedicated mouse ventilator (model 845, Harvard Apparatus, Holliston, MA). The left anterior 
descending coronary artery (LAD) was ligated with a 7-0 ethilon suture (Johnson and Johnson, 
New Brunswick, NJ, USA), just distal to the left atrial appendage. Ischemia was visually confirmed 
by bleaching of the LV. The thorax was closed and the mice received an intraperitoneal injection of 
anexate (0.5 mg/kg BW), antisedan (2.5 mg/kg BW), naloxon (1.2 mg/kg BW) to antagonize the 
anesthesia. Analgesic temgesic (1.5 µg in 50 µL PBS) was administered subcutaneously. Thereafter, 
the mice were allowed to recover on a temperature controlled heating pad.
Hemodynamic measurements 
Thirteen days after induction of the MI, transthoracic, cardiac echocardiography was performed 
using a VisualSonics Vevo 770 with a 30 MHz ultrasound transducer (VisualSonics, Toronto, 
Canada) as described earlier.18 The following parameters were obtained: heart rate (HR), stroke 
volume (SV), cardiac output (CO), end-diastolic volume (EDV) end-systolic volume (ESV), ejection 
fraction (EF), fractional area change (FAC) and area change. Briefly, mice were anesthetized with 
3% isoflurane, and placed supine on a temperature-controlled animal platform. Parasternal long 
axis and short axis images were recorded in all animals. Analysis of the data was performed with 
software provided by VisualSonics. Subsequently, 2 days later (at day 15 post MI), LV function was 
assessed by invasive PV-loops as described earlier.18 Mice were anesthetized with a starting dose 
of 4% isoflurane and a maintenance dose of 1.5% isoflurane. After intubation mice were ventilated 
and the jugular vein was cannulated for infusion of hypertonic saline to determine parallel 
conductance. Via the right carotid artery a 1.2F PV catheter (FTS-1212B-4518, Scisense Inc., 
London, Ontario, Canada) was placed into the LV. The catheter was connected to a Scisense ADV 
signal processor (Scisense Inc) to generate high-fidelity pressure and volume signals. Positioning 
of the catheter was guided by online pressure and volume signals. On-line display and acquisition 
of the signals (2000 samples/s) was performed with a PowerLab 8/30 data acquisition system and 
LabChart Pro software (AD Instruments GmbH, Spechbach, Germany). Off-line data analysis was 
performed with custom-made software (CircLab, P. Steendijk). The following parameters were 
measured: heart rate (HR), stroke volume (SV), cardiac output (CO), end-diastolic volume (EDV) 
end-systolic volume (ESV), ejection fraction (EF), end-diastolic pressure (EDP) and end-systolic 
pressure (ESP). Stroke work (SW) was determined as the area of the PV-loop and the maximal 
and minimal rate of LV pressure change, dP/dtMAX and dP/dtMIN were obtained. Effective arterial 
elastance (EA) was calculated as ESP/SV. Relaxation time tau was calculated as the time-constant 
of mono-exponential pressure decay during isovolumic relaxation.
Myocardial (immuno)histochemistry
Hearts were fixed overnight in paraformaldehyde and cut into five 1 mm-thick slices, perpendicular 
to the long axis of the heart. These slices were flat embedded in paraffin and 5 µm-thick sections 
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were prepared. To delineate LV area and infarct area the lower 3 sections were stained for collagen 
with Sirius Red. Total LV wall area (including septum) and infarct area were measured with cell^D 
imaging software (Olympus Soft Imaging Solutions, Tokyo, Japan). The infarct area was expressed 
as percentage (v/v) of the LV wall volume.
Additionally, sections were immunohistochemically stained for macrophages (rat anti-mouse 
MAC-3, 1:200; BD Biosciences, Erembodegem, Belgium) to count the infiltrating macrophages 
into the myocardium, TLR4 (rabbit anti-human TLR4, 1:150 SantaCruz, Heidelberg, Germany) 
to observe presence of TLR4 in the different areas of the myocardium, RP105 (rabbit anti-human, 
1:250 SantaCruz) to verify the presence of the accessory molecule in WT mice, and fibronectin-
EDA (mouse anti-human 1:800, Abcam, Cambridge, United Kingdom) whose presence precedes 
that of collagen and serves as an endogenous ligand for TLR4, which is frequently induced upon 
tissue injury and is known to play a role in cardiac remodeling. Images were scored by an observer 
blinded for the study groups. Per image three specific areas of the myocardium were distinguished: 
the infarcted area, the border zone and the remote, undamaged, healthy myocardium. MAC-3 
staining was analyzed by counting the number of macrophages in three consecutive fields of 
view per specific area. For TLR4, RP105 and fibronectin-EDA stainings were scored in a semi-
quantitative manner, using zero staining as grade 0, mild to moderate staining as grade 1 and a 
profound staining as grade 2. 
Statistical methods
Significance of differences between the groups was calculated non-parametrically using a Mann-
Whitney U-test. Difference in survival rate after MI was calculated using a chi-squared test. 
P-values <0.05 were considered statistically significant. SPSS 17.0 for Windows (SPSS, Chicago, IL, 
USA) was used for statistical analysis. Values are presented as means ± SD. 
Results
Increased inflammatory response in RP105-/- mice after TLR4 
stimulation by LPS
To demonstrate whether an increased TLR4 mediated inflammatory response is present 
in RP105-/- mice as compared to WT mice, an ex vivo whole blood stimulation assay was 
performed in the presence and absence of LPS. After an overnight LPS stimulation with 
25 ng/mL and 50 ng/mL LPS, TNFα levels were markedly increased in RP105-/- mice 
compared to WT mice for both concentrations, whereas no significant difference was 
observed under non-stimulated conditions (table 1). 
RP105 deficiency does not affect baseline cardiac function 
To determine possible differences in baseline cardiac function between WT and RP105-/- 
mice, echocardiography and PV-loops were measured in animals without MI. Since 
body weight differed between the groups (25.7 ± 0.7 g in WT vs. 28.9 ± 2.7 g in RP105-/-, 
CHAPTER 5
88
p=0.036) all volumetric parameters were corrected for body weight. Results for the main 
PV-loop derived parameters show no significant differences between the WT and the 
RP105-/- mice (see supplemental table 1). These findings indicate that RP105 deficiency 
per se does not influence basal cardiac function.
RP105 deficiency promotes cardiac dilatation after myocardial 
infarction
To investigate whether RP105 deficiency influences cardiac function after MI, the LAD 
was permanently ligated in 12 WT and 12 RP105-/- mice. No significant difference in 
survival rates was observed (92% in WT vs. 75% in RP105-/-, p=0.273), suggesting that 
both strains were equally able to cope with the severe cardiac damage.
Table 1  Effect of RP105 deficiency TLR4 mediated inflammatory response.
TNFα (ng/mL) WT TNFα (ng/mL) RP105-/-
LPS dose (ng/mL)
25 20.0±4.1 ng/mL 108±24 ng/mL
50 28.7±7.0 ng/mL 128±25 ng/mL
Blood samples of WT and RP105-/- mice were diluted 1:25 with RPMI 1640, and incubated 
overnight with 25 or 50 ng/mL LPS. Subsequently TNFα levels were measured and expressed as 
ng/mL. Values represent means ± SD; n=5 per group. 
Figure 2 PV-loops after MI. WT and RP105-/- mice underwent ligation of the LAD, and 15 
days post myocardial infarction (MI) pressure-volume loops (PV-loops) were recorded in each 
mouse. Average PV-loops and PV-relations, corrected for body weight, are shown per group. n=8 
per group. ESPVR, end-systolic pressure volume relation; EDPVR, end-diastolic pressure volume 
relation.
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Fifteen days after induction of the MI, functional parameters were obtained by 
intraventricular PV-loop measurements. The results of these analyses are summarized in 
table 2. Based on mean values for end-diastolic and end-systolic pressures and volumes, 
average PV-loops were created for both groups (figure 2). Corresponding end-diastolic 
and end-systolic PV-relations were added, based on mean EES and EED values. These 
measurements revealed that RP105 deficiency significantly affected heart function 
after MI. Compared with WT mice, RP105-/- mice showed significantly higher heart 
rate (+21% p=0.003), ESV index (+42%, p=0.038), ESP (+22%, p=0.021) and lower Tau 
(-12%, p=0.046). Furthermore a clear tendency for a higher EDV (+35%, p=0.058) and 
higher –dP/dtMIN (+24%, p=0.093) was observed. Taken together, RP105
-/- mice showed 
more prominent cardiac dilatation after MI, but general hemodynamics appeared to be 
relatively unaffected at this stage.
Table 2  Effect of RP105 deficiency on cardiac function after an MI. 
WT RP105-/- P-value
General
HR (beats/min) 446±19 538±44 0.003
SV (µL/g) 0.8±0.3 0.9±0.4 0.490
CO ((mL/g)/min) 0.4±0.1 0.5±0.2 0.300
SW (mmHg.(µL/g)) 42±14 57±44 0.916
EA (mmHg/(µL/g)) 0.2±0.1 0.1±0.1 0.223
EES/EA 0.7±0.3 0.6±0.3 0.395
Systolic
ESP (mmHg) 58±9 70±9 0.021
ESV (µL/g) 1.1±0.7 1.8±0.7 0.038
EF (%) 43±16 35±10 0.372
dP/dtMAX (mmHg/ms) 5±2 6±2 0.462
EES (mmHg/(µL/g)) 48±10 49±27 0.955
Diastolic
EDP (mmHg) 1±2 2±2 0.293
EDV (µL/g) 1.9±0.6 2.7±0.9 0.058
Tau (ms) 11.9±0.9 10.4±1.5 0.046
-dP/dtMIN (mmHg/ms) 4±0.8 5±2 0.093
EED (mmHg/(µL/g)) 6±4 5±3 0.721
KED (1/(µL/g)) 0.2±0.1 0.1±0.0 0.114
HR, heart rate; SV, stroke volume; CO, cardiac output; SW, stroke work; EA, arterial elastance 
(afterload); EES/EA, ventricular arterial coupling; ESP, end-systolic pressure; ESV, end-systolic 
volume; EF, ejection fraction; dP/dtMAX, maximal rate of pressure increase; EES, end-systolic 
elastance (slope of ESPVR); EDP, end-diastolic pressure; EDV, end-diastolic volume; Tau, 
relaxation time constant; -dP/dtMIN, maximal rate op pressure decline; EED, end-diastolic stiffness 
(slope of EDPVR); KED, diastolic stiffness constant. Values represent means ± SD; n=8 per group.
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RP105 deficiency does not influence infarct size
Then it was investigated whether the enhanced dilatation of the RP105-/- mice could 
be secondary to an increased myocardial infarct size. Directly after the PV-loop 
measurements, 15 days after MI, mice were sacrificed and hearts were isolated. Figure 
3 shows representative Sirius red stained cross sections of the infarcted heart. No 
differences in total LV area were observed (27*106 ± 4*106 µM in WT vs 31*106 ± 3*106 
µM in RP105-/-, p=0.11) whereas the infarct area comprised 12 ± 5% of the total LV in 
the WT animals versus 16 ± 10% in the RP105-/- mice (p=0.53). The infarct sizes in both 
groups were thus similar, which may suggest that the more pronounced dilatation in 
RP105-/- mice reflects that the remote ‘healthy’ myocardium of the RP105-/- mice is less 
able to maintain cardiac function after MI as compared to WT mice. 
Structural analysis of the myocardium and infarct area
To investigate potential underlying mechanisms causing the observed differences in 
cardiac function after MI, (immuno)histochemical analyses on the myocardium of both 
groups were performed. We focused on inflammatory components in specific areas 
of the myocardium: the infarcted area, the border zone and the remote ‘undamaged/
healthy’ myocardium. Figure 4 shows representative images of the different stainings for 
Sirius red, TLR4, fibronectin-EDA, MAC-3 and RP105. All stainings showed little to no 
response in the undamaged myocardium remote from the infarct area. An upregulation 
of TLR4, fibronectin-EDA staining and the number of macrophages (figure 5) were 
observed in the area adjacent to the infarcted zone. As expected, the infarcted area 
consisted mainly of collagen (scar tissue) and macrophages. No differences in staining 
patterns were observed between WT and RP105-/- mice. 
Figure 3  Left ventricular area and myocardial infarct size in WT and RP105-/- mice. 
Representative cross sections, after Sirius red staining, are shown above the corresponding bars for 
myocardial infarct size. Each bar represent mean ± SD; n= 8-10 per group.




The innate immune system, and especially TLRs, plays a pivotal role in the remodeling 
process that is initiated after an MI. Since the role of TLR accessory molecules and 
especially the negative regulator of TLR4, RP105, in cardiovascular disease is still largely 
unknown, we investigated its role in post MI cardiac function and remodeling. Our 
results show, for the first time, that deficiency of the TLR accessory molecule RP105, 
results in hampered post MI repair and subsequent loss of cardiac function. This causal 
involvement of RP105 in the post MI inflammatory processes provides new opportunities 
for therapeutic approaches to reduce cardiac remodeling and thereby improving cardiac 
function after a myocardial event. 
Figure 4  Typical examples of (immuno)histological stainings. Images are shown of (A) 
Sirius red staining indicating the collagen in the tissue adjacent to the infarcted area (*), (B) TLR4 
staining in tissue adjacent to the infarcted area (*), (C) fibronectin-EDA staining in tissue adjacent 
to the infarcted area (*), (D) MAC-3 (macrophages) and (E) RP105 staining in tissue adjacent to 
the infarcted area (*). All images were photographed in sections adjacent to the infarcted area and 
this example is from a WT mouse. No differences were observed for Sirius red, TLR4, fibronectin-
EDA or MAC-3 staining between the two groups. 200x magnification.
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RP105 was originally identified as a B-cell specific molecule, but turned out to be 
also present on myeloid cells including macrophages and dendritic cells.16, 19 Since the 
expression of RP105 mirrors that of TLR4, and TLR4 is an important player in the 
pathophysiology of cardiovascular disease processes, we hypothesized that RP105 might 
be an essential regulator in cardiovascular diseases. In this study we demonstrate that 
after an MI, RP105 deficiency results in an increased ESV and EDV which is associated 
with a more dilated LV. Since infarct size was similar in both groups, this effect suggests 
that the unaffected healthy myocardium of RP105-/- mice is less able to preserve cardiac 
function after MI as compared to WT mice. 
After MI, loss of function in the infarct zone may be compensated by the unaffected 
myocardium, for example by hypertrophy, or by invoking the Frank-Starling mechanism 
via cardiac dilatation. In addition, cardiac output may be maintained by increased heart 
rate. No significant differences in cardiac output were observed between the two groups, 
but the RP105-/- mice showed a more pronounced dilatation and higher heart rate. This 
suggests that the intrinsic myocardial function in the undamaged myocardium was less 
in these mice, requiring more pronounced compensatory responses.
This conclusion is supported by the results regarding the end-systolic pressure volume 
relation (ESPVR) as shown in figure 2. The figure illustrates that the differences between 
the groups do not merely reflect altered loading conditions, but changes in intrinsic LV 
function as well reflected by a rightward shift of the ESPRV. Interestingly, in contrast to 
the ESPVR which indicates a depressed systolic LV function, the downward shift of the 
end-diastolic pressure volume relation (EDPVR) points towards an improved diastolic 
function in line with the positive effects on Tau and dP/dtMIN.
Although macrophages in the infarcted zone are essential for the removal of necrotic tissue 
20, they may also contribute to cardiac dysfunction by adherence to cardiomyocytes.21 
Figure 5 Amount of macrophages per specific area of the myocardium in WT and RP105-/- 
mice. the infarcted area, the border zone and the remote ‘undamaged/healthy’ myocardium Per 
image three specific areas of the myocardium were distinguished per image; the infarcted area, the 
border zone and the remote, undamaged, healthy myocardium. The number of macrophages was 
in three consecutive fields of view per specific area. Each bar represent mean ± SD; n= 8-10 per 
group.
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However, as both WT and RP105-/- mice show a comparable density of macrophages in 
the border and infarcted areas, this cannot explain the differences in cardiac function. 
Another factor that may contribute to the observed LV dilatation could be the availability 
of ligands for TLR4. Previously we showed presence of TLR4 and the endogenous TLR4 
ligand fibronectin-EDA after MI resulting in deteriorating effects on cardiac remodeling.12, 
22 Similarly, in this study we observed an upregulation of fibronectin-EDA in WT mice 
when the damaged myocardium is compared to the undamaged myocardium. This 
was similar in the RP105 deficient mice showing equal fibronectin-EDA expression. 
We thereby demonstrated that RP105 does not influence local endogenous TLR ligand 
fibronectin-EDA expression. 
In the current study we did not observe any effects of RP105 deficiency on histologic 
parameters. This could be explained by the lack of RP105 expression in the myocardium, 
since RP105 is known to be present on antigen presenting cells (APC)16 but not on 
cardiomyocytes. APCs are well known to be involved in the cardiac remodeling process.
Alternatively it could be that RP105 has no direct signaling capacities. Since RP105 has 
no direct signaling function, but rather acts as a potent inhibitor of TLR4 signaling, it is 
more likely that the effects of RP105 deficiency are due to enhanced TLR4 signaling. In 
line with previously published results of Divanovic et al.16, 23 we were able to demonstrate 
an enhanced inflammatory response in whole blood in RP105-/- mice. Ex vivo stimulation 
of whole blood samples of RP105-/- mice by the TLR4 ligand LPS resulted in strong 
upregulation of TNFα levels compared to the controls (table 1), a difference in TNFα 
levels that was not observed under unstimulated conditions. This supports the hypothesis 
that the TLR4 mediated inflammatory response is enhanced by RP105 deficiency. 
RP105 alters TLR4 signaling via the RP105-MD1 complex which forms an unusual 2:2 
homodimer. Two possible mechanisms for signaling inhibition effects on TLR4-MD2 
were suggested previously; a lateral binding of TLR4-MD2 to the RP105-MD1 complex 
or the formation of TLR4-MD2/RP105-MD1 complexes reminiscent of the usual ligand-
induced TLR homodimers.24 Therefore the final effects of same amount of endogenous 
ligands activating TLR signaling, and thereby initiating cardiac remodeling, may have 
been increased due to the lack of RP105. While TLR4 expression in the myocardium was 
also comparable in both groups, this supports the hypothesis that RP105 does not cause 
its effects in remodeling directly via endogenous ligand or modulation of TLR4 receptor 
expression but probably via its previously described alternation of TLR4 signalling. 
By demonstrating that deficiency of the TLR accessory molecule RP105 affects the 
remodelling process, we reveal that a non-signalling extracellular receptor may be a 
potential target in the prevention of cardiac remodelling. 
In summary, this study provides the first evidence that RP105 is involved in mechanisms 
underlying the TLR4 pathway induced post-infarction healing process. We show that 
RP105 deficiency has deleterious effects on cardiac function after an MI compared to 
WT mice with similar infarct size. These results underscore the role of the TLR4-pathway 
in post-infarction remodelling and as a result modulating RP105 may be an interesting 
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Supplemental table 1 Baseline cardiac function of WT and RP105-/- mice. 
WT RP105-/- P-value
General
HR (beats/min) 587 ± 51 545 ± 79 1.000
SV (µL/g) 0.7±0.3 0.8±0.3 1.000
CO ((mL/g)/min) 0.4 ± 0.1 0.4 ± 0.2 0.886
SW (mmHg.(µL/g)) 69±20 71±19 1.000
EA (mmHg/(µL/g)) 0.2±0.1 0.2±0.1 0.486
EES/EA 1.0±0.1 0.9±0.1 0.343
Systolic
ESP (mmHg) 96 ± 14 90 ± 17 0.686
ESV (µL/g) 1.0 ± 0.3 0.9 ± 02 0.686
EF (%) 42.3 ± 5.7 45 ± 10.4 0.686
dP/dtMAX (mmHg/ms) 8.9±1.8 8.0±1.4 0.686
Ees (mmHg/(µL/g)) 138±57 116±66 0.686
Diastolic
EDP (mmHg) 6 ± 5 3 ± 3 0.686
EDV (µL/g) 1.7 ± 0.6 1.7 ± 0.4 1.000
Tau (ms) 10±3 9±1 1.000
-dP/dtMIN (mmHg/ms) 8±2 7±1 1.000
EED (mmHg/(µL/g)) 6±1 8±4 1.000
KED (1/(µL/g)) 0.16±0.03 0.09±0.0 0.500
HR, heart rate; SV, stroke volume; CO, cardiac output; SW, stroke work; EA, arterial elastance 
(afterload); EES/EA, ventricular arterial coupling; ESP, end-systolic pressure; ESV, end-systolic 
volume; EF, ejection fraction; dP/dtMAX, maximal rate of pressure increase; EES, end-systolic 
elastance (slope of ESPVR); EDP, end-diastolic pressure; EDV, end-diastolic volume; Tau, 
relaxation time constant; -dP/dtMIN, maximal rate op pressure decline; EED, end-diastolic stiffness 
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Toll-like receptor 2 and Toll-like receptor 4 
deficiency modestly influence cardiac function 
in mice on a high-fat diet
Abstract
High-fat diet (HFD) feeding is a potent trigger for the development of obesity and 
cardiovascular disease. In addition, we previously reported that HFD feeding modestly 
impairs cardiac function in mice. Toll-like receptors (TLR) 2 and TLR4, receptors of 
the innate immune system, are hypothesized to be activated by ligands associated with 
HFD exposure such as (modified) fatty acids. Although TLR2 and 4 are involved in 
inflammation in cardiac disease, a direct relationship between HFD, TLR activation and 
cardiac dysfunction has not been reported. We therefore investigated the role of TLR2 
and TLR4 in the impairment of cardiac function after exposure to HFD.
Male TLR2-deficient (TLR2-/-) mice, TLR4-deficient (TLR4-/-) mice and their 
corresponding wild-type (WT) littermates were fed a HFD for 12 weeks. Body weights 
were measured weekly, plasma lipid levels were obtained at week 10, and left ventricular 
pressure-volume relationships were measured at week 12. 
As compared to their respective WT littermates, TLR2-/- and TLR4-/- mice showed no 
difference in body weight, plasma phospholipid, total cholesterol and triglyceride levels. 
In TLR2-/- mice, an increased end-diastolic volume (51±12 versus 73±18 µL; p=0.03) 
was observed, whereas other parameters of cardiac function were not different from 
WT littermates. In TLR4-/- mice, we observed trends of a decreased pressure half time 
(5.3±1.0 versus 4.3±0.6 ms; p=0.06) and an increased end-systolic elastance (1.6± 0.6 
versus 3.3±2.0 mm Hg/µL; p=0.07). 
This study shows that deficiency for TLR2 or TLR4 only mildly impairs cardiac function 





Overweight and obesity are reaching epidemic proportions worldwide, due to reduced 
physical activity in combination with a calorie rich diet. Since adipose tissue has a limited 
capacity to store fat, excess fat may be stored in non-adipose tissue such as liver and 
muscle, contributing to the pathogenesis of type 2 diabetes and cardiovascular diseases 
(CVD). 
Saturated fatty acids such as palmitate and stearate which are abundantly available in 
most HFDs induce the accumulation of lipids in non-adipose tissues which is thought 
to give rise to chronic activation of inflammatory signalling pathways.1 The onset of 
the inflammatory response is marked by the release of pro-inflammatory cytokines2 
resulting in the infiltration of inflammatory cells, e.g. macrophages, in the tissue.3
The exact molecular mechanisms responsible for the activation of inflammatory pathways 
in obesity are still poorly understood. One mechanism may be related to the finding that 
fatty acids and fatty acid derivative are able to activate TLRs.4 TLRs play a key role in 
the innate immune response and are not only expressed on immune cells, but also by 
other cell types including cardiomyocytes.4, 5 Thus far thirteen different TLRs have been 
discovered, and particularly the role of TLR2 and TLR4 in CVD and atherosclerosis 
have been studied extensively.6 It has been observed that the absence of TLR2 and TLR4 
has favourable effects on post-infarction healing during cardiac ischemia7-10, and in 
atherosclerosis results in a reduced plaque formation.11-13 Furthermore, there is evidence 
that TLRs also have adverse effects on the development of acute coronary syndrome14 
and aggravate heart failure.15
As HFD is clearly related to the development of coronary heart diseases, deleterious 
effects of HFD on the heart may be, at least partially, mediated through TLRs, which 
to our knowledge has not been studied before. We previously demonstrated that HFD 
feeding impairs cardiac function, preferentially in male mice.16 In the current study, we 
show that a HFD intervention in TLR2 and TLR4 deficient mice results in very mild 
changes in cardiac function, thereby suggesting that TLR2 and TLR4, if anything, play a 
moderately protective role in HFD-induced cardiac dysfunction.
Materials and methods
Animals and experimental design
We used male B6.129-Tlr2tm1Kir/J (TLR2-/-) mice, purchased from The Jackson Laboratory 
(Indianapolis, USA), TLR4 knock out (TLR4-/-) mice, kindly provided by Prof. S. Akira (Department 
of Biochemistry, Hyogo College of Medicine, Hyogo, Japan) and T. van der Poll (Center for 
Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, the Netherlands), 
and their respective wild-type (WT) littermates (all C57Bl/6J background). All mice were housed 
under standard conditions with a 12-hour light-dark cycle and had free access to food and water. 
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At the age of 13-15 weeks (TLR2-/- mice and WT littermates) or 7-12 weeks (TLR4-/- mice and 
WT littermates) mice were assigned to a lard based low-fat diet (LFD) or HFD which provided 
45% energy from lipids (D12451, Research Diets Services, Wijk bij Duurstede, the Netherlands). 
Body weight was measured weekly and after 10 weeks of diet feeding, blood was drawn to measure 
plasma lipids. Heart function assessment with echocardiography and pressure volume loops (PV-
loops) were performed in week 11 and 12, respectively. At the end of the experiment the mice 
were sacrificed and hearts were isolated for further examination. The protocol was approved by 
the Animal Ethics Committee from the Leiden University Medical Center and was conform to the 
Guide for Care and Use of Laboratory Animals (NIH publication No.85-23, Revised 1996).
Plasma lipids
After a 4 hour fast (9.00-13.00 h), blood was collected via tail vein bleeding in potassium EDTA-
coated plastic tubes (Sarstedt, Germany). Plasma total cholesterol, triglycerides and phospholipids 
were determined individually using commercially available kits (kit no. 1489232; 11488872 and 
101140, Roche Diagnostics, Mannheim, Germany) in 96-wells plates (Greiner Bio-One), according 
to the manufacturer’s protocols. 
Hemodynamic measurements 
At week 12, left ventricular (LV) function was assessed by invasive PV-loops as described earlier.16 
Briefly, mice were anesthetized with 4% isoflurane, intubated, ventilated and the jugular vein was 
cannulated for infusion of hypertonic saline to determine parallel conductance. Via the right 
carotid artery a 1.2F PV catheter (FTS-1212B-4518, Scisense Inc., London, Ontario, Canada) was 
placed into the LV. The catheter was connected to a Scisense ADV signal processor (Scisense Inc) 
to generate high-fidelity pressure and volume signals. Positioning of the catheter was guided by 
online pressure and volume signals. On-line display and acquisition of the signals (2000 samples/s) 
was performed with a PowerLab 8/30 data acquisition system and LabChart Pro software (AD 
Instruments GmbH, Spechbach, Germany). Off-line data analysis was performed with custom-
made software (CircLab, P. Steendijk).
Immunohistochemistry
After isolation, hearts were fixed in formalin and cut into five 1-2mm thick slices perpendicular 
to the long axis of the heart. These slices were flat embedded in paraffin and cross-sectioned (5 
µm-thick) throughout the entire heart for immunohistological analysis. To determine the amount 
of macrophages in the myocardium an F4/80 staining was performed (F4/80; 1:10. The F4/80 
monoclonal antibody was a gift from Dr. P.J. Nijweide, (Dept. of Molecular Cell Biology, Leiden 
University Medical Centre, the Netherlands). Five images were acquired throughout the ventricles 
of the heart with a 400x magnification. The number of macrophages per image was counted by two 
observers blinded for the study results. A macrophage was defined as brown/red staining which 
touched a blue nucleus and the average number of macrophages in the heart was calculated. 
Statistical analysis
Significance of differences between the groups was calculated non-parametrically using a Kruskal-
Wallis test for independent samples, followed by a Mann-Whitney U-test for independent samples. 
P-values ≤0.05 were considered statistically significant. SPSS 17.0 for Windows (SPSS, Chicago, IL, 




HFD feeding similarly increases body weight gain in TLR2-/-, TLR4-/- 
and WT mice
To determine the effect of HFD feeding on induction of obesity in TLR2-/- and TLR4-/- 
mice, body weight was measured weekly. At the start of the experiment, body weight did 
not significantly differ between groups. After HFD feeding for 12 weeks no differences 
in body weight between HFD fed TLR2-/- and TLR4-/- mice and corresponding WT 
mice were observed, although there was a tendency towards a diminished body weight 
gain for the TLR2-/- group (figure 1). However, 12 weeks of HFD feeding significantly 
increased body weights in all strains as compared to their LFD controls. LFD feeding 
in TLR2-/- resulted in a lower body weight gain compared to WT mice, whereas TLR4-/- 
mice did not differ in body weight gain compared to WT mice (supplemental figure A).
HFD feeding does not lead to differences in plasma lipids between 
TLR2-/- and TLR4-/- and WT mice
After 10 weeks of HFD feeding, blood was drawn to determine the concentration of total 
cholesterol, triglycerides and phospholipids in plasma (figure 2). For total cholesterol 
levels no differences were observed between the TLR2-/- and TLR4-/- mice and WT 
mice after HFD feeding, whereas HFD feeding did increase total cholesterol levels in 
all groups as compared to the LFD controls. LFD feeding did not influence cholesterol 
levels (supplemental figure B). 
HFD feeding did not induce differences in triglyceride levels between TLR2-/- and 
TLR4-/- mice and WT mice. No differences in triglyceride levels were observed between 
HFD and LFD fed mice for TLR-/- and WT groups. Also, compared to LFD feeding, 
triglyceride levels were hardly affected. However, triglyceride levels tended to increase in 
TLR2-/- mice compared to WT mice, whereas TLR4-/- mice did not show an increase in 
triglyceride levels compared to WT mice. Phospholipids showed no differences between 
Figure 1 Effect of TLR deficiency in HFD fed mice on body weight gain. Male TLR2-/- and 
TLR4-/- mice and WT littermates were fed a high-fat diet (HFD) for 12 weeks. Body weight was 
measured at the beginning and end of the dietary intervention. Values represent means ± SD (n=7-
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both TLR-/- and WT mice after HFD. Levels were increase in all groups upon HFD 
feeding compared to LFD feeding, whereas phospholipid levels after LFD feeding alone 
did not differ between both TLR-/- and WT mice. 
HFD feeding influences heart function modestly in TLR2-/- and TLR4-/- 
mice
To examine the effect of HFD feeding on cardiac function in TLR-/- mice, PV-loops were 
performed in all groups and the obtained results are summarized in table 1. Based on 
the mean values for end-diastolic and end-systolic volumes, average PV-loops of HFD 
groups were generated and corresponding end-diastolic and end-systolic PV-relations 


























































Figure 2  Effect of TLR deficiency on HFD fed mice on plasma lipids. Male TLR2-/- and 
TLR4-/- mice and corresponding WT littermates were fed a high-fat diet (HFD) for 12 weeks. After 
10 weeks blood was drawn to determine total cholesterol (A), triglyceride (B) and phospholipid 
levels (C). Values represent means ± SD (n=5-8 per group) 
Figure 3  Effect of TLR deficiency on HFD fed mice on pressure-volume loops and pressure-
volume relations. Male TLR2-/- (A) and TLR4-/- (B) mice and corresponding WT littermates were 
fed a high-fat diet (HFD). After 12 weeks pressure-volume loops (PV-loops) were recorded in each 
mouse, and average PV-loops are shown per group (n= 3-8 per group).
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After HFD feeding differences were observed between the TLR-/- and WT mice. 
TLR2-/- mice increased ESV (+76%, p<0.009) and EDV (+42%, p<0.03) compared to 
their respective littermates. TLR4-/- mice tended to decrease pressure half time (-18%, 
P<0.06) and tended to increase end-systolic elastance (EES) (+200%, p<0.07) under HFD 
conditions compared to their respective littermates. 
Both studies showed differences between LFD and HFD fed TLR-/- and WT mice, 
although not on similar parameters and not in a similar direction. TLR2-/- mice fed a 
HFD had a tendency towards an increased ESV (+46%, p<0.09) and an EDP (+360%, 
p<0.06) compared to LFD fed mice. WT mice in this study increased arterial elastance 
Mice were fed a high-fat diet (HFD) for 12 weeks and cardiac function was determined. LV 
volume signals obtained by conductance catheter were calibrated by matching EF and CO with 
corresponding echocardiographic values obtained by measurements four days earlier. Values 
represent means ± SD (n= 4-8 per group). HR, heart rate; SV, stroke volume; CO, cardiac output; 
SW, stroke work; EA, arterial elastance (afterload); PHT, pressure half time; ESP, end-systolic 
pressure; ESV, end-systolic volume; EF, ejection fraction; dP/dtMAX, maximal rate of pressure 
increase; SB-EES, end-systolic elastance; EDP, end-diastolic pressure; EDV, end-diastolic volume; 









HR (beats/min) 494 ± 45 514 ± 33 0.49 546 ± 77 601 ± 74 0.14
SV (µL) 27 ± 10 31 ± 8 0.30 30 ± 13 27 ± 16 0.12
CO (mL/min) 13 ± 5 16 ± 4 0.36 17 ± 9 17 ± 10 0.29
SW (mm Hg.µL) 2559 ± 866 2883 ± 803 0.42 2178 ± 1029 2468 ± 1535 0.29
EA (mm Hg/µL) 3.6 ± 1.3 2.9 ± 0.7 0.22 2.7 ± 1.0 4.1 ± 1.8 0.19
PHT (ms) 5.3 ± 0.8 4.9 ± 0.5 0.77 5.3 ± 1.0 4.3 ± 0.6 0.06
Systolic
ESP (mm Hg) 84 ± 11 84 ± 11 1.00 70 ± 18 86 ± 8 0.37
ESV (µL) 24 ± 4 42 ± 14 0.009 34 ± 17 33 ± 9 0.17
EF (%) 52 ± 8 43 ± 9 0.30 48 ± 23 43 ± 13 0.94
dP/dtMAX (mm Hg/ms) 7120 ± 1245 7254 ± 1250 0.91 6060 ± 2499 8583 ± 1738 0.12
SB-EES (mm Hg/µL) 2.8 ± 0.4 2.3 ± 0.5 0.09 1.6 ± 0.6 3.3 ± 2.0 0.07
Diastolic
EDP (mm Hg) 1.0 ± 2.5 0.9 ± 2.1 0.64 1.9 ± 1.0 2.3 ± 2.8 0.94
EDV (µL) 51 ± 12 73 ± 18 0.028 64 ± 5 61 ± 17 0.12
Tau (ms) 10.6 ± 1.5 9.9 ± 0.8 0.91 10.3 ± 2.3 8.4 ± 1.3 0.14
-dP/dtMIN (mm Hg/ms) -6096 ± 1493 -6358 ± 904 0.73 -5209 ± 1937 -7911 ± 1499 0.17
SB-EED (mm Hg/µL) 0.14 ±0.03 0.12 ± 0.05 0.20 0.13 ± 0.04 0.20 ±0.09 0.12
Table 1 Effect of TLR deficiency in HFD fed mice cardiac function
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(EA) (+55%, p=0.03) and EES (+44%, p=0.02) and tended to increase the ESP (+15%, 
p=0.09) on a HFD compared to WT mice on a LFD. TLR4-/- mice fed a HFD showed a 
tendency towards a decreased pressure half time (-12%, p=0.06) and an increased end-
diastolic elastance (EED) (+62%, p=0.07) compared to TLR4
-/- mice on a LFD. WT mice 
in this study on a HFD showed a tendency towards a decreased dP/dtMAX (-32%, p=0.08) 
and a decreased SB-EES (-50%, P=0.07) compared with LFD feeding in WT mice.
In LFD conditions, differences in cardiac function were observed between the TLR-/- 
and WT mice (supplemental table 1 and supplemental figure C). Compared with their 
respective LFD WT littermates, TLR2-/- mice showed an increase in EES (+54%, P<0.02), 
whereas TLR4-/- mice on a LFD showed an increased stroke volume (+69%, P<0.02) 
and EDV (+32%, P=0.05) and a decreased heart rate (-13%, P<0.02), dP/dtMAX (-19%, 
P=0.05), EA (-41%, P=0.05), EES (-38%, P=0.05) and EED (-46%, P<0.03).
HFD feeding does not increase cardiac macrophage numbers in TLR2-/- 
TLR4-/- and WT mice
To determine if macrophages infiltrated more in cardiac tissue by HFD feeding, and their 
possible influence on cardiac dysfunction, the number of macrophages in the ventricles 
was counted. Images of representative pictures are given in figure 4. There were no 
differences in the average number of macrophages per image in HFD fed TLR2-/- mice 
compared to WT (1.2±1.9 vs. 2.9±1.2 macrophages per image). Likewise, no difference 
was found between HFD TLR4-/- and WT mice (11.4±16.4 vs. 14.1±13.8 macrophages 
per image). HFD feeding itself did not result in an increased number of macrophages 
neither in both TLR-/- groups nor WT groups as compared to the LFD control groups. 
Furthermore, no difference was observed for the amount of macrophages in all LFD fed 
groups (supplemental figure D). 
Figure 4  Effect of TLR deficiency in HFD fed mice on cardiac macrophage infiltration. 
Representative images of macrophage staining by F4/80 in cardiac tissue for of high-fat diet (HFD) 
fed WT mice (A) and TLR2-/- mice (B). The shown example was from the TLR2-/- experiment, no 





Since the discovery that HFD derived ligands activate TLR2- and TLR4-dependent 
pathways and play a role in HFD induced obesity, insulin resistance4 and atherosclerosis13, 
studies have been performed to further investigate the underlying mechanisms. We 
previously demonstrated that HFD feeding impairs cardiac function specifically in 
male and not female mice. Therefore we set out to determine the role of TLR2 and 
TLR4 signaling in HFD-induced cardiac function. Here, we show that TLR2 or TLR4 
deficiency does not induce major differences in heart function under HFD conditions. 
HFD intervention for 12 weeks results in subtle differences in cardiac function in TLR2-/- 
and TLR4-/- mice compared to HFD fed WT littermates, even though body weight and 
some plasma lipid parameters are increased due to HFD feeding.
The modestly induced cardiac dysfunction between TLR deficient mice and WT 
littermates after HFD intervention is independent of the HFD, as high-fat feeding 
did induce several other previously described metabolic changes. First, HFD feeding 
significantly induced body weight gain in all groups. Second, as expected, HFD feeding 
increased total cholesterol levels in all HFD fed groups. Plasma phospholipids levels 
also tended to be increased upon high-fat feeding. Interestingly, possibly due to the 
genetic background, the mice displayed triglyceride levels just above detection level. 
Therefore, small variations in triglyceride levels may result in larger and thus significant 
differences. Third, contrary to expectations, we observed no difference in macrophages 
between the different groups. The HFD we used, without supplemented cholesterol, 
might be a too mild inflammatory trigger unable to stimulate macrophage attraction 
to the myocardium. Overall, these data show that HFD feeding resulted in the expected 
phenotypic effects, even though cardiac dysfunction was only mildly induced. 
Despite evidence that mice lacking TLRs have a lower incidence of atherosclerosis 
and other cardiovascular pathology, in this study cardiac function in the TLR2-/- and 
TLR4-/- mice was slightly impaired when compared to their corresponding HFD fed WT 
littermates. 
One of the contributing factors to the activation of TLRs, leading to the onset of 
inflammatory pathways, are fatty acids derived from the diet. Lard based HFD is rich in 
mainly C18:1 (43.3%), C16:0 (29.2%) and C18:0 (15.0%). In vitro studies show that in 
particular C12:0 and C16:0; and C14:0 and C18:0; are able to activate TLR2 and TLR4, 
respectively.4, 17, 18 Therefore we assume that this particular lard diet is able to stimulate 
those specific TLRs, and thus does not clarify the lack of the TLR effect. 
A possible explanation for the mild effects of the HFD in TLR deficient mice on cardiac 
function might be that we have chosen for male mice in this experiment. A sexual 
dimorphism has been reported for TLR deficient mice, showing that TLR2-/- and TLR4-/- 
female mice fed a HFD are more evidently protected against metabolic disturbances 
compared to males, who showed no difference in insulin response between WT and 
TLR deficient mice.4, 19 In addition, as more often is seen with receptors belonging to the 
innate immune system, it is possible that the absence of one TLR causes compensatory 
up regulation of other TLRs, resulting in a similar inflammatory status which thus not 
lead to cardiac dysfunction. 
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Contradictory to previous findings16, in the current study HFD-induced cardiac 
dysfunction in WT mice did not reach statistical significance. The fact that these 
WT mice have a less pronounced cardiac impairment could explain why only subtle 
differences were found in cardiac function between TLR-/- and WT mice. We cannot 
explain why the WT mice react differently to the HFD feeding compared to an earlier 
study, however it might be that small variations in study setup, e.g. the average age of 
the mice or environmental factors in the animal facilities, are causing this effect. Clearly, 
more research is needed to fully determine the exact role of TLR2 and TLR4 signaling in 
HFD-induced cardiac function.
To summarize, in this study we show that HFD feeding in TLR2-/- mice and TLR4-/- mice, 
compared to WT mice, neither results in differences in body weight nor in plasma lipids. 
Cardiac dysfunction is observed HFD fed TLR2-/- mice for the EDV parameter, whereas 
HFD fed TLR4-/- mice showed a tendency towards a decreased pressure half time and 
an increased SB-EES, leading to the conclusion that TLR2 and TLR4, if anything play a 
moderately protective role in HFD-induced cardiac dysfunction. 
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Supplemental figure A  Effect of LFD feeding on body weight gain. Male TLR2-/- and TLR4-
/- mice and WT littermates were fed a low-fat diet (LFD) for 12 weeks. Body weight was measured 
at the beginning and end of the dietary intervention. Values represent means ± SD (n=6-8 per 





























































Supplemental figure B  Effect of LFD feeding on plasma lipids. Male TLR2-/- and TLR4-/- mice 
and corresponding WT littermates were fed a low fat diet (LFD) for 12 weeks. After 10 weeks 
blood was drawn to determine total cholesterol (A), triglyceride (B) and phospholipid (C) levels. 




Supplemental figure C  Effect of LFD feeding on pressure-volume loops and pressure-
volume relations. Male TLR2-/- (A) and TLR4-/- (B) mice and corresponding WT littermates were 
fed a low-fat diet (LFD). After 12 weeks pressure-volume loops (PV-loops)were recorded in each 
mouse, and average PV-loops are shown per group (n= 4-5 per group).
A B
Supplemental figure D  Effect of LFD feeding on cardiac macrophage infiltration. 
Representative images of macrophages stained cardiac tissue for A) low-fat diet (LFD) WT 
littermate group and B) LFD TLR-/- group. The shown example was from the TLR2-/- experiment, 
no between group differences was observed. Magnification 400x.
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HR (beats/min) 499 ± 59 526 ± 51 0.46 640 ± 18 558 ± 46 0.014
SV (µL) 33 ± 8 25 ± 14 0.33 19 ± 6 33 ± 12 0.014
CO (mL/min) 17 ± 5 13 ± 7 0.33 12 ± 4 18 ± 8 0.22
SW (mm Hg.µL) 2331 ± 612 2192 ± 1372 0.62 2105 ± 564 2683 ± 842 0.62
EA (mm Hg/µL) 2.3 ± 0.4 4.3 ± 2.2 0.07 4.8 ± 1.5 2.8 ± 0.9 0.05
PHT (ms) 5.1 ± 1.21 5.1 ± 0.6 0.62 4.3 ± 0.6 4.9 ± 0.6 0.14
Systolic
ESP (mm Hg) 73 ± 12 82 ± 16 0.33 84 ± 6 81 ± 13 0.62
ESV (µL) 28 ± 11 29 ± 8 0.81 39 ± 13 45 ± 12 0.46
EF (%) 56 ± 10 44 ± 10 0.09 35 ± 15 43 ± 10 0.33
dP/dtMAX (mm Hg/ms) 6248 ± 1938 6948 ± 1997 0.62 8870 ± 1254 7224 ± 1160 0.05
SB-EES (mm Hg/µL) 1.9 ± 0.3 3.0 ± 0.5 0.019 3.2 ± 0.9 2.0 ± 0.6 0.05
Diastolic
EDP (mm Hg) -0.2 ± 1.9 0.2 ± 2.1 0.81 1.8 ± 1.9 2.7 ± 4.2 1.00
EDV (µL) 61 ± 14 54 ± 20 0.62 58 ± 10 77 ± 16 0.05
Tau (ms) 10.5 ± 2.1 10.0 ± 1.3 1.00 8.3 ± 1.4 9.4 ± 1.2 0.14
-dP/dtMIN (mm Hg/ms) -5393 ± 1446 -6249 ± 1581 0.14 -7808 ± 1369 -6592 ± 995 0.22
SB-EED (mm Hg/µL) 0.12 ± 0.03 0.11 ± 0.03 0.81 0.20 ± 0.11 0.11 ± 0.02 0.027
Mice were fed a low-fat diet (LFD) for 12 weeks and cardiac function was determined. LV 
volume signals obtained by conductance catheter were calibrated by matching EF and CO with 
corresponding echocardiographic values obtained by measurements four days earlier. Values 
represent means ± SD (n= 4-5 per group). HR, heart rate; SV, stroke volume; CO, cardiac output; 
SW, stroke work; EA, arterial elastance (afterload); PHT, pressure half time; ESP, end-systolic 
pressure; ESV, end-systolic volume; EF, ejection fraction; dP/dtMAX, maximal rate of pressure 
increase; SB-EES, end-systolic elastance; EDP, end-diastolic pressure; EDV, end-diastolic volume; 
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Niacin reduces atherosclerosis development 
in APOE*3Leiden.CETP mice mainly by 
reducing nonHDL-cholesterol
Abstract
Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely 
increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from 
previous small clinical studies, the large outcome trials, AIM-HIGH and HPS2-THRIVE 
did not reveal additional beneficial effects of niacin (alone or in combination with 
laropiprant) on top of statin treatment. We aimed to address this apparent discrepancy 
by investigating the effects of niacin without and with simvastatin on atherosclerosis 
development and determine the underlying mechanisms, in APOE*3Leiden.CETP 
mice, a model for familial dysbetalipoproteinemia (FD).
Mice were fed a western-type diet containing cholesterol without or with niacin (120 
mg/kg/day), simvastatin (36 mg/kg/day) or their combination for 18 weeks. Similarly 
as in FD patients, niacin reduced total cholesterol by -39% and triglycerides by -50%, 
(both p<0.001). Simvastatin and the combination reduced total cholesterol (-30%; -55%, 
p<0.001) where the combination revealed a greater reduction compared to simvastatin 
(-36%, p<0.001). Niacin decreased total cholesterol and triglycerides primarily by 
increasing VLDL clearance. Niacin increased HDL-cholesterol (+28%, p<0.01) and 
mildly increased reverse cholesterol transport. All treatments reduced monocyte 
adhesion to the endothelium (-46%; -47%, p<0.01; -53%, p<0.001), atherosclerotic lesion 
area (-78%; -49%, p<0.01; -87%, p<0.001) and severity. Compared to simvastatin, the 
combination increased plaque stability index [(SMC+collagen)/ macrophages] (3-fold, 
p<0.01). Niacin and the combination reduced T-cells in the aortic root (-71%, p<0.01; 
-81%, p<0.001). Lesion area was strongly predicted by nonHDL-cholesterol (R2=0.69, 
p<0.001) and to a much lesser extent by HDL-cholesterol (R2=0.20, p<0.001).
Niacin decreases atherosclerosis development mainly by reducing nonHDL-cholesterol 
with modest HDL-cholesterol-raising and additional anti-inflammatory effects. The 
additive effect of niacin on top of simvastatin is mostly dependent on its nonHDL-
cholesterol-lowering capacities. These data suggest that clinical beneficial effects of niacin 





The beneficial effects of niacin, also known as nicotinic acid or vitamin B3, on plasma 
lipids and lipoproteins were first described in the 1950s.1 According to a meta-analysis of 
30 randomized controlled trials, niacin potently reduced triglycerides (TG) by ~15-30% 
and increased HDL-cholesterol (HDL-C) by ~10-25%, while mildly reducing plasma 
total cholesterol (TC) by ~5-15% and LDL-cholesterol (LDL-C) by ~5-20%, suggesting 
an atheroprotective effect.2 Whereas previous small clinical studies supported this 
notion3-6, the recent large outcome trials AIM-HIGH and HPS2-THRIVE failed to reveal 
additional beneficial effects of niacin on top of statin treatment.7, 8 
In patients with atherosclerotic disease or those at risk for atherosclerotic disease due to 
dyslipidemia, the primary goal of lipid-modifying therapy is the lowering of LDL-C.9 To 
this end, statins are currently the standard treatment for cardiovascular disease (CVD) 
resulting in a 25-45% risk reduction for cardiovascular events.10 However, a substantial 
residual risk for adverse cardiovascular outcomes remains with statin therapy.3, 11 
Moreover, despite maximally tolerated statin treatment, some patients cannot reach 
LDL-C goals. This high risk population together with statin intolerant patients verify the 
need for another LDL-C-lowering agent to (further) reduce LDL-C levels.12 Treatment 
of low HDL-C is currently considered a secondary lipid target in the reduction of 
cardiovascular risk3, since low HDL-C is an independent risk factor for CVD.2, 13 
Considering the current treatment options, the question remains whether to further 
reduce LDL-C or to increase HDL-C in addition to LDL-C-lowering.12 Therefore, due 
to both its nonHDL-C-lowering and HDL-C-raising properties, niacin was considered 
an attractive candidate for further cardiovascular risk reduction in addition to statin 
therapy.
Indeed, an initial small clinical study suggested that the addition of niacin to statin 
treatment may cause potentially clinical significant reductions in relative risk of 
cardiovascular events.6 Recently a number of relatively small secondary prevention 
studies (ARBITER-2 4, ARBITER-3 5 and ARBITER-6-HALTS 3) have shown reduced 
progression and even regression of atherosclerosis with combination treatment of niacin 
and statins compared to statins alone, as measured by carotid artery intima media 
thickness as a surrogate for clinical endpoints. Magnetic resonance imaging results from 
another study confirmed the reduction in carotid atherosclerosis with niacin in statin-
treated patients.14 These clinical data were corroborated by recent observations that 
niacin reduces atherosclerosis development, independent of lipid-lowering or HDL-C-
elevation, in hyperlipidemic LDL receptor knockout mice on a high-fat diet containing 
1.5% cholesterol.15 Despite these promising data, the large outcome trial, AIM-HIGH, 
addressing the effect of niacin on top of aggressive LDL-lowering treatment, has 
recently been prematurely terminated due to futility.8 In accordance, the much larger 
HPS2-THRIVE trial failed to reveal additional risk reduction of cardiovascular events 
with extended-release (ER)-niacin/laropiprant in combination with statin treatment as 
compared to statin mono-treatment.7 ER-niacin2 and ER-niacin/laropiprant combination 
treatment16 are more tolerable formulations that have been developed due to a reluctance 
to use niacin for clinical treatment as a result of extreme flushing as a side effect.17
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In the present study, we aimed to address the seeming discrepancy between the beneficial 
effects of niacin in initial clinical trials3-6, 14, as well as in LDL receptor knockout mice, 
a model irresponsive to the lipid-modulating effects of niacin15, and the lack of effect 
of niacin on top of statin treatment on reduction of cardiovascular events in the AIM-
HIGH 8 and HPS2-THRIVE trials.7 Therefore, we evaluated the effects of niacin without 
and with simvastatin on atherosclerosis development and investigated the underlying 
mechanisms and contributing factors in APOE*3Leiden.CETP mice. This is a well-
established mouse model for familial dysbetalipoproteinemia (FD) with human-like 
lipoprotein metabolism and atherosclerosis development. These mice respond to the 
lipid-lowering effects of both niacin18 and statins, e.g. atorvastatin19, as well as the HDL-
C-raising effect of niacin18.
Materials and methods
Animals, diets and experimental design 
Female APOE*3Leiden.CETP transgenic mice20, expressing human cholesteryl ester transfer 
protein (CETP) under control of its natural flanking regions, were housed under standard 
conditions with a 12 h light-dark cycle and had free access to food and water during the experiment 
unless indicated otherwise. Body weight (BW) and food intake were monitored during the entire 
study. To increase plasma cholesterol levels up to ~12 mmol/L, 8-12 week-old mice were fed a 
semi-synthetic cholesterol-rich diet, containing 15% (w/w) cacao butter and 0.1% cholesterol 
(Western-type diet; Hope Farms, Woerden, the Netherlands) for 3 weeks. After matching based 
on age, BW, TC, TG and HDL-C mice (n=15 per group) received a control western-type diet 
(WTD) without or with 0.1% (w/w) niacin (120 mg/kg/day), 0.03% (w/w) simvastatin (36 mg/kg/
day) or their combination for 18 weeks. During the treatment period, the effects of treatment on 
plasma lipids, lipoprotein profiles, CETP activity and CETP mass were assessed at the indicated 
time points.   
The dose of simvastatin targeted a 30-35% reduction in TC and that of niacin a 20-30% increase 
in HDL-C. While we achieved these targets, it should be noted that the dose of simvastatin was 
3 times higher than the maximum dose used in the clinic taking into account a 10 times faster 
metabolism in mice. For niacin the dose was comparable to that in patients, about 1 g/day. At 
the end of the experiment all animals were sacrificed by CO2 inhalation. Liver and white adipose 
tissue (WAT) were isolated to assess CETP expression (n=6-8 per group) and hearts were isolated 
to assess atherosclerosis development (n=15 per group). Separate additional experiments were 
performed to evaluate the effects of niacin on VLDL production and clearance, as well as reverse 
cholesterol transport (RCT). Animal experiments were approved by the Institutional Animal Care 
and Use Committee of The Netherlands Organization for Applied Research (TNO). 
Plasma lipids and lipoprotein profiles
After a 4 h fast, blood was collected via tail vein bleeding and plasma was isolated. Plasma TC, 
HDL-C after precipitation of apoB-containing lipoproteins using MnCl2 
21 and TG were determined 
individually using enzymatic kits 1489437 and 1488872 (both from Roche diagnostics), according 
to the manufacturer’s protocols. After 4 and 18 weeks of treatment, pooled lipoprotein profiles for 
TC were measured by fast protein liquid chromatography (FPLC).20
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VLDL production and clearance experiments
APOE*3Leiden.CETP mice (11-14 weeks of age) were fed a WTD containing 0.1% cholesterol 
for 3 weeks. Upon subsequent matching according to plasma TC and TG levels, mice received the 
cholesterol-containing WTD without or with 0.1% (w/w) niacin for an additional 3 weeks18 and 
VLDL production and clearance were determined as described.22
Plasma was obtained via tail vein bleeding in heparin microvettes for randomization (Sarstedt, 
Germany) and in chilled paraoxon-coated capillary tubes to prevent ex vivo TG hydrolysis for 
VLDL production and clearance, and assayed for TG and TC using commercially available kits 
1488872 and 236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA), respectively.
For the VLDL production experiment, 6 control and 6 niacin-treated mice were fasted for 4 h. 
During the experiment, mice were sedated with 6.25 mg/kg acepromazine (Alfasan), 6.25 mg/
kg midazolam (Roche) and 0.31 mg/kg fentanyl (Janssen-Cilag). At t=0 min, blood was taken via 
tail bleeding and mice were injected intravenously with 100 µL PBS containing 100 µCi Trans35S 
label to measure de novo total apoB synthesis. After 30 min, the mice received 500 mg of tyloxapol 
(Triton WR-1339, Sigma-Aldrich) per kg BW as a 10% (w/w) solution in sterile saline, to prevent 
systemic lipolysis of newly secreted hepatic VLDL-TG. Additional blood samples were taken 15, 30, 
60, and 90 min after tyloxapol injection and used for determination of plasma TG concentration. 
After 120 min, the mice were sacrificed and blood was collected by orbital puncture for isolation 
of VLDL by density gradient ultracentrifugation. Incorporation of 35S-label was measured in the 
VLDL fraction as marker of de novo apoB synthesis.
For the VLDL clearance experiment, glycerol tri[3H]oleate (triolein, TO)- and [1α,2α(n)-14C]
cholesteryl oleate (CO)-double labeled VLDL-like emulsion particles (80 nm) were used.23 In 
short, radiolabeled emulsions were obtained by adding 100 µCi of [3H]TO and 10 µCi of [14C]
CO to 100 mg of emulsion lipids before sonication (isotopes obtained from GE Healthcare, Little 
Chalfont, UK). APOE*3Leiden.CETP mice (5 control and 5 niacin-treated mice) were fasted for 4 
h, sedated as described above, and injected intravenously with the radiolabeled emulsion particles 
(1.0 mg TG in 200 µL PBS). Blood was taken from the tail vein to determine the content of [3H]TO 
and [14C]CO in serum at 2, 5, 10 and 15 min after emulsion injection. Fifteen min after injection, 
plasma was collected by orbital puncture and mice were sacrificed by cervical dislocation. Organs 
were harvested and saponified to determine uptake of radioactivity derived from [3H]TO and [14C]
CO by various organs.22
Endogenous CETP activity, CETP mass and CETP mRNA expression 
analysis
Plasma endogenous CETP activity was determined by a fluorescent method using donor liposomes 
enriched with nitrobenzoxadiazole-labeled cholesteryl esters (RB-CETP, Roar Biomedical, New 
York, NY) as described.19 CETP activity was calculated as nmol cholesteryl ester transfer/mL 
plasma/h. Plasma CETP mass was determined by using the DAIICHI CETP ELISA kit according 
to manufacturer’s instructions (Daiichi, Tokyo, Japan).18 Total RNA was extracted from liver and 
white adipose tissue (WAT) using an RNA isolation kit according to manufacturer’s specifications 
(Macherey-Nagel, Düren, Germany). Total RNA concentrations were measured with Nanodrop. 
One µg of RNA was reversed-transcribed to cDNA with iScriptcDNA Synthesis kit (Bio-Rad) and 
purified with Nucleospin Extract II kit (Macherey-Nagel, Düren, Germany). Real-time PCR (RT-
PCR) was carried out on an iQ5 PCR detection system (Bio-Rad) using Sensimix SYBR Green 
RT-PCR mix (Quantace, London, UK). Hypoxanthine-guanine phosporibosyltransferase (HPRT) 
and acidic ribosomal phosphoprotein PO (36B4) were used as the standard housekeeping genes 
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and expression levels were normalized to these housekeeping genes. Primer sequences are listed 
in supplemental table 1.
Histological assessment of atherosclerosis 
After isolation, hearts were fixed in formalin, embedded in paraffin and cross-sectioned (5 
µm) throughout the aortic root area. For each mouse, four sections at intervals of 50 µm were 
used for quantitative and qualitative assessment of the atherosclerotic lesions after staining 
with hematoxylin-phloxin-saffron. For determination of severity of atherosclerosis, the lesions 
were classified into five categories: I) early fatty streak, II) regular fatty streak, III) mild plaque, 
IV) moderate plaque, and V) severe plaque according to the American Heart Association 
classification.19, 24 Lesion severity as a percentage of the number of lesions was calculated. To 
this end, type I-III lesions were classified as mild lesions and type IV-V lesions were classified as 
severe lesions. Total lesion area and number of lesions per cross section, as well as the percentage 
undiseased segments, were calculated. In each segment used for lesion quantification, the number 
of monocytes adhering to the endothelium and the numbers of T-cells in the total aortic root area 
were counted after immunostaining with AIA 31240 antibody (1:1000; Accurate Chemical and 
Scientific, New York, New York, USA) and CD3 (1:500; AbD Serotec, Oxford, UK), respectively. 
Macrophage content of the lesions was measured after immunostaining with Mac-3 (1:50; BD 
Pharmingen, the Netherlands). In addition, sirius red staining was used to quantify the collagen 
content in the plaque 25 and the antibody alpha actin (1:800; DAKO, Glostrup, Denmark) was used 
to quantify the smooth muscle cell (SMC) content.26 Stained areas were measured using Cell^D 
imaging software (Olympus Soft Imaging Solutions, Tokyo, Japan).
Reverse cholesterol transport experiment
16 recipient APOE*3Leiden.CETP mice (10-12 weeks of age) were fed a WTD containing 0.1% 
cholesterol for a run-in period of 3 weeks after which they were subdivided into 2 groups according 
to age, BW, TC, TG and HDL-C. After matching, mice (n=8 per group) received a control 
cholesterol-containing WTD without or with 0.1% (w/w) niacin (120 mg/kg/day) for 3 weeks.
6 donor APOE*3Leiden.CETP mice (10-12 weeks of age) fed a WTD containing 0.1% cholesterol 
for 3 weeks were injected intraperitoneally with 1 mL solution of 3% thioglycollate to induce an 
inflammatory response. Three days after the injection, mice were injected intraperitoneally with 
approximately 300 µCi [3H]-cholesterol together with 100 µg/mL acetylated LDL. Mice were 
sacrificed 1 h later by CO2 inhalation. [
3H]-cholesterol-labeled macrophages were collected from 
the 6 donor mice by peritoneal lavage. These macrophages were washed twice with cold PBS and 
injected intraperitoneally into the 16 recipient APOE*3Leiden.CETP mice. Each recipient mouse 
received 2.8 x 106 [3H]-cholesterol-labeled macrophages containing 7.8 x 106 dpm [3H]-cholesterol. 
Mice were individually caged for 48 h in order to collect feces and sacrificed by CO2 inhalation. 
3H-activity was determined in the plasma, liver and feces. The in vivo RCT experiment was based 
on methods previously described.27, 28
Statistical analyses
Significance of differences between the groups was calculated non-parametrically using a Kruskal-
Wallis test followed by a Mann-Whitney U-test for independent samples. We performed a 
univariate analysis of variance (ANOVA) to investigate the role of TC, nonHDL-C and HDL-C 
exposure as contributing factors in lesion development. A two-way analysis of covariance 
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(ANCOVA) was performed to test for group differences in lesion area, monocyte adhesion, T-cell 
abundance and macrophage area after correcting for HDL-C and nonHDL-C exposure. SPSS 17.0 
for Windows (SPSS, Chicago, USA) was used for statistical analysis. All groups were compared to 
the control group and the combination group was also compared to the simvastatin group. Values 
are presented as means ± SD. P-values <0.05 were considered statistically significant. In the figures, 
the symbol * is used to compare to the control group, and # to compare to the simvastatin group.
Results
Niacin, simvastatin and their combination reduce plasma total 
cholesterol and triglycerides and niacin increases HDL-cholesterol in 
APOE*3Leiden.CETP mice
To verify the lipid-lowering effect of niacin alone and in combination with simvastatin, 
we measured plasma TC (figure 1A), TG (figure 1B) and HDL-C (figure 1C) levels during 
the study. The western-type diet resulted in an average TC of 13.4 ± 1.7 mmol/L, TG of 4.3 
± 1.4 mmol/L and HDL-C of 0.65 ± 0.13 mmol/L (control group). TC and TG levels were 
reduced by niacin (-39%, p<0.001; -50%, p<0.001), simvastatin (-30%, p<0.001; -19%, 
NS) and the combination (-55%, p<0.001; -52%, p<0.001). The combination reduced TC 
to a greater extent than simvastatin alone (-36%, p<0.001). Niacin increased HDL-C by 
+28% (p<0.01) as compared to the control, whereas the combination increased HDL-C 
by +14% (p<0.05) as compared to simvastatin mono-treatment. Niacin alone resulted in 
higher HDL-C than the combination (p<0.001). The reductions in plasma TC induced by 
niacin, simvastatin and the combination were confined to apoB-containing lipoproteins 
as measured after lipoprotein separation by FPLC (figure 1D).
Niacin reduces apoB-containing lipoprotein cholesterol by modestly 
increasing VLDL clearance without affecting VLDL production
To determine by which mechanism the level of apoB-containing lipoprotein cholesterol 
is decreased, first the VLDL-TG production was assessed after injection of Tran35S 
label and tyloxapol. VLDL-TG production did not differ between controls and niacin-
treated mice (figure 2A; control 6.1 ± 0.7 μmol/mL/h versus niacin 6.2 ± 0.8 μmol/
mL/h; p=0.94). In addition, the apoB production rate, as measured by incorporation of 
35S-activity in the VLDL fraction (figure 2B; control 2.9 ± 0.5 μmol/mL/h versus niacin 
2.9 ± 0.4 μmol/mL/h; p=0.94) and VLDL-apoB lipidation (control 1.3 ± 0.4 nmol/100 
dpm versus niacin 1.4 ± 0.3 nmol/100 dpm; p=0.69) did not differ between groups.
We then examined the clearance and uptake of [3H]TO and [14C]CO-labeled VLDL-
like emulsion particles. Despite lack of statistical power, due to unexpected loss of mice, 
there was a trend towards a faster plasma clearance rate of [3H]TO (figure 2C control 
t1/2 = 6.4 ± 2.2 min versus niacin t1/2 = 4.9 ± 0.9 min; p=0.19) and a significantly faster 
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initial [3H]TO clearance in the first 5 min after niacin treatment (p<0.05). Tissue-specific 
3H-accumulation did not differ between groups, although there was a tendency (p=0.07) 
for a higher 3H-accumulation in the spleen from the niacin-treated mice (figure 2D). 
This was accompanied by a non-significant increase in the plasma clearance rate of [14C]
CO (control t1/2 = 11.6 ± 5.5 min versus niacin t1/2 = 7.1 ± 1.7 min; p=0.12) with no 
differences in 14C-accumulation in the various organs between groups (data not shown).
Figure 1  Effect of niacin, simvastatin and their combination on plasma lipid levels. Plasma 
total cholesterol (A), triglycerides (B) and HDL-cholesterol levels were measured at various 
time points throughout the study. The average HDL-cholesterol levels were calculated for all the 
treatment groups (C). Lipoproteins were separated by FPLC and cholesterol was measured in the 
fractions after 18 weeks of treatment (D). (Simva, simvastatin; values are means ± SD; n=15 per 




Niacin, simvastatin and their combination reduce plasma CETP 
activity, CETP mass and niacin alone and together with simvastatin 
reduces hepatic CETP gene expression
In a previous study we showed that niacin increased HDL-C by decreasing hepatic 
CETP expression and plasma CETP concentration.18 To verify this, we measured plasma 
CETP activity and mass and hepatic CETP mRNA expression after 4 and/or 18 weeks 
of treatment (table 1). Niacin, which most prominently increased HDL-C, reduced the 
average plasma CETP activity by -21% (p<0.01) and mass by -22% (p<0.01). Simvastatin 
Figure 2  Effect of niacin on VLDL production and clearance. To determine VLDL production, 
mice were injected with Trans35S label and tyloxapol and the accumulation of TG in plasma (A) 
and the production rate of VLDL-TG and apoB, as well as VLDL lipidation, defined as the ratio 
of VLDL-TG/apoB, were determined (B). To determine VLDL clearance, mice were injected with 
glycerol tri[3H]oleate- and [14C]cholesteryl oleate-labeled VLDL-like emulsion particles. Plasma 
3H-activity was determined as percentage of the initial dose (C), and uptake of 3H-activity by 
various organs was determined as percentage of the injected dose per gram wet tissue (D). (BAT, 
brown adipose tissue; gonWAT, gonadal white adipose tissue; subWAT, subcutaneous white 
adipose tissue; visWAT, visceral white adipose tissue; values are means ± SD; n=6 per group for 
VLDL production and n=3-5 per group for VLDL clearance; *p<0.05 as compared to control).
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reduced CETP activity and mass by -25% and -37%, respectively (both p<0.001) without 
affecting HDL-C levels. The combination reduced CETP activity (-34%; p<0.001) and 
mass (-48%; p<0.001) to an even higher extent. Previously, we demonstrated that this 
reduction was due to reduced CETP mRNA expression in the liver. In line with these 
results, we found that niacin alone and in combination with simvastatin tended to 
reduce hepatic CETP expression to -76% (p=0.072) and -58% (p=0.059), respectively. 
Besides the liver, WAT is considered as a major source of CETP and since WAT is a target 
of niacin29, we also determined the effect of all treatments on CETP mRNA expression 
in WAT. Niacin did not decrease CETP expression in WAT (data not shown), which is 
consistent with a recent study in CETP transgenic mice.30 For the control group, a 125 
times lower relative CETP expression was measured in WAT compared to the liver (data 
not shown). A mild correlation was found between hepatic CETP expression and plasma 
CETP mass (R2=0.25, p=0.006), whereas CETP expression in WAT did not correlate with 
plasma CETP mass (R2=0.02, p=0.45) (data not shown). Taken together, we concluded 
that the liver is the major determinant for circulating CETP levels in this model, which 
were affected by all the treatments.
Niacin alone and in combination with simvastatin reduces 
atherosclerosis development to a greater extent than simvastatin 
treatment alone
After 18 weeks of treatment, we measured the effect of niacin, with and without 
simvastatin on atherosclerosis development in the aortic root. Figure 3 illustrates 
representative images of atherosclerotic lesions for each group. We determined the 
number of lesions per cross section (figure 4A), the lesion severity as a percentage of 
all lesions (figure 4B), the percentage undiseased segments (figure 4C) and the total 
lesion area per cross section (figure 4D). To determine lesion severity as a percentage of 
all lesions, type I-III lesions were classified as mild lesions and type IV-V lesions were 
classified as severe lesions.
Table 1 The effect of niacin, simvastatin and their combination on plasma CETP activity 
after 4 and 18 weeks of treatment, as well as plasma CETP mass and hepatic CETP expression 
after 18 weeks of treatment.
Average plasma CETP 
activity (nmol/mL/h)





Control 64.3 ± 11.4 21.3 ± 3.4 100 ± 30
Niacin 50.6 ± 6.6 ** 16.6 ± 3.5 ** 76 ± 23   p=0.072
Simva 48.1 ± 8.4 *** 
p=0.081
13.4 ± 3.5 *** 
p=0.050
76 ± 25
Niacin + Simva 42.6 ± 8.9 ***   11.0 ± 2.2 ***    58 ± 33   p=0.059
CETP, cholesteryl ester transfer protein; Simva, simvastatin. Values are means ± SD (n=15 per 
group for plasma CETP activity and mass and n=6-8 per group for hepatic CETP expression). 
**p<0.01 and ***p<0.001 as compared to control
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In the control group, a fair amount of atherosclerosis developed with 3.5 ± 0.9 lesions per 
cross section, of which 62 ± 16% were severe and only 17 ± 16% undiseased segments. 
The total lesion area was 144 ± 63 x103 µm2 per cross section. When compared to 
the control, niacin reduced the number of lesions (-23%; p=0.056), attenuated lesion 
severity (p<0.001) and increased the percentage undiseased segments (+141%, p<0.001). 
Furthermore, niacin strongly decreased the total lesion area by -78% (p<0.001). 
Simvastatin alone was less effective as it only reduced lesion severity (p<0.01) and total 
lesion area (-49%, p<0.01). The combination had potent inhibiting effects on lesion 
development, as evidenced by reductions in lesion number (-48%, p<0.001), severity 
(p<0.001) and area (-87%, p<0.001), and by an increase in the percentage of undiseased 
segments (+210%, p<0.001). Furthermore, the percentage undiseased segments, as well as 
the reduction in the lesion number and area was greater after the combination compared 
to simvastatin alone (-44%; +110%; -74%, all p<0.01). These results showed that niacin 
mono-treatment was very potent in inhibiting atherosclerotic lesion development in 
APOE*3Leiden.CETP mice and that niacin added to the atherosclerosis-reducing effects 
of simvastatin.
Figure 3  Effect of niacin, simvastatin and their combination on plaque morphology. 
Representative images of hematoxylin-phloxine-saffron-stained atherosclerotic lesions in a cross 
section of the aortic root area for the control group (A), niacin group (B), simvastatin group (C) 
and the combination group (D) after 18 weeks of treatment.
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Niacin improves lesion stability index and decreases functional 
markers of vascular inflammation
After investigation of lesion morphology, we analyzed the treatment effects on plaque 
composition. For all lesions, the macrophage area as destabilization factor (figure 5A), as 
well as SMC (figure 5B) and collagen area (data not shown) as stabilization factors were 
calculated per cross section. The macrophage, SMC and collagen area per cross section 
in the control group were 24.3 ± 8.6 x103 µm2, 4.6 ± 2.3 x103 µm2 and 64.2 ± 37.0 x103 
µm2, respectively. All treatments reduced the macrophage (-73%, -52% and -90%; all 
p<0.001) and the SMC area (-66%, p<0.01; -50%, p<0.01; -79%, p<0.001). As a measure 
of the lesion stability index, the ratio of collagen and SMC area (i.e. stabilization factors) 
to macrophage area (i.e. destabilization factor) was determined for all lesions (data 
not shown). The lesion stability ratio for the control group was 2.7 ± 1.4. Combination 
treatment tended to increase this ratio by +201% (p=0.085).
Figure 4  Effect of niacin, simvastatin and their combination on atherosclerosis development 
in aortic root area. After 18 weeks of treatment, number of lesions (A), lesion severity (B), 
percentage undiseased segments (C) and total lesion area (D) were determined per cross 
section. Lesion severity was classified as mild (type I-III) and severe (type IV-V) lesions. (Simva, 
simvastatin; values are means ± SD; n=15 per group; **p<0.01 and ***p<0.001 as compared to 
control; ##p<0.01 as compared to niacin + simvastatin).
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After finding indications for more stable lesions, we specifically focused on the 
composition of the more severe lesions, which are considered to be the most vulnerable 
lesions. Additionally, we corrected for the lesion area. Thus, we measured the macrophage 
(figure 5C), SMC (figure 5D) and collagen content (data not shown) as a percentage of 
Figure 5  Effect of niacin, simvastatin and their combination on lesion composition. 
Macrophage area (A) and SMC area (B) were determined for all lesions and calculated per cross 
section. To correct for lesion size, macrophage content (C), SMC content (D), as well as plaque 
stability index (ratio of collagen and SMC content to macrophage content) (E) were also calculated 
as a percentage of lesion area, specifically in severe lesions (type IV-V). (Simva, simvastatin; SMC, 
smooth muscle cells; values are means ± SD; n=15 per group; *p<0.05, **p<0.01 and ***p<0.001 as 
compared to control; #p<0.05, and ###p<0.001 as compared to niacin + simvastatin).
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lesion area. The severe lesions in the control group consisted of 20% macrophages, 4% 
SMC and 45% collagen (latter data not shown). Niacin alone and in combination with 
simvastatin reduced the relative macrophage content by -18% (NS) and -54% (p<0.001), 
respectively and increased the relative SMC content by +97% (p<0.01) and +102% 
(p<0.05), respectively. The combination was superior to simvastatin mono-treatment 
in stabilizing the plaque as seen by a reduction in macrophage content (-54%; p<0.05) 
and an increase in SMC content (+79%; p=0.057). There were no significant differences 
in collagen content between groups (data not shown). The lesion stability index was 
also calculated for the severe lesions based on the relative area (figure 5E). Combination 
treatment increased this ratio by +371% (p<0.01) compared to the control (2.6 ± 1.0) and 
to a greater extent compared to simvastatin (p<0.05) alone.
As functional markers of vessel wall inflammation, the number of monocytes adhering 
to the activated endothelium (figure 6A) and T-cells in the aortic root area (figure 6B) 
were counted and calculated per cross section. In the control group, 3.8 ± 1.2 adhering 
monocytes and 11.3 ± 8.3 T-cells were present. A marked reduction of adhering 
monocytes of more than -45% (p<0.01; p<0.01 and p<0.001, respectively) was found 
in all treatment groups, where T-cells abundance was reduced by niacin alone (-71%, 
p<0.01) and in combination with simvastatin (-81%, p<0.001).
Niacin reduces atherosclerosis progression primarily by reducing 
nonHDL-cholesterol
In addition to inflammation, plasma cholesterol is certainly a strong determinant for 
atherosclerosis progression. We evaluated whether the anti-atherogenic effect of niacin 
and simvastatin could be explained by the reduction in plasma TC (figure 7). Since 
atherosclerotic lesion area showed a quadratic dependence on plasma TC exposure, 
lesion area was transformed using a square root transformation. Lesion area was strongly 
predicted by plasma TC exposure (R2=0.70, p<0.001; figure 7A), and nonHDL-C 
Figure 6  Effect of niacin, simvastatin and their combination on monocyte adhesion and 
T-cell number. The number of monocytes adhering to the endothelium (A) and the number of 
T-cells in the aortic root area (B) were determined per cross section. (Simva, simvastatin; values 
are means ± SD; n=15 per group; **p<0.01; ***p<0.001 as compared to control; ###p<0.001 as 
compared to niacin + simvastatin).
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exposure (R2=0.69, p<0.001; figure 7B) and to a much lesser extent by HDL-C exposure 
(R2=0.20, p<0.001; figure 7C). Together, nonHDL-C and HDL-C exposure accounted 
for 71% of the variability in lesion area and predicted the lesion area independently of 
each other (p<0.001 and p<0.05, respectively). Importantly, the effects of niacin and 
simvastatin on lesion area were lost after correcting for both HDL-C and nonHDL-C 
exposure (p=0.16; p=0.61, respectively). Furthermore, no effect of niacin and 
simvastatin on monocyte adhesion was found after correcting for nonHDL-C exposure 
(p=0.50; p=0.20, respectively). However, niacin decreased the square-root transformed 
macrophage area and T-cell abundance even after correcting for nonHDL-C exposure 
(both p<0.01), whereas simvastatin did not (p=0.12; p=0.26, respectively).
Collectively, these data are compatible with a mechanism that niacin and simvastatin 
mainly decrease atherosclerotic lesion development via a reduction of nonHDL-C 
with an additional effect of HDL-C-elevation for niacin, while a direct effect on lesion 
macrophages and T-cell abundance may contribute to the anti-atherogenic effect of 
niacin, but not simvastatin.
Figure 7 Correlation between plasma cholesterol exposure and lesion area. The square root 
of the lesion area was plotted against total cholesterol exposure (A), nonHDL-cholesterol exposure 
(B) and HDL-cholesterol exposure (C). Linear regression analyses were performed. (Simva, 
simvastatin; n=15 per group).
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Niacin mildly increases reverse cholesterol transport
To investigate the possible mechanism by which the HDL-C-raising effect of niacin may 
contribute to its anti-atherogenic effect, we performed an in vivo RCT experiment. After 
3 weeks of treatment, mice were injected with [3H]-cholesterol-labeled macrophages. 
Forty eight hours after injection, plasma total 3H-activity tended to be decreased (-36%, 
P=0.065), whereas 3H-activity in the HDL fraction was increased after niacin treatment 
(+155%, p<0.01; figure 8A). In addition, niacin increased 3H-activity in the liver (+33%; 
p<0.05) and tended to increase fecal 3H-activity (+26%; p=0.065; figure 8B).
Discussion
In this study, we aimed to address the discrepancy between the beneficial effects of niacin 
in initial clinical trials3-6, 14 and the lack of effect of niacin on top of statin treatment 
on reduction of cardiovascular events in the AIM-HIGH8 and HPS2-THRIVE7 trials 
by investigating the effects of niacin without and with simvastatin on atherosclerosis 
development and determine the underlying mechanisms in APOE*3Leiden.CETP 
mice, a mouse model for FD. We demonstrated that niacin decreased atherosclerosis 
development mainly by reducing nonHDL-C with a modest HDL-C-raising and anti-
inflammatory effect and that the additive effect of niacin on top of simvastatin was 
mostly dependent on its nonHDL-C-lowering capacities. 
First, we showed that niacin and simvastatin both reduced plasma lipid levels. Niacin 
reduced (V)LDL-C and (V)LDL-TG and increased HDL-C, whereas simvastatin 
mainly reduced (V)LDL-C. Combination treatment of niacin and simvastatin 
reduced nonHDL-C more effectively as compared to simvastatin alone. In our study, 
Figure 8  Effect of niacin on reverse cholesterol transport. [3H]-cholesterol-labeled 
macrophages were injected in control and niacin-treated mice and 3H activity was determined in 
plasma and HDL (A) and the liver 48 h after injection, as well as in feces collection between 0-48 




the reduction in plasma TC after niacin treatment alone and in combination with 
simvastatin was greater compared to recent clinical trials. The APOE*3Leiden mouse was 
initially developed as an animal model for FD or type III hyperlipoproteinemia, which 
is characterized by elevated levels of cholesterol and an increased ratio of cholesterol 
to TG in the VLDL and intermediate density lipoprotein (IDL) fractions, resulting in 
the appearance of β-VLDL particles.31, 32 Similarly as in FD patients, in APOE*3Leiden 
and APOE*3Leiden.CETP mice as a model for mixed dyslipoproteinemia, a major part 
of plasma cholesterol is contained in the VLDL and VLDL-remnant particles, leading 
to formation of β-VLDL particles, which further increases after cholesterol feeding. 
Whereas niacin reduces plasma TC by ~5-15%, LDL-C by ~5-20% and TG by ~15-30% 
in patients with hyperlipidemia2, in two small studies in FD patients, niacin decreased TC 
by 23-50% and TG by 43-62% 33, 34 with -56% reduction of VLDL-C and 48% reduction of 
VLDL-TG.34 Thus, the extent of lipid-lowering observed with niacin in APOE*3Leiden.
CETP mice is comparable to that of FD patients.
Since plasma VLDL-TG and apoB levels are determined by the balance between VLDL 
production and clearance, we evaluated their individual contribution. VLDL production 
was not affected in niacin-treated mice, neither was apoB production or lipidation of the 
VLDL particle. However, a modest effect of niacin on VLDL clearance was observed. 
The mechanism behind the lipid-lowering effect of niacin has been generally ascribed 
to a reduced hepatic VLDL production, as a result of decreased free fatty acid (FFA) 
flux from WAT after inhibition of hormone sensitive lipase. However, an initially 
decreased FFA flux is followed by a rebound effect with increased release of FFA.1, 35 In 
humans, contradicting data describe that niacin decreased VLDL production without 
affecting VLDL clearance36-38 and on the other hand that niacin enhanced clearance of 
apoB without affecting production.39 The latter study is in line with our results, which 
implicate VLDL clearance rather than VLDL production as the possible mechanism by 
which niacin reduces apoB. 
The niacin-induced increase in HDL-C in the present study may be attributed to a 
decrease in hepatic and plasma CETP leading to an inhibition of HDL delipidation as 
previously described.18 As similar effects on CETP levels and activity were observed after 
simvastatin treatment, without affecting HDL, different mechanisms are likely involved 
in either treatment. Interestingly, a decreased macrophage content accompanying 
decreased hepatic cholesterol accumulation as a result of niacin’s lipid-lowering effect was 
recently proposed as a mechanism by which niacin decreases hepatic CETP expression.30
An important observation from our studies is that niacin decreases atherosclerosis 
progression and adds to the anti-atherogenic effect of simvastatin, in particular regarding 
its enhancing effect on plaque stability. Niacin decreased lesion number, severity and 
area, and increased the percentage undiseased segments. Moreover, niacin improved 
lesion composition by reducing the macrophage content and increasing the SMC 
content. Importantly, the combination treatment increased the plaque stability index, 
defined as the ratio of SMC and collagen over macrophage area, as compared to either 
niacin or simvastatin alone.
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It is interesting to speculate on the mechanism(s) underlying the anti-atherogenic effect 
of niacin. In the APOE*3Leiden.CETP mouse model, statistical analyses revealed that the 
effects of niacin and simvastatin were largely explained by their reduction in nonHDL-C, 
as evidenced by a strong correlation between plasma nonHDL-C and lesion area. The 
fact that the combination treatment reduced nonHDL-C beyond the level reached by 
simvastatin alone can thus largely explain why niacin added to the anti-atherosclerotic 
effect of simvastatin. Though, HDL-C also appeared to predict lesion area independent 
of nonHDL-C, albeit that the predictive value of HDL-C was much smaller than that 
of nonHDL-C. The HDL-C-raising effect of niacin, may, therefore, have contributed to 
some extent to the anti-atherosclerotic activity of niacin.
To explore the contribution of the niacin-induced increase in HDL-C to the reduction 
of atherosclerosis, we investigated the functionality of HDL by performing an RCT 
experiment. From this experiment, we conclude that the effect of niacin on RCT may 
partially contribute to, but is not the driving force behind its anti-atherogenic effects. 
This is in accordance with our statistical correlations, which showed nonHDL-C to be 
a much stronger contributor to atherogenesis. Although HDL-C contributed to some 
extent, we observed that niacin’s attenuating effect on atherosclerosis development in 
APOE*3Leiden.CETP mice, fed a Western-type diet with 0.1% cholesterol, is largely 
explained by its lipid-lowering effect. At first sight, this seems to contradict a recent report 
showing that niacin reduced atherosclerosis development in LDL receptor-deficient 
mice under conditions that left plasma cholesterol levels unaffected.15 In that mouse 
model, the atheroprotective effects of niacin were mainly explained by impaired homing 
macrophage recruitment to atherosclerotic plaques and by promoting cholesterol efflux 
from macrophages by upregulation of ABCG1. However, it should be noted that those 
mice were fed a high-fat diet containing as much as 1.5% cholesterol. A previous study 
from our laboratory showed that dietary cholesterol induced dose-dependent marked 
inflammation in mice40, where the liver switches to an inflammatory, pro-atherosclerotic 
state as reflected by a strong increase in serum amyloid A levels at dietary cholesterol 
levels exceeding 0.5%. Previously, Lukasova et al.15 evaluated the anti-atherogenic 
effect of niacin under highly inflammatory conditions, at which the anti-inflammatory 
properties of niacin may become dominant and may not necessarily reflect the mode of 
action for niacin under mild cholesterol intake as used in the present study.
It should be noted that we also obtained evidence that niacin exerted anti-inflammatory 
effects in our mouse model under milder dietary conditions. Firstly, niacin reduced 
monocyte adhesion and macrophage area of the atherosclerotic lesions. In fact, niacin 
reduced macrophage area independent of nonHDL-C, whereas simvastatin did not. 
These data not only corroborate the findings in LDL receptor-deficient mice 15, but 
also the recent observations that niacin reduced collar-inflicted vascular inflammation 
and inhibited intima-media neutrophil recruitment in New Zealand White rabbits 
independent of changes in plasma lipids.41 Secondly, we observed that niacin, but not 
simvastatin, strongly reduced the number of T-cells in the aortic root area, which are 
involved in the progression of atherosclerosis.42 The reduction was independent of 
nonHDL-C exposure, suggesting the anti-inflammatory effect observed was brought 
about by niacin, instead of HDL derived. This is in accordance with a study where 
niacin inhibited monocyte chemotactic protein 1 (MCP-1), RANTES and fractalkine in 
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adipocytes. These chemokines contribute to the recruitment of T-cells and macrophages. 
WAT is known to express the GPR109A receptor and has the ability to contribute to both 
systemic and local (perivascular) inflammation associated with atherosclerosis.29, 43
Although initial clinical studies showed that niacin reduced atherosclerosis development 
in combination with statins3-5 and reduced the relative risk of cardiovascular events6, 
results from the large outcome trials AIM-HIGH and HPS2-THRIVE did not confirm 
earlier findings.8, 44, 45 In order to test the HDL hypothesis, the AIM-HIGH investigators 
minimized the differences in LDL levels between the groups. Patients enrolled in the 
trial were subjected to aggressive LDL-C-lowering treatment, aimed at LDL-C of 40-80 
mg/dL (1.03-2.07 mmol/L), reaching mean baseline LDL-C of 71 mg/dL (1.84 mmol/L) 
and HDL-C of 35 mg/dl (0.91 mmol/L).46 A modest increase in HDL-C was observed 
in the placebo group, resulting in a 4-5 mg/dl (0.10-0.13 mmol/L) difference in HDL-C 
between groups. This, together with the aggressive LDL-C-lowering may have given rise 
to insufficient power to detect a reduction in events.45 Unexpectedly, the much larger 
outcome trial HPS2-THRIVE failed to reveal further cardiovascular risk reduction 
when adding ER-niacin/laropiprant to vigorous statin treatment, plus if required 
ezetimibe, as compared to statin/(ezetimibe) mono-treatment.7 Furthermore, there was 
a significant increase in non-fatal serious adverse events and drop-out rate in the ER-
niacin/laropiprant-treated patients. The lack of inclusion criteria for HDL-C resulted 
in a baseline HDL-C of >40 mg/dl (1.14 mmol/L) with a low baseline LDL-C level of 
<70 mg/dl (1.64 mmol/L). Patient stratification revealed that baseline HDL-C levels did 
not predict efficacy of niacin and that indeed only in patients with high LDL-C niacin 
reduced major cardiovascular events. 
In conclusion, our results show that niacin decreases atherosclerosis development mainly 
by reducing nonHDL-C with modest HDL-C-raising and additional anti-inflammatory 
effects. The additive effect of niacin on top of simvastatin is mostly dependent on its 
nonHDL-C-lowering capacities. These data suggest that clinically beneficial effects of 
niacin are largely dependent on its ability to lower LDL-C on top of concomitant lipid-
lowering therapy and may explain the failure of niacin in the clinical outcome trials.
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Supplemental data
Supplemental table 1  RT-PCR primer sequences.
Forward primer Reverse primer
Gene
HPRT TTGCTCGAGATGTCATGAAGGA  AGCAGGTCAGCAAAGAACTTATAG
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG
CETP CAGATCAGCCACTTGTCCAT CAGCTGTGTGTTGATCTGGA
HPRT, hypoxanthine-guanine phosporibosyltransferase; 36B4, acidic ribosomal phosphoprotein 
PO; CETP, cholesteryl ester transfer protein.
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Despite advances in diagnosis and therapy, cardiovascular disease (CVD) remains a 
major cause of morbidity and mortality in Western society and is an increasing problem 
especially in low-to-middle income countries. The most prevalent cardiovascular 
disorders are myocardial infarction (MI) and stroke, both are predominantly caused by 
atherosclerosis. Atherosclerosis is a complex disease associated with a variety of genetic 
and environmental factors. Main pathogenic phenomena underlying atherosclerosis 
are disturbed lipid metabolism and inflammation. The studies described in this thesis 
have explored the effects of specific aspects of these two components on atherosclerosis 
and MI. In this chapter, the main conclusions and implications of these findings are 
discussed.
Gender, nutrition and cardiac function
In the first part of this thesis, the effect of high-fat diet feeding (HFD) on cardiac function 
with and without an MI was studied. We first set out to investigate if feeding a diet 
rich in saturated fatty acids (SFA) resulted in cardiac dysfunction. Chapter 2 describes 
that long term HFD feeding led to alterations in cardiac function solely in male mice, 
although the observed increase in body weight and plasma lipids due to HFD feeding 
was independent of gender. We therefore concluded that male mice are the preferred 
model to investigate effects of ischemia and drug treatments on cardiac function in a 
setting of HFD-induced obesity. 
The observation that female mice seem protected from HFD-induced cardiac dysfunction 
is probably related to beneficial effects of sex hormones and in particular estrogen. In 
animal studies beneficial effects of estrogen treatment are reported in models of cardiac 
hypertrophy1, 2, ischemia/reperfusion3, 4 and atherosclerosis5. These effects are likely 
mediated by effects of estrogen on cardiomyocytes and endothelial cells, but effects 
on other cell types including inflammatory cells and stem cells may be involved as 
well. In addition, estrogen exerts a part of its protective effect via beneficial effects on 
serum lipoproteins, e.g. an increased high-density lipoprotein (HDL)-cholesterol and a 
decreased low-density lipoprotiein (LDL)-cholesterol, accounting for approximately one 
third of the observed clinical benefits.6 Thus, in animal studies, treatment with estrogen 
results in predominantly favorable effects. 
In premenopausal women, the incidence of atherosclerotic diseases is relatively low and 
a sharp increase is observed with the occurrence of the menopause.7 Results from these 
observations and established results of positive effects of estrogen on the cardiovascular 
system, including increased vasodilatation and an inhibited response of blood vessels 
to injury8, suggested that hormone replacement therapy could have beneficial effects on 
CVD in postmenopausal women. However, two large prospective studies, the Women’s 
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Health Initiative and the Heart and Estrogen/Progestin Replacement study, found 
that hormone replacement therapy did not lead to an improvement in cardiovascular 
outcomes, even though lipid profiles were improved and incidence of type 2 diabetes was 
reduced.9-11 A possible explanation for these outcomes could be age-related metabolic 
changes, partly independent of estrogen or the estrogen receptor, thereby reducing the 
protective effect or even leading to detrimental rather than cardioprotective effects.12 
In addition, the Women’s Health Initiative study was prematurely aborted since an 
increased risk for invasive breast cancer was observed.10 Therefore, hormone replacement 
therapies for prevention of CVD, and possibly other chronic diseases, are currently not 
recommended. 
The results in Chapter 2 underscore the detrimental effects of a SFA rich HFD on 
cardiac health. From meta-analysis of randomized controlled trials13 it is recommended 
to replace dietary SFA by polyunsaturated fatty acids (PUFA) to reduce coronary heart 
disease (CHD). Consumption of PUFAs lowers the total cholesterol to HDL-cholesterol 
ratio and may improve insulin resistance and reduce systemic inflammation. The two 
best known PUFAs are omega-3 and omega-6 PUFAs which are present in mainly fish, 
shellfish and seeds, respectively. Although the beneficial effects of omega-6 regarding 
CHD have been under debate, the American Heart Association recommended recently 
that a minimum daily consumption of 5-10% of energy from omega-6 PUFAs is sufficient 
to reduce CHD risk.14 
Regarding omega-3 PUFAs; national and international guidelines have converged on 
consistent recommendations for adults to consume at least 2 servings of fish (particularly 
fatty species) per week. However, clinical trials have not indisputably proven that 
omega-3 PUFAs have beneficial effects on CVD.15, 16 Possibly omega-3 does not solely 
contribute to the observed effects and the interplay between omega-3 and other nutrients 
in fish is also important.17 For the vulnerable CVD patient population, especially those 
on suboptimal pharmaceutical treatment or those who have additional risk factors as a 
result of comorbidities, intake of omega-3 fatty acids in form of oily fish is advised as 
they may benefit the CVD patient.17
Chapter 3 continues with examining the effect of HFD feeding in presence of an MI. 
Unexpectedly, no aggravated cardiac dysfunction was observed upon HFD feeding and 
subsequent induction of MI. However, there was a tendency towards an increase in the 
amount of macrophages in the infarcted area compared to the low-fat diet (LFD) fed 
group. After an MI an extensive inflammatory response takes place which is a critical 
factor in the balance between cardiac repair and adverse ventricular remodeling. Since 
macrophages have an important contribution in this inflammatory process occurring 
post-MI, it is possible that in the longer term this secondary effect could aggravate 
cardiac dysfunction after MI. However, since the follow-up period after MI was only 2 
weeks no long-term conclusion could be drawn from this study.
Although it seems relevant to adapt diet and nutrition style after an MI and other 
symptoms of heart failure, scarce information is provided in the major heart failure 
management guidelines.18, 19 The most recent guidelines from the Heart Failure Society 




report that, besides a sodium restriction for all heart failure patients, dietary instructions 
are mainly recommended in patients with heart failure in combination with diabetes, 
dyslipidemia, or severe obesity. Often patients need personalized dietary advice and it 
has been shown that supervision by dieticians benefits their wellbeing with a decreased 
sodium intake, fluid retention and increased quality of life score.20, 21 Unfortunately, it is 
difficult to provide general recommendations since diet is generally disregarded as factor 
in observational studies and dietary intake is highly heterogeneous. 
Inflammation and cardiac function
The metabolic system and the inflammatory system are evolutionary conserved, as 
survival of organisms depends on the ability to fight infections and to withstand 
starvation.22 Coupling of metabolism and immunity is important since mounting an 
immune response requires much energy and thus regulation of energy homeostasis is 
essential. As a result, there is a delicate balance between the two systems and dysfunction 
of one leads to dysfunction of the other, with malnutrition and immune suppression on 
one side and obesity and immune activation on the other side.23 The current chronic 
caloric overload in the Western world results in complications at the intersection of 
metabolism and immunity, including obesity-linked inflammatory diseases like diabetes, 
fatty liver disease and CVD. 
The liver, adipose tissue, immune cells and blood cells, which perform key metabolic and 
inflammatory functions in humans, have evolved from one functional unit, the ‘fat body’, 
which is still present in the fruit fly Drosophila melanogaster.22 The fat body coordinates a 
variety of actions including nutrient sensing, pathogen and survival responses. Although 
in humans, the different organs acquired specialized functions, they maintained their 
developmental heritage. Partly overlapping pathways regulate both metabolic and 
immune functions through shared signaling systems.22 Consequently, nutrients and 
especially fatty acids (FAs) act through pathogen-sensing systems like Toll-like receptors 
(TLRs), giving rise to metabolically or nutritionally induced inflammatory responses.22, 24 
It was discovered that in particular TLR2 and TLR4 dependent pathways are activated by 
FAs and contribute via this pathway to the low-grade inflammation in several metabolic 
diseases. However, in Chapter 6 we demonstrate that HFD-induced cardiac dysfunction, 
as observed in Chapter 2, is not likely to be mediated by TLR2 and/or TLR4. Very mild 
beneficial changes in cardiac function are observed in TLR-deficient mice, suggesting 
that TLR2 and TLR4, if anything, play a moderately protective role in HFD-induced 
cardiac dysfunction. A possible explanation for the absense of cardiac dysfunction might 
be that in absence of one TLR, another TLR is upregulated as a compensatory effect, 
resulting in a comparable inflammatory status that does not lead to cardiac dysfunction. 
Such a compensatory mechanism is not inconceivable in an evolutionary conserved 
process. 
Although we did not observe HFD-induced TLR2 and TLR4-mediated dysfunction in 
the heart, others reported that TLR4 exerts an important role in myocardial infarction 
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healing and left ventricular (LV) remodeling.25 This difference is probably caused by the 
strong inflammatory activation which is exerted post-MI and the subsequently released 
‘danger’ signals activate the TLR pathway. The importance of the TLR signaling pathway 
is also emphasized in Chapter 5 where we show that RP105, a negative regulator of TLR4, 
is involved in post-infarction cardiac remodeling. Deficiency of the accessory molecule 
RP105 aggravates systolic and diastolic cardiac function indices after MI, indicating that 
reduced inhibition (=activation) of TLR4 signaling aggravates cardiac dysfunction. 
The influence of the TLR pathway on infections in general and cardiac function 
specifically opens opportunities as a therapeutic target. Targeting of TLRs is explored for 
the treatment of e.g. cancer, rheumatoid arthritis, sepsis and cardiac malfunctioning.26 
Different strategies are being considered to pharmaceutically modify TLR2 and TLR4 
including receptor agonists and antagonists and inhibition of the signal transduction 
pathway.27 Despite the evidence shown by animal studies that TLRs are involved in 
several pathological cardiovascular processes, this has so far not been translated into 
clinical applications. The only drugs thus far that have been evaluated for treatment of 
ischemia/reperfusion injury are the TLR4 antagonist Eritoran and the TLR2 antibody 
OPN-305. Preclinical results showed that inhibition of TLR2 by OPN-305 preserved 
cardiac function.28 TLR4 inhibition by Eritoran, in a similar murine model, led to a 
reduced infarct size and decreased cytokine production.29 Although Eritoran was studied 
in a Phase III clinical trial for sepsis, cardiovascular events were not part of the study end 
points.30 However, the results in Chapter 5 provide new opportunities for therapeutic 
approaches to reduce cardiac remodeling through RP105 and thereby improve cardiac 
function after a myocardial event.
High-density lipoprotein, atherosclerosis and 
cardiac function 
An inverse correlation of plasma HDL-cholesterol with CVD risk is found in numerous 
epidemiological studies 31, 32, resulting in the concept that by increasing HDL-cholesterol 
levels, the risk for CHD could be reduced. This risk reduction can be achieved via 
therapeutic elevation of HDL-cholesterol levels, including treatments with niacin and 
cholesteryl ester transfer protein (CETP) inhibitors. Niacin is one of the most potent 
HDL-cholesterol-raising compounds clinically available. Relatively small secondary 
prevention studies have shown positive effects of niacin in combination with statin 
therapy leading to a reduced progression or even regression of atherosclerosis compared to 
statin treatment alone.33-35 These results were supported by animal studies demonstrating 
anti-atherogenic properties of niacin.36-38 Despite these initially promising data, two 
large clinical trials investigating the effects of niacin on top of LDL-lowering treatment 
revealed no beneficial effect of niacin treatment (HPS2-THRIVE39 and AIM-HIGH40). In 
Chapter 7 we aimed to investigate the reason for the failure of these trials and showed 




cholesterol. In addition, the additive effect of niacin on top of simvastatin treatment is 
mostly dependent on the non-HDL-cholesterol-lowering capacities, thereby suggesting 
that beneficial effects of niacin for patient treatment may only be observed when niacin 
lowers LDL-cholesterol on top of related lipid-lowering therapy.
Niacin is not the only HDL-raising drug that did not meet the expectations. Trials with 
the CETP inhibitors torcetrapib and dalcetrapib were also prematurely terminated due 
to off-target toxic effects and the absence of effect, respectively.41, 42 These results indicate 
that the relation between increased plasma HDL-cholesterol levels and reduction of CVD 
risk is rather complex. Although increasing plasma HDL-cholesterol levels as such could 
be relevant, HDL function might be more important in preventing CVD. An increase 
in plasma HDL-cholesterol levels per se does not necessarily translate into a decreased 
CVD risk when the HDL particle is ‘dysfunctional’. However, assessment of HDL quality 
in clinical situations is rather difficult, whereas quantification of HDL quantity is easily 
achieved by measuring plasma HDL-cholesterol levels. 
HDL exerts many functions such as mediating cholesterol efflux from macrophages as a 
first step of reverse cholesterol transport (RCT).  Although in Chapter 7 we concluded 
that RCT is not the driving force behind the anti-atherogenic effects of niacin, in general 
RCT is thought to be an important contributor to cardioprotection. Other properties of 
HDL, including the anti-inflammatory, anti-thrombotic and anti-apoptotic effects, may 
contribute to the anti-atherogenic effects of HDL. It remains difficult to discriminate 
between these different functions especially since the effects are achieved via a variety of 
mechanisms.
Recently, it was proposed that the cholesterol efflux capacity by macrophages may be an 
appropriate tool to measure HDL functionality.43 Consistent with studies in animals, an 
inverse association was observed in patients between early steps in the RCT pathway and 
carotid intima-media thickness and the likelihood of coronary artery disease assessed 
by angiography. However, these effects were independently of HDL-cholesterol levels, 
indicating that increasing HDL levels per se does not necessarily lead to a reduction in 
the atherosclerotic burden.  Importantly, issues related to the reported clinical results44, 
45, including the measurement of cholesterol efflux transport46, remain the subject of 
on-going discussions, therefore requiring further investigations before  measuring 
cholesterol efflux as a marker of HDL functionality can be of clinical value. 
Alternative strategies are actively being explored to develop HDL-targeted therapeutics 
and specifically drugs that increase cholesterol efflux from the arterial wall. One of the 
mechanisms by which cholesterol content in the atherosclerotic lesion, and indirectly 
CVD risk, is reduced is via RCT by removal of cholesterol from the arterial macrophage 
foam cells to the liver for biliary excretion. Active cholesterol removal is mediated by the 
ATP-binding cassette transporters ABCA1 and ABCG1. Deletion of both transporters 
in macrophages results in an impaired cholesterol efflux and a rapid development 
of atherosclerosis.47, 48 Furthermore, prevention of ABCA1 mRNA degradation by 
administration of antagomirs of miR-33, resulted in an enhanced expression of ABCA1 
in the macrophages present in the lesion and a subsequent improved cholesterol 
removal.49 These results support the anti-atherogenic properties of increasing RCT 
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and suggest a promising tool for the treatment of CVD. Although numerous studies 
have been conducted on the effects of ABCA1 on atherosclerosis, no studies have 
been published on the role of ABCA1 after an MI. In Chapter 4 we found much to our 
surprise, that despite its protective effects regarding the development of atherosclerosis, 
ABCA1 exerts detrimental effects on cardiac function after MI. This is possibly caused 
by a reduced activation status of immune cells resulting in less efficient repair after 
MI. Although ABCA1 is considered as a potential therapeutic target for the treatment 
of atherosclerosis, our data clearly indicate that it is of great importance to carefully 
consider potential adverse effects of ABCA1 on cardiac remodeling post-MI. 
Concluding remarks 
The ever increasing prevalence of CVD in the Western world urges industry and society 
to develop novel solutions to decrease this burden. Since lifestyle interventions to reduce 
CVD risk prove difficult to realize, novel solutions and therapies are needed. However, 
for the development of new drugs and therapies it is essential to evaluate their effects 
on both lipid metabolism and inflammation in all aspects of the development of cardiac 
pathophysiology. In this thesis we show that HFD feeding has mild but significant 
detrimental effects on cardiac function. In contrast to our expectations, this effect is not 
likely to be mediated by TLR2 or TLR4. Also, we demonstrated in mice that HFD feeding 
does not significantly aggravate cardiac dysfunction post-MI. Despite these findings, it 
would be of great scientific and societal interest to conduct a more in depth investigation 
on these effects in a prospective obese patient population. 
Deficiency of RP105, a modulator of inflammation, improved cardiac function after 
induction of MI. In addition, ABCA1 had adverse effects on cardiac function post-
MI, possibly via a reduced activation of immune cells. This confirms the important 
role of inflammation in recovery after an MI. Furthermore, we elucidated a possible 
reason for the failure of niacin in recent clinical trials and found that niacin’s anti-
atherogenic properties are most potent by lowering LDL-cholesterol on top of statin 
treatment. Altogether, these results provide novel insights and targets for the prevention 
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Cardiovascular diseases (CVD) are the leading cause of death in the Western world 
and despite greatly improved treatment options during the last decades, the number 
of patients suffering from CVD is still increasing. The risk for CVD is determined by a 
variety of factors, including genetic variation, gender, age, lifestyle, blood pressure and 
plasma lipid levels. Myocardial infarction (MI) and stroke caused by atherosclerosis 
are the most prevalent cardiovascular disorders. Atherosclerosis is a complex disease 
mainly caused by a disturbed lipid metabolism and inflammation. The studies in this 
thesis address specific aspects of inflammation and dietary lipids in the development 
of CVD. These two components are of particular interest as each, both individually and 
collectively, can lead to the onset or maintenance of pathological cardiac conditions.
An increased availability of high-fat diet (HFD) derived fatty acids (FA) may lead to 
excess FA uptake in non-adipose organs like the heart, as adipose tissue has a limited 
capacity to expand. The ectopic storage of FA in the form of TG is probably inert, 
but accumulation of toxic FA intermediates in the heart may affect cardiac function. 
In Chapter 2 we investigated to what extent HFD feeding leads to alterations in left 
ventricular function and whether this depends on gender and (or) duration of HFD 
feeding. For this purpose we used wild-type (WT) male and female C57Bl/6J mice and 
subjected them to a low fat diet (LFD) or HFD for an intermediate (6 weeks) or long 
term (12 weeks) period. We demonstrated that HFD gradually increased body weight 
and plasma lipid levels in mice independent of gender. Furthermore, cardiac function 
assessed by combined echocardiography and invasive pressure-volume loop (PV-loop) 
measurements, was only affected in male mice, but not in female mice after long term 
HFD feeding. This was indicated by an increased end-systolic volume and end-systolic 
pressure and decreased ejection fraction, all symptoms of a reduced systolic function. 
We concluded from these data that male mice are the preferred model to investigate 
effects of ischemia and drug treatment on cardiac function in a setting of diet induced 
obesity. 
Obesity is accompanied by low-grade systemic inflammation that is associated with 
increased risk of CVD including MI. Furthermore, inflammation in the heart, by for 
example local macrophage accumulation, might impair cardiac function. We therefore 
investigated in Chapter 3 if HFD feeding results in aggravated cardiac dysfunction after 
an MI, due to an increased inflammatory response as compared to LFD feeding. We 
subjected WT male mice to a long term LFD and HFD and induced MI by permanent 
ligation of the left anterior descending coronary artery or performed sham surgery. Two 
weeks hereafter, cardiac function was determined by echocardiography and PV-loop 
measurements. Comparable with previous findings, HFD feeding increased body weight 
and induced dyslipidemia in mice. In addition, the sham surgery group showed that 
HFD feeding per se induced mild cardiac dysfunction. No differences in mortality rate 
nor in infarct sizes were observed between LFD and HFD mice with MI. Additionally, 
HFD did not further aggravate cardiac dysfunction after MI, despite a more prominent 
macrophage infiltration in the infarcted myocardial area in HFD MI mice compared to 
LFD MI mice. We concluded that long term HFD did not aggravate cardiac dysfunction 
two weeks after MI induction. 
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ATP-binding cassette transporter A1 (ABCA1), a transporter involved in cellular 
cholesterol transport, exerts anti-atherogenic functions in the pathogenesis of 
atherosclerosis. Since the actual role of ABCA1 during MI, is not established, we explored 
the role of ABCA1 after MI induction in Chapter 4. To this end, we induced an MI in 
ABCA1 knockout (KO) mice, WT controls and WT mice transplanted with ABCA1 
KO or WT bone marrow. Surprisingly, compared to their respective WT controls, 
reduced infarct sizes were found in ABCA1 KO mice as well as WT mice transplanted 
with ABCA1 KO bone marrow. No effect of ABCA1 deficiency on infarct size was 
found in isolated hearts, as investigated in an ex vivo Langendorff perfusion system. 
The smaller infarct size in vivo in ABCA1 KO mice was thus likely due to a secondary 
effect of ABCA1 deficiency on myocyte function. Interestingly, after in vivo MI, ABCA1 
KO mice compared to WT controls, showed higher levels of circulating leukocytes. 
After bone marrow transplantation no differences in leukocyte numbers were observed. 
However, white blood cell counts were increased compared to the first experiment. We 
concluded that despite the fact that ABCA1 has a protective role in atherosclerosis, it 
has adverse effects on cardiac function after MI. In addition, the observed detrimental 
effects are possibly caused by a reduced activation status of immune cells resulting in less 
efficient repair after MI. As a consequence, strategies aiming at up-regulation of ABCA1 
function should be pursued with care in the light of potential adverse effects on cardiac 
remodeling post MI.
The innate immune system of the heart becomes activated after MI injury. Toll-like 
receptor 4 (TLR4), a receptor of the innate immune system, is suggested to negatively 
affect cardiac function after MI. RP105 is a TLR4 homolog which lacks the intracellular 
signalling domain that competitively inhibits TLR4-signalling. In Chapter 5, we 
hypothesized that deficiency of RP105, via an amplified signalling of TLR4, aggravates 
cardiac dysfunction after MI. First we proved that an increased inflammatory response 
was present in RP105 KO mice after TLR4 stimulation by LPS as compared to WT 
male C57Bl/6N mice. Subsequently, we found that baseline heart function, assessed 
by PV-loop measurements, revealed no differences between RP105 KO and WT mice. 
In addition, MI was induced and 15 days post MI, infarct size measurements revealed 
no differences between groups. However, PV-loop measurements showed that RP105 
deficiency promoted cardiac dilatation after MI Furthermore, histological analysis of 
the myocardium and the infarcted area showed that in the area adjacent to the infarct 
zone, expression of RP105, TLR4 and the endogenous TLR4 ligand fibronectin-EDA 
and macrophage count were increased compared to healthy myocardium. However, 
no differences between RP105 and WT were found. Taken together, we showed that 
deficiency of the endogenous TLR4 inhibitor RP105 led to an enhanced inflammatory 
status and more pronounced cardiac dilatation after MI induction. Our findings 
underscored the role of the TLR4 pathway in post MI remodelling and modulating 
RP105 may be an interesting new therapeutic strategy.
TLR2 and TLR4 are hypothesized to be activated by ligands associated with HFD 
exposure such as (modified) FAs. Although TLR2 and TLR4 are involved in inflammation 
in cardiac disease, a direct relationship between HFD, TLR activation and cardiac 
dysfunction has not been reported. In Chapter 6 we studied the role of TLR2 and 4 in the 
impairment of cardiac function after exposure to HFD. TLR2 KO, TLR4 KO mice and 
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their corresponding WT littermates received a long term HFD. No differences in body 
weight or plasma lipid levels were observed between the genotypes after HFD feeding. 
In TLR2 KO mice PV-loop measurements showed an increased end-diastolic volume, 
whereas other parameters of cardiac function were not different from WT littermates. In 
TLR4 KO mice trends were observed of a decreased pressure half time and an increased 
end-systolic elastance. These findings showed that deficiency for TLR2 or TLR4 only 
mildly impaired cardiac function in mice on HFD. This suggested that TLR2 and TLR4, 
The primary goal of lipid-modifying therapy in patients with atherosclerotic disease 
is the lowering of LDL-cholesterol. Statins are currently the standard treatment for 
CVD, however a substantial residual risk for adverse cardiovascular outcomes remains. 
Treatment of low HDL-cholesterol is currently considered a secondary lipid target in 
the reduction of cardiovascular risk, since low HDL- cholesterol is an independent risk 
factor for CVD. Niacin is the most potent HDL-cholesterol raising drug clinically used 
and is considered as a novel therapy for reducing atherosclerosis. Despite evidence for 
an atheroprotective effect of niacin from previous small clinical studies, large outcome 
trials did not reveal additional beneficial effects of niacin on top of statin treatment. In 
Chapter 7 we aimed to elucidate this apparent discrepancy by investigating the effects 
of niacin without and with simvastatin on atherosclerosis development and determine 
the underlying mechanisms in APOE*3Leiden.CETP mice. To this end, mice were 
fed a cholesterol-rich diet without or with niacin, simvastatin or their combination. 
Niacin treatment and the combination reduced total cholesterol and triglycerides, 
whereas simvastatin reduced total cholesterol. The combination treatment revealed a 
greater reduction of total cholesterol compared to simvastatin. Niacin decreased total 
cholesterol and triglycerides primarily by increasing VLDL clearance. Niacin increased 
HDL-cholesterol and mildly increased reverse cholesterol transport. All treatments 
reduced monocyte adhesion to the endothelium, atherosclerotic lesion area and severity. 
Compared to simvastatin, the combination increased the atherosclerotic plaque stability. 
Niacin and the combination reduced T-cells in the aortic root. Lesion area was strongly 
predicted by non-HDL-cholesterol and to a much lesser extent by HDL-cholesterol. In 
conclusion, niacin decreased atherosclerosis development mainly by reducing nonHDL-
cholesterol with minor HDL-cholesterol-raising and additional anti-inflammatory 
effects. The additive effect of niacin on top of simvastatin was mostly dependent on 
its nonHDL-cholesterol-lowering capacities. These data suggest that clinical beneficial 
effects of niacin are largely dependent on its ability to lower LDL-cholesterol on top of 
concomitant lipid-lowering therapy.
Taken together, the studies in this thesis described the effects of both lipid metabolism 
and inflammation on several aspects of cardiac pathophysiology. We showed that HFD 
aggravated cardiac function, although this effect was likely not mediated by TLR2 or 
TLR4. Also, HFD has no detrimental effects on cardiac function post-MI. Deficiency 
of RP105 improved cardiac function after MI induction, whereas ABCA1 had adverse 
effects on cardiac function post MI. Last, we found that the anti-atherogenic properties 
of niacin were mostly dependent on its non-HDL-cholesterol-lowering capacities on top 
of statin treatment. Altogether, these studies offer novel strategies and insights for the 









Hart- en vaatziekten en de risicofactoren
Hart- en vaatziekten (HVZ) zijn de meest voorkomende doodsoorzaak in de westerse 
maatschappij. Ondanks nieuwe en succesvolle behandelmethodes, blijft het aantal 
patiënten met HVZ nog steeds stijgen. Er zijn verschillende factoren die het risico op het 
ontstaan van HVZ verhogen. Hierbij kan onderscheid gemaakt worden tussen factoren 
waar je zelf invloed op kunt uitoefenen (roken, overgewicht en vetrijke en eenzijdige 
voeding) en factoren die je zelf niet kunt beïnvloeden (genetische factoren, geslacht 
en leeftijd). Een gezonde levensstijl kan veel van de sterfgevallen als gevolg van HVZ 
voorkomen. Het blijkt echter dat het aanpassen van de levensstijl voor veel personen 
moeilijk haalbaar is. Ondanks de reeds bestaande therapieën voor de behandeling van 
HVZ is de verwachting dan ook dat HVZ de komende jaren wereldwijd doodsoorzaak 
nummer één zal blijven. Het is daarom noodzakelijk om inzicht te krijgen in de 
mechanismes die ten grondslag liggen aan het ontstaan van HVZ, waarmee nieuwe en 
effectievere behandelmethodes ontwikkeld kunnen worden. 
Atherosclerose en hartinfarcten
De belangrijkste oorzaak van HVZ is atherosclerose (slagaderverkalking). Atherosclerose 
kenmerkt zich door vernauwingen in de bloedvaten als gevolg van de ophoping van vetten 
(waaronder cholesterol) en cellen van het immuunsysteem in de bloedvatwand. Dit kan 
uiteindelijk leiden tot een volledige afsluiting van het bloedvat. Als deze afsluiting in de 
kransslagaderen van het hart plaatsvindt, ontstaat een hartinfarct. Als gevolg hiervan 
worden delen van de hartspier niet langer van zuurstofrijk bloed voorzien. Aangezien 
het hart zuurstof nodig heeft om adequaat te kunnen functioneren, heeft een afsluiting 
als gevolg dat een deel van de hartspier afsterft en dat de kracht waarmee het hart het 
bloed door het lichaam pompt afneemt. 
Vetstofwisseling
De belangrijkste vetten in ons dieet zijn cholesterol en triglyceriden (TG), die beiden 
essentieel voor het menselijk lichaam zijn. Cholesterol wordt onder andere gebruikt voor 
de aanmaak van sommige hormonen en TG zijn een belangrijke energiebron voor het 
lichaam. Omdat vetten slecht oplosbaar zijn in bloed worden ze voor transport door het 
lichaam opgenomen in zogeheten lipoproteïnen, die wel oplosbaar zijn in bloed. In het 
bloed circuleren vier klassen lipoproteïnen die variëren in samenstelling en dichtheid. 
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Tezamen zijn deze lipoproteïnen verantwoordelijk voor het transport van cholesterol en 
TG van en naar organen.
Vetten die na een maaltijd worden opgenomen in de darmen worden in chylomicronen 
verpakt en getransporteerd naar organen als vet, (hart)spier en de lever. Wanneer er 
enige tijd niet gegeten is worden TG in het vetweefsel afgebroken tot vetzuren (lipolyse), 
die via het bloed in de lever terecht komen. De lever is op dat moment de belangrijkste 
distributeur van lipoproteïnen. Om het lichaam van vetten te blijven voorzien, verhoogt 
de lever daarom de productie van lipoproteïnen met zeer lage dichtheid (Engels: VLDL). 
Chylomicronen en VLDL bevatten voornamelijk TG en daarom worden deze deeltjes 
ook wel TG-rijke lipoproteïnen genoemd. De vetzuren die onderdeel uitmaken van 
TG worden door de organen vervolgens uit het bloed opgenomen en verbrand waarbij 
energie vrijkomt. Daarnaast zijn er lipoproteïnen die relatief rijk zijn aan cholesterol: 
lipoproteïnen met lage dichtheid (LDL) en lipoproteïnen met hoge dichtheid (HDL). 
Cholesterol dat zich in de ‘slechte’ LDL-lipoproteïnen bevindt kan zich ophopen in de 
vaatwand, wat kan leiden tot de ontwikkeling van atherosclerose. Daarnaast zijn er de 
‘goede’ HDL-lipoproteïnen, deze bevatten cholesterol dat vanuit de vaatwand naar de 
lever wordt getransporteerd. Daar wordt het hergebruikt of afgebroken om vervolgens 
via de darm het lichaam te verlaten. Waar hoge niveaus van het HDL-cholesterol het 
lichaam beschermen tegen HVZ, zijn hoge niveaus van het LDL-cholesterol juist een 
risicofactor voor HVZ. 
Ontstekingen en het immuunsysteem
Een ontsteking is een proces dat het lichaam normaal gesproken beschermt tegen 
schadelijke stoffen, inclusief virussen en bacteriën. De ontsteking zorgt er op dat moment 
voor dat ziekteverwekkers netjes opgeruimd worden. Sinds een aantal jaar is bekend 
dat mensen met overgewicht een lichte mate van ontsteking hebben, onder andere in 
het vetweefsel. Dit wordt echter niet veroorzaakt door ziekteverwekkers, maar door 
de aanwezigheid van overtollig vet. Overgewicht ontstaat door een verstoorde balans, 
waarbij er in het lichaam meer energie binnenkomt dan verbruikt wordt. De overtollige 
energie kan in het vetweefsel worden opgeslagen, maar de opslagcapaciteit van het 
vetweefsel is beperkt. Bij te grote hoeveelheden wordt vet daarom ook opgeslagen in 
vitale organen zoals de lever en het hart, wat kan leiden tot een lokaal ontstekingsproces. 
Het gaat hier om een chronische ontsteking die de orgaanfunctie kan aantasten.
Er wordt gedacht dat de ontsteking in vetweefsel en vitale organen, als gevolg van 
overgewicht, ontstaat doordat vetzuren bepaalde receptoren van het aangeboren 
immuunsysteem activeren. Receptoren kunnen signalen van binnen of buiten de cel 
doorgeven nadat een signaalmolecuul zich aan de receptor gebonden heeft. Activatie van 
een receptor van het immuunsysteem, bijvoorbeeld door binding van een deel van een 
bacterie, leidt bijvoorbeeld tot een immuunreactie die de ziekteverwekker onschadelijk 
maakt. Recent is gebleken dat delen van vetzuren kunnen binden aan een aantal specifieke 
receptoren van het immuunsysteem, de zogeheten Toll-like receptoren (TLR), waardoor 
er een ontstekingsreactie op gang komt. Er zijn momenteel onderzoeken gaande naar de 




Doel van dit onderzoek en muismodellen
De studies die beschreven zijn in dit proefschrift hebben betrekking op twee 
specifieke processen, de vetstofwisseling en ontsteking, die zowel individueel als 
gezamenlijk invloed kunnen hebben op de ontwikkeling van atherosclerose en 
hartinfarcten. Om deze effecten te bestuderen werden onder andere gespecialiseerde 
hartfunctie-metingen uitgevoerd door middel van echocardiografie en druk-
volume metingen (Engels: PV-loops). Dit is gedaan in de harten van gewone muizen 
en muizen waarbij belangrijke genen voor de vetstofwisseling of ontsteking waren 
uitgeschakeld. Door genen uit te schakelen kunnen de effecten van deze genen op 
het lichaam nauwkeurig bestudeerd worden. Het is zeer lastig om deze effecten met 
behulp van celkweken te onderzoeken, gezien de complexiteit en betrokkenheid van 
meerdere organen bij het ontstaan van HVZ. Ook de mogelijkheden rondom het 
gebruik van humaan weefselmateriaal zijn beperkt omdat de weefsels vaak alleen 
beschikbaar zijn na een chirurgische ingreep of als een patiënt overleden is, waarbij 
het ziekteproces zich vaak al in een eindstadium bevindt. Voor het ontwikkelen van 
nieuwe behandelmethodes is het juist noodzakelijk om meer te weten te komen over 
het ontstaan van HVZ. Diermodellen bieden hiervoor een belangrijke mogelijkheid.
Resultaten van de studies
In Hoofdstuk 2 is onderzocht welke effecten vetrijke maaltijden hebben op de werking 
van het hart. Om te zien wat de bijdrage is van geslacht of de tijdsduur van het dieet, is dit 
onderzoek uitgevoerd bij zowel mannelijke als vrouwelijke muizen die een laag-vet dieet 
(LVD) of een hoog-vet dieet (HVD) kregen gedurende 6 of 12 weken. Het bleek dat door 
een HVD bij beide geslachten het lichaamsgewicht toenam en ook dat de cholesterol en 
TG niveaus in het bloed verhoogd waren. Een 12 weken HVD leidde echter alleen bij 
mannelijke muizen tot een slechtere hartfunctie. Een verklaring hiervoor zou kunnen 
zijn dat vrouwelijke hormonen een beschermende werking op het hart hebben. Uit deze 
studie is ook duidelijk gebleken dat mannelijke muizen het voorkeursmodel zijn om 
de effecten van dieet-geïnduceerde obesitas en de invloed van geneesmiddelen op de 
hartfunctie te onderzoeken. 
In Hoofdstuk 3 hebben we vervolgens onderzocht wat de effecten zijn van gezonde 
(LVD) of ongezonde voeding (HVD) op de hartfunctie na een hartinfarct in mannelijke 
muizen. Een HVD kan een chronische ontstekingsreactie tot gevolg hebben. Daarnaast 
treedt er na een hartinfarct een acute ontstekingsreactie op. Het is interessant om dit te 
bestuderen, omdat beide ontstekingsprocessen de hartfunctie kunnen beïnvloeden. De 
resultaten van deze studie laten zien dat het voor het herstel van het hart korte tijd na 
een hartinfarct niet veel uitmaakt of er gezonde (LVD) of ongezonde (HVD) voeding 
aan vooraf is gegaan. Het aantal ontstekingscellen in het geïnfarcteerde gebied van het 
hart was wel hoger in de HVD muizen, maar dit had vooralsnog geen invloed op de 
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hartfunctie. Deze resultaten, samen met die uit hoofdstuk 2, suggereren dat in muizen 
gezonde voeding een verslechterde werking van het hart kan voorkómen, maar dat een 
vetrijk dieet het herstel na een hartinfarct niet nadelig beïnvloedt.
Zoals al eerder genoemd kunnen HDL-deeltjes cholesterol vanuit de vaatwand naar 
de lever transporteren. Hierbij spelen ABC-transporters een belangrijke rol, omdat ze 
cholesterol vanuit de cellen in de vaatwand naar het HDL-deeltje kunnen transporteren. 
Eerdere studies hebben aangetoond dat de aanwezigheid van de ABC transporter A1 
(ABCA1) beschermt tegen de ontwikkeling van atherosclerose. In Hoofdstuk 4 hebben 
wij onderzocht of de aanwezigheid van ABCA1 ook beschermt tegen de schadelijke 
effecten van een hartinfarct. Echter, in tegenstelling tot de verwachting voortkomend 
uit de beschermende rol van ABCA1 tijdens de ontwikkeling van atherosclerose, bleek 
dat afwezigheid van ABCA1 in muizen juist zorgde voor minder schade aan de hartspier 
na een hartinfarct. Omdat activatie van het immuunsysteem invloed kan hebben op de 
infarctgrootte, hebben we de concentratie van immuuncellen in het bloed onderzocht. 
Hierbij zagen we een opmerkelijke verhoging van de concentratie immuuncellen bij 
ABCA1-deficiënte muizen. Om te bestuderen of het effect op infarctgrootte veroorzaakt 
werd door ABCA1 op immuuncellen zelf, hebben we vervolgens het beenmerg van 
normale muizen vervangen door dat van ABCA1 deficiënte muizen. Het bleek dat 
de afwezigheid van ABCA1 op de immuuncellen inderdaad resulteerde in kleinere 
infarcten. Hoe dit fenomeen tot stand komt moet nog verder uitgezocht worden. Deze 
resultaten laten zien dat therapeutische strategieën gericht op het activeren van ABCA1 
ter preventie of behandeling van HVZ met zorg moeten worden overwogen, in verband 
met mogelijke schadelijke effecten op het hart.
Daarnaast hebben we onderzocht of Toll-like receptoren en RP105 een belangrijke 
rol spelen bij het herstel van het hart na een hartinfarct. TLR en RP105 zijn eiwitten 
die een belangrijke rol spelen in het immuunsysteem. Van TLR4 is al bekend dat deze 
receptor een negatieve invloed heeft op de hartfunctie na een hartinfarct. RP105 is een 
molecuul dat qua structuur veel op TLR4 lijkt, alleen kan dit molecuul, in tegenstelling 
tot de TLR4 receptor, geen signalen doorgeven. Wel kunnen signaalmoleculen die zich 
normaal gesproken aan TLR4 binden ook binden aan RP105. Dit zorgt uiteindelijk 
voor een verminderde ontstekingsreactie omdat TLR4 minder geactiveerd wordt. In 
Hoofdstuk 5 testten wij de hypothese dat de afwezigheid van RP105, via een versterkte 
signalering van TLR4, leidt tot een verslechtering van de hartfunctie na een hartinfarct. 
De hartfunctie in muizen met normale en afwezige expressie van RP105 was niet 
verschillend voorafgaande aan het induceren van het infarct. Na een infarct zagen wij 
inderdaad dat, ondanks gelijke infarctgroottes tussen beide groepen, de RP105 deficiënte 
muizen een slechtere hartfunctie hadden ten opzichte van de normale muizen. Hoe dit 
effect precies tot stand komt is nu nog onbekend. Wel onderstrepen onze bevindingen 
de rol van TLR4 in het hart na een hartinfarct. Tevens kan het moduleren van RP105 
een interessante nieuwe therapeutische strategie zijn om de schade na een hartinfarct te 
beperken.
In Hoofdstuk 6 hebben we de effecten van TLR2 en TLR4 op de hartfunctie na 
blootstelling aan een HVD onderzocht. Hoewel bekend is dat TLR2 en TLR4 betrokken 
zijn bij ontsteking geassocieerd met HVZ, is er nog geen direct verband gevonden tussen 
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een HVD, de activering van TLR en een slechter werkend hart. In deze studie hebben 
we zowel normale muizen als muizen deficiënt voor TLR2 en TLR4 een HVD gegeven 
voor 12 weken. Na deze periode vonden we geen verschillen in lichaamsgewicht noch 
in cholesterol of TG niveaus in het bloed. Met behulp van de hartfunctiemetingen 
vonden we dat zowel TLR2- als TLR4-deficiënte muizen, zeer kleine verslechteringen in 
hartfunctie vertonen. Deze resultaten suggereren dat als TLR2 en/of TLR4 al een invloed 
heeft op de hartfunctie na HVD, dit een bescheiden rol zal zijn. 
Als laatste hebben we in Hoofdstuk 7 een medicijn bestudeerd waarvan bekend is dat 
het het goede HDL-cholesterol verhoogt, genaamd niacine. Recente experimentele 
patiënten-studies lieten zien dat niacine geen verlaging gaf van het risico op HVZ als het 
gegeven werd in combinatie met statines, ten opzichte van patiënten die alleen statines 
kregen. Statines zijn de huidige LDL-cholesterol verlagende middelen. Het ontbreken 
van de gunstige effecten van niacine is tegenstrijdig met eerder gevonden resultaten 
in kleinere groepen patiënten, waarbij de niacine leidde tot een stagnatie of zelfs een 
afname van de ontwikkeling van atherosclerose. Wij hebben in experimentele studies 
met muizen bestudeerd wat de effecten zijn van niacine in vergelijking met simvastatine 
alsook de combinatie behandeling van niacine met simvastatine. In deze studie hebben 
we ten eerste aangetoond dat de werking van niacine voornamelijk te verklaren is door 
verlaging van het nonHDL-cholesterol (dus voornamelijk het VLDL en LDL). Tevens 
zorgde niacine voor een milde verhoging van het HDL-cholesterol. Daarnaast zagen wij 
dat de behandeling met een combinatie van niacine en simvastatine ten opzichte van 
simvastatine alleen, een gunstig effect had op de ontwikkeling van atheroslcerose. Dit 
effect van niacine bovenop een statine bleek vooral te komen door een extra verlaging 
van het nonHDL-cholesterol. Deze resultaten wijzen er op dat de gunstige effecten van 
niacine in patiënten voor het grootste deel toe te schrijven zijn aan het verlagen van het 
LDL-cholesterol, in combinatie met reeds bestaande LDL verlagende medicijnen. 
Conclusie
De in dit proefschrift gepresenteerde bevindingen beschrijven de gevolgen van zowel 
een verstoorde vetstofwisseling als ontsteking op verschillende aspecten van de 
hartfunctie. We hebben aangetoond dat een HVD de hartfunctie verslechtert, en dat dit 
effect vermoedelijk niet gemedieerd wordt door TLR2 en TLR4. Ook heeft een HVD 
geen extra schadelijke effecten op de hartfunctie na een infarct. Deficiëntie van RP105 
verbetert de hartfunctie na een hartinfarct, terwijl de aanwezigheid van ABCA1 juist 
leidt tot een groter infarct. Als laatste hebben we gevonden dat de anti-atherosclerotische 
eigenschappen van niacine voornamelijk worden verklaard door het verlagen van LDL-
cholesterol, en dat een combinatiebehandeling met statines tot betere effecten zou 
kunnen leiden. Tezamen bieden deze studies nieuwe strategieën en inzichten voor de 






List of publications (full papers)
Revsin Y, Rekers NV, Louwe MC, Saravia FE, De Nicola AF, de Kloet ER, Oitzl MS. 
Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive 
impairment in streptozotocin-induced type 1 diabetes mice. Neuropsychopharmacology 
(2009) 34, 747–758
Louwe MC, van der Hoorn JW, Jukema JJ, Romijn JA, Willems van Dijk K, Rensen PC, 
Smit JW, Steendijk P. Gender-dependent effects of high-fat lard diet on cardiac function 
in C57Bl/6J mice. Applied Physiology, Nutrition, and Metabolism (2012) 37 (2), 214-
224
Louwe MC*, Kühnast S*, van Klinken JB, Smit JW, Havekes LM, Rensen PC, van der 
Hoorn JW, Princen HM†, Jukema JW†. Niacin reduces atherosclerosis progression 
and inflammation on top of simvastatin in APOE*3Leiden.CETP mice. *Both authors 
contributed equally, †These authors share equal responsibility for the manuscript. 
Accepted for publication in PLOS ONE
Louwe MC*, Karper JC*, de Vries MR, Bastiaansen AJ, van der Hoorn JW, Willems van 
Dijk K, Rensen PC, Steendijk P, Smit JW, Quax PH. RP105 deficiency aggravates cardiac 
dysfunction after myocardial infarction in mice *Both authors contributed equally. 
Submitted
Louwe MC, Maas S, van der Hoorn JW, Salvatori D, Rensen PC, Willems van Dijk K, 
Steendijk P, Smit JW. High-fat diet does not aggravate cardiac function after a myocardial 
infarction in C57Bl/6J mice. Submitted
Louwe MC*, Lammers B*, Frias MA, Foks AC, Hildebrand RB, Kuiper J, Smit JW, Van 
Berkel TJ, Rensen PC, Van Eck M. ABCA1 deficiency protects the heart against injury 







Maria Cornelia Louwe (roepnaam Mieke) werd geboren op 31 mei 1984 te Egmond aan 
den Hoef. Na het behalen van haar VWO diploma in 2002 op het Petrus Canisius College 
te Alkmaar, startte zij datzelfde jaar met de studie Bio-Farmaceutische Wetenschappen 
aan de Universiteit Leiden. In 2006 behaalde zij haar Bachelor of Science.
Tijdens haar Master koos zij voor de specialisatie onderzoek en voerde zij twee stages 
uit. De eerste stage vond plaats bij de afdeling Medische Farmacologie van het Leiden/
Amsterdam Center for Drug Research aan de Universiteit Leiden, onder begeleiding van 
Prof. dr. M. Oitzl en Dr. Y. Revsin. Tijdens deze stage deed zij onderzoek naar de invloed 
van chronisch hoge corticosteron concentraties op het geheugen en het leergedrag in 
muizen met diabetes type 1. Haar tweede stage voerde zij uit aan de Uppsala Universitet 
in Uppsala, Zweden, onder begeleiding van Prof. dr. F. Nyberg en Dr. A-L. Svensson. 
Hier bestudeerde zij de effecten van opioïden- en neursteroïden-behandeling op de 
overleving van neuronale cellen.
Na haar afstuderen in mei 2008 startte ze in september datzelfde jaar met haar 
promotieonderzoek bij de afdeling Endocrinologie en Metabole Ziekten van het Leids 
Universitair Medisch Centrum onder supervisie van Prof. dr. J.W.A. Smit, Prof dr. K. 
Willems van Dijk en Dr. P. Steendijk. Als promovendus ontving zij voor de presentatie 
over haar onderzoek in 2010 de poster award op het 13e symposium van de Dutch 
Atherosclerosis Society. Verder won zij tijdens de 2e PREDICCt meeting in 2010 de 
schrijfwedstrijd ‘scientific writing for the public’. Het promotieonderzoek, waarvan de 
resultaten zijn beschreven in dit proefschrift, werd afgerond in maart 2013. 

